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Head and neck squamous cell carcinoma (HNSCC) is a common and debilitating form of 
cancer with few effective treatment options.  HNSCC tumors display a complex array of 
molecular changes, and sequencing studies have identified the phosphatidylinositol 3-kinase 
pathway (PI3K) as the most frequently mutated oncogenic and targetable pathway in this cancer 
type.  PI3K signaling contributes to cell growth and survival and is most commonly dysregulated 
by alterations in the gene PIK3CA, which encodes the catalytic subunit and alpha isoform of 
PI3K. In spite of this, PI3K inhibition has shown underwhelming efficacy in HNSCC clinical 
trials to date.  Thus, my thesis seeks to evaluate the hypothesis that resistance to PI3K targeting 
therapies is the result of compensatory signals, which are activated in the presence of PI3K 
inhibitors.  To test this, I examined how aberrant PI3K signaling was influenced by co-
expression of EGFR, co-alteration of NOTCH1, and co-dependence of multiple RTKs, including 
ALK and IGF-1R. 
EGFR is overexpressed in most HNSCCs and its signaling is a widely studied means by 
which HNSCC cells evade death in the presence of PI3K inhibition.  Consistent with previous 
studies, I demonstrated activation of the Ras-MEK-ERK pathway, downstream of EGFR, 
following treatment with PI3K inhibitor monotherapy in multiple PIK3CA amplified UM-SCC 
cell lines.  I also showed that co-inhibition of PI3K with MEK or EGFR was synergistic in a 




additional in vitro models.  My pharmacologic analysis revealed that combinations including 
irreversible EGFR inhibitors were more effective than those utilizing reversible EGFR inhibitors. 
In HNSCC, NOTCH1 acts as a tumor suppressor, and inactivating alteration in this gene 
is observed in nearly 20% of tumors. Emerging data suggests interplay between PI3K and 
NOTCH signaling in this cancer type.  Our CRISPR/Cas9 partial knockout model of PIK3CA in 
UM-SCC-47, reveal the cooperativity between the PI3K and NOTCH pathways.  We confirmed 
this relationship and its potential importance using a transgenic mouse model: following 
treatment with 4-nitroquinoline N-oxide, mice with overexpression of mutant Pik3ca and 
knockout of Notch1 reach endpoint faster than animals with alterations in just one of these genes. 
Finally, in order to characterize additional signaling pathways driving compensatory 
PI3K inhibitor resistance, we developed and optimized an unbiased, high-throughput screening 
approach.  We used this assay to test ~1400 inhibitors as monotherapies and in combination with 
PI3K inhibitors HS-173 and BKM120 in ten HNSCC cell lines. Our initial screening data 
suggested that combinations of PI3K inhibitors and ALK/IGF-1R inhibitors were among the 
most effective drug pairs.  Using viability, apoptosis and cell cycle assays to test single-agent 
and combined treatments, we validated the combinatory effects of FDA-approved agents PI3K 
inhibitor pictilisib and ALK inhibitor brigatinib in a subset of cell lines.  These inhibitors were 
similarly effective in a xenograft model.  Furthermore, we identified additional synergistic dual-
therapies; many of these inhibited PI3K in combination with upstream receptor tyrosine kinases, 
while combining PI3K inhibition with inhibition of downstream pathway members did not 
display synergy.   
Collectively, these data deepen our understanding of the combined effects of PI3K 




the use of targeted PI3K inhibitors, motivate further analyses of PI3K combination treatments 





Chapter 1 : Genetic Determinants in Head and Neck Squamous Cell 
Carcinoma and Their Influence on Global Personalized Medicine1 
Abstract 
 While sequencing studies have provided an improved understanding of the genetic 
landscape of head and neck squamous cell carcinomas (HNSCC), there remains a significant lack 
of genetic data derived from non-Caucasian cohorts. Additionally, there is wide variation in 
HNSCC incidence and mortality worldwide both between and within various geographic regions. 
These epidemiologic differences are in part accounted for by varying exposure to environmental 
risk factors such as tobacco, alcohol, high risk human papilloma viruses and betel quid. 
However, inherent genetic factors may also play an important role in this variability. As limited 
sequencing data is available for many populations, the involvement of unique genetic factors in 
HNSCC pathogenesis from epidemiologically diverse groups is unknown. Here, we review 
current knowledge about the epidemiologic, environmental, and genetic variation in HNSCC 
cohorts globally and discuss future studies necessary to further our understanding of these 
differences. Long-term, a more complete understanding of the genetic drivers found in diverse 
HNSCC cohorts may help the development of personalized medicine protocols for patients with 
rare or complex genetic events. 
                                               
1 This chapter was published in Genes and Cancer and completed in collaboration with the following authors: 





 Recent next generation sequencing (NGS) studies of head and neck squamous cell 
carcinomas (HNSCC) have shed light onto the underlying genetic profiles for this aggressive 
disease (1, 2) and enabled a move towards personalized medicine, in which therapy is guided by 
tumor genetics. Notably, however, the vast majority of patients sequenced thus far have been 
restricted to a single epidemiologic population—human papillomavirus (HPV) negative, 
Caucasian, and high tobacco and/or alcohol use. There has been little information on the genetic 
profiles in other epidemiologic cohorts; thus, the genomic events driving pathogenesis in these 
patients remain poorly understood. The rationale to overcome this void is clear and detailed 
below.  
In the US and other high-income countries, personalized medicine approaches are 
increasingly being applied for many advanced cancers including HNSCC (2-4). Personalized 
medicine protocols, such as the National Cancer Institute-Molecular Analysis for Therapy 
Choice (NCI-MATCH) trial, seek to test molecularly targeted therapies in patients with 
corresponding mutations (5). However, these protocols often rely on targeted NGS approaches, 
which are resource intensive and unlikely to be implemented in low- or middle-income countries 
in the near future. Thus, the idea of targeted and personalized therapy may need to be adjusted in 
areas where sequencing-based medicine is not yet achievable. One way to do this is to 
understand the genetic events common to different epidemiologic populations and guide 
biomarker-based research and medicine towards the most frequent and tractable biomarkers in 
the region.  
Genetic studies comparing ethnic and epidemiologic sub-groups have also been very 




example of differential distributions of genetic events based on ethnicity, the TMPRSS2:ETS 
gene fusions are found in approximately 50% of prostate cancers in the US, but only 10% of 
prostate cancers in China. As a result, focused deep sequencing of TMPRSS2:ETS gene fusion 
negative Chinese prostate cancers identified high frequency and previously unrecognized 
genomic events in alternative pathways (6, 7). Similarly, we recently performed NGS analysis of 
an epidemiologically low risk HNSCC (from a young, non-smoker/drinker, HPV-negative 
patient) with the hypothesis that the tumor would have relatively few mutations compared to a 
tobacco-related HNSCC. Indeed, our analysis found a potential driver amplification of the 
tyrosine kinase receptor FGFR1. Extending the discovery to The Cancer Genome Atlas (TCGA) 
HNSCC cohort, we demonstrated that the FGF/FGFR pathway is dysregulated in >30% of 
HNSCCs and likely represents a previously unrecognized aberration driving disease 
pathogenesis (8). Consequently, carefully designed studies focusing on the genetics of under-
studied epidemiologic populations can be very informative.  
In this review, we will discuss current knowledge of the variations in prevalence, 
environmental factors, and genetic factors in HNSCC across different regions from around the 
world. We also include discussion of the variation in HNSCC incidence and severity evidenced 
in black and white American cohorts (9-12). (In this review, we will use the New England 
Journal of Medicine convention of black as opposed to African American (13).)  It is evident 
from these early studies that different epidemiologic subsets of HNSCC may associate with 






HNSCC Rates Globally  
Historically, different rates of HNSCC have been evidenced in different epidemiologic 
populations (Figure 1-1, Table 1-1). While environmental factors are thought to be a major 
contributor to this variability, it is unclear if the underlying acquired genetic events are similar 
across cohorts. Furthermore, the mutational effects of other factors associated with HNSCC 
globally (most notably high risk HPV, but also betel nut in Southeast Asia, nitrosamines in Asia, 
Epstein-Barr virus (EBV) in Africa and Asia) have not been identified. Here, we will review 
what is known about HNSCC incidence and mortality in representative countries from around 
the world.  
Developed Countries: United States, Canada, and Europe 
Two thirds of HNSCC cases occur in developed countries, where the use of tobacco and 
alcohol is prevalent (14). Odds ratios for developing HNSCC due to tobacco and/or alcohol use 
are 3-4 times higher in Europe and Latin America, where the use of both substances is more 
widespread, than in North America (15). In general, between 1983 and 2002, incidence rates for 
oral cavity cancers (for which increased risk is particularly noted in smokers) increased in 
Europe and decreased in the US and Canada (16). During this time period, incidence of 
oropharyngeal cancer also increased in eastern and northern Europe. These trends may reflect 
changes in the proportion of the population using tobacco and/or alcohol.  
Tobacco use alone, however, does not account for variation in HNSCC throughout 
Europe. Based on rates reported by Simard et al., HNSCC incidence in all anatomic subsites is 
somewhat increased in France compared to eastern European countries and is markedly higher in 
France compared to other European nations (such as the UK and Italy) (16). Of the 




Italy, and the UK. Increased tobacco use, then, cannot completely explain the increased rate of 
oral cavity cancers between France and other European nations or the higher incidence of 
cancers of other sites in men from Italy as compared to the UK (16). While HNSCC in France 
may be driven somewhat by elevated levels of tobacco use, other factors, including biological 
differences, may also be crucial for tumorigenesis. 
Asia 
Increased rates of HNSCC, particularly oral squamous cell carcinoma, in southern and 
southeastern Asian countries are often attributed to betel quid exposure (17). Head and neck 
tumors are one of the most common malignancies in males in some parts of south central Asia. 
Parkin et al. identified the highest incidence of oral cancer in Melanesia (31.5 per 100,000 in 
men, 21.2 per 100,000 in women) (18). While nasopharyngeal tumors also have greatest 
incidence in southeastern Asia, trends in oropharynx cancer vary by specific country (18).  
Fewer oral cancer cases are observed in Chinese and Middle Eastern cohorts, where betel 
quid is used more rarely, as compared to other Asian countries (19). High rates of laryngeal and 
other types of HNSCC in China may be due in part to increased tobacco use in this country. 
Lower incidences of HNSCC at all sites in the Middle East are possible for a variety of reasons, 
including, but not limited to, the lower use of betel quid, tobacco, and alcohol in this region. 
Africa 
There is relatively little data available on HNSCC in African cohorts; nevertheless, tumor 
epidemiologic differences may exist. A systematic review of the literature since 1990 by 
Faggons et al. found that 7750/8861 (87.5%) patients with HNSCC in sub-Saharan Africa 
presented with cancer of the oral cavity or oropharynx (20). Subsite specificity may vary 




review of the literature on head and neck cancer in Nigeria (21), but there were much less 
frequent reports of tumors of the nasopharynx, nasal cavity, or paranasal sinuses (410/8861, 
4.8%), larynx (385/8861, 4.5%), or hypopharynx (66/8861, 0.8%) in sub-Saharan Africa (20). 
These differences may be due to difficulties in screening for cancers in these subsites. Consistent 
with prevalences in the sub-Saharan cohort, oral cavity and oropharyngeal tumors accounted for 
27/46 (58.7%) cases in black TCGA patients while larynx cancer was also common (18/46, 
39.1%) and hypopharynx tumors were infrequent (1/46, 2.2%).  
Within Africa, reports of HNSCC incidence vary widely, from 0.8/100,000 in Ghana (22) 
to 11.1/100,000 in South Africa (18). Tumors of the pharynx and larynx are the second and 
seventh most common types of cancer seen at the Korle Bu teaching hospital in Ghana, 
representing 7.4% and 3.5% of all malignancies, respectively (23). Furthermore, age at tumor 
presentation in African patients was approximately 20 years younger than in American 
populations, which may be explained by biological, exposure and/or other differences between 
these populations (20). Several epidemiologic factors may contribute to differences in African 
HNSCC including HIV infection, which has been shown to increase the risk of HNSCC by two 
to three times in the US (24). Despite this fact, the role of HIV in African HNSCCs is unclear 
due to a lack of studies comparing HIV positive and negative patients; anecdotal evidence 
suggests that HIV positive patients have poorer clinical outcomes but further comparison is 
necessary (20). 
Variation within Geographic Regions 
Variation in HNSCC rates are also observed within different ethnic groups within 
specific geographic regions (25). For example, Ho et al. considered head and neck cancer 




(26). Between 1979 and 1997, compared to Fukkien groups, HNSCC mortality rates decreased in 
Hakka and increased in Aboriginal tribes. Incidence trends between 1979 and 1996 were similar, 
particularly in Aboriginals with high chewing prevalence for betel quid. While environmental 
and socioeconomic factors vary between groups, these differences alone may not explain the 
observed variation in incidence of and mortality from HNSCC. Interestingly, genetic differences 
have been noted between Fukkiens and Aboriginal in alleles responsible for metabolic activation 
of carcinogenic nitrosamines (27). 
Additionally, significant differences in HNSCC incidence, particularly for larynx cancer, 
have been noted between black and white Americans. In a study by DeSantis et al., there was a 
higher incidence of laryngeal cancer in black (10.4/100,000) compared to white males 
(6.6/100,000); differences were not noted in the incidence of tumors at other HNSCC subsites 
(9). Goodwin et al. evidenced 15% and 77% increased incidence of oral cavity/pharynx and 
larynx tumors, respectively, in black as compared to white male Americans. These authors also 
observed increased incidence of larynx cancer (but not other sites) in black females (10). The 
differences in this study were observed to the greatest degree in patients under the age of 65, 
suggesting that hereditary or early onset factors may be involved. Furthermore, black women 
displayed higher rates of non-oral cavity, non-oropharyngeal HNSCCs compared to white and 
other ethnic female cohorts worldwide (16).  
HNSCC incidence varies not only by subsite but also by severity and survival rates. 
Black patients are more likely to present with late stage, poor prognosis HNSCC than whites (10, 
11). Regardless of cancer site, mortality for black males is on the order of two times higher when 
compared to that of similar white patients (10). Furthermore, independent of cancer stage, 63% 




differences in survival are most significant in patients under the age of 60 (12), cancer growth 
may be driven by biological factors rather than exposure to environmental toxins or 
socioeconomic influences. Further investigation is necessary to determine these potential 
hereditary factors and how they may diverge between ethnic cohorts to cause more aggressive 
disease phenotypes. 
 
High Risk Human Papillomavirus is Changing HNSCC Epidemiology 
Infection with high risk is a major risk factor for head and neck cancers, particularly in 
the oropharynx (28-35), and the recent HPV epidemic is contributing to a rapid change in the 
epidemiologic distribution of HNSCC globally. To place this in perspective, HPV-positive 
oropharyngeal squamous cell carcinoma incidence surpassed that of invasive cervical cancer in 
2013 (36). While cervical lesions are often diagnosed early and treated pre-neoplastically to 
avoid disease progression (37, 38), most oropharyngeal cancer patients present with advanced 
stage III/IV disease (34). 70-80% of HPV-positive oropharynx cancers respond to intensive 
therapy consisting of chemoradiation or surgery in most series (39, 40). The remaining 20-30% 
of patients’ tumors progress to lethal recurrent or metastatic disease, indicating the need to define 
biomarkers that will predict the subset of patients that would benefit from more aggressive 
therapy and minimize morbidity in less difficult cases.  
 In the face of the HPV epidemic, high risk viral infection has been associated with 
oropharyngeal cancers in studies from across the world. A systematic review by Stein et al. 
compared the prevalence of HPV-positive oropharynx cancer in 23 countries worldwide (41). 
Taiwan, Canada, and the Czech Republic had the highest prevalence of HPV-positive 




Overall, the results of this analysis suggest that HPV-positive tumors may be more common in 
developed countries. In another systematic review, Mehanna et al. identified HPV-positive 
cancers of the oropharynx in 59.9% of 2550 North American patients, but only 39.7% of 2278 
European patients and 32.5% of 568 patients from other regions (42). An additional cohort of 
31/67 (46.2%) Australian patients also displayed high prevalence of HPV-positive oropharyngeal 
cancer (43). Chinese patients displayed lower infection rates with 43/207 (20.8%) HPV-positive 
oropharyngeal tumors and 36/124 (29.4%) HPV-positive tonsil lesions (44). The prevalence of 
oral and oropharyngeal HPV was also lower across Africa as compared to many developed 
countries. 5/125 (4%) South African men were identified with HPV-positive oropharyngeal 
cancer, and only two of these cases were high risk HPV (45). Similarly, 0/22 (0%) oropharyngeal 
cancer and 2/29 (6.9%) oral tongue cancer patients in Mozambique tested positive for HPV 
infection (46). In Senegal, only 4/117 (3.4%) HNSCC patients had HPV-related tumors and none 
of these were located in the oropharynx (47).  
Of note, the use of numerous testing methodologies to access a diverse array of HPV 
variants may introduce inconsistency in HPV detection outcomes. HPV16 accounts for over 90% 
of HPV-positive HNSCC cases (48) and can be detected by accessing HPV DNA, HPV RNA, 
viral oncoprotein, cellular protein and/or HPV-specific serum antibody levels (49). The most 
sensitive and reliable method of detecting HPV-related HNSCC has been strong staining for p16 
by immunohistochemistry (IHC), although reverse transcriptase (RT)-PCR, PCR-mass 
spectrometry and in situ hybridization (ISH)-based protocols are also used in some cases (50, 
51). Thus, consideration of further studies with controlled testing of the global prevalence of 




discordance between high cervical and low oropharyngeal HPV-positive cancer rates in this 
region. 
While rates of HPV infection worldwide are not fully realized, evidence does indicate 
that prevalence may be rising globally and may drive increased incidence of HNSCC. 
Considering the large proportion of the population that is infected with HPV (52), malignant 
transformation is comparatively rare as HPV infections are usually cleared quickly (53). In rare 
cases, however, genomic instability and unrestricted proliferation caused by viral oncogene 
activity lead to tumorigenesis. Cervical infection with HPV, if not cleared, can lead to precancers 
in the genital area as well as the head and neck region through sexual contact. Thus, as a high-
level surrogate for oropharyngeal cancer prevalence, we can analyze the reports of HPV 
prevalence in women, noting a wide range of cervical infection rates in cohorts worldwide (54-
56). Based on a meta-analysis of women with normal cytology, Bruni et al. estimated that the 
regionally-adjusted prevalence of high risk HPV infection, as detected by polymerase chain 
reaction (PCR) or Hybrid Capture 2 (a DNA hybridization assay for detecting HPV strains with a 
fluorescent readout), in females is 47,271/851,901 (5.0%) worldwide. The prevalence of both 
low and high-risk HPV strains is 73,019/1,016,719 (11.7%), which varies between rates as high 
as 75/225 (35.4%) in the Caribbean to those as low as 31/1,435 (1.7%) in Western Asia (56). Of 
all viral strains, HPV16 was the most commonly detected in this study but tended to correlate 
inversely with overall HPV prevalence. In the more limited analysis of data from male patients, 
an important population given the increased prevalence of HNSCC in this group, a similar 
overall prevalence (182/1139, 16%) and even more significant amount of variation was 
observed, particularly when separating low- and high-risk groups (57, 58). We compared 




consider possible associations between these two variables (Figure 1-2). In a subset of countries, 
both increased HPV prevalence and oropharyngeal cancer incidence were observed. (For 
example, women in Eastern Europe have high prevalence of cervical HPV infection (904/4053, 
21.4%), and the oropharyngeal cancer incidence in Slovakian men is also elevated 
(15.4/100,000).)  Alternatively, in other regions, decreased HPV prevalence and increased 
oropharyngeal cancer incidence were noted. (In India, only 1816/23,061 (7.1%) women tested 
positive for HPV infection, but 9.1/100,000 men develop oropharyngeal tumors (56, 59).)  These 
findings may be explained by regional differences in HPV infection rates; however, developing a 
more complete understanding of this relationship is additional motivation for controlled HPV 
testing in global cohorts. 
Sexual activity, particularly oral sex with multiple partners, increases HPV-positive 
cancer risk at all sites. As is the case with other risk factors, sexual practices are widely divergent 
across populations globally. For instance, 78% of American, but only 9% of Indian men reported 
ever having oral sex, and individuals born after 1960 have more commonly engaged in this 
activity (60). Men are also more likely to have multiple partners than women (61-63) and the 
prevalence of HPV infection was much higher in high-risk populations of males as compared to 
females with similar numbers of sexual partners (64). Given these differences, it stands to reason 
that HPV-positive HNSCC rates will vary widely between cohorts globally.  
Similarly, variation between HPV-positive head and neck cancer rates has already been 
observed in whites and blacks in the US and may explain racial disparity in survival rates at least 
partially. Settle et al. found that differences in the median overall survival (OS) of an American 
cohort were driven primarily by differences in tumors of the oropharynx (white 69.4 months, 




months, difference n.s.) (65). In a separate analysis of OS for black and white Americans with 
HPV-positive or HPV-negative HNSCC, Jiron et al. determined that the hazard ratio was greatest 
for black patients with tumors of the oropharynx but that adjustment for HPV status drastically 
reduced this ratio to a value close to unity (66). These results suggest that the poorer prognosis of 
black patients in the US may be due to the reduced rate of HPV-positive oropharyngeal cancers 
in this group. Nevertheless, further studies are necessary to more fully evaluate this hypothesis. 
 
Variation in Genetic Landscape between Epidemiologic Sub-Groups 
Despite the majority of HNSCCs occurring in non-American populations (incidence rate 
of 60,000 annually in US vs 490,000 annually in rest of world), NGS studies have been limited 
to cohorts of primarily European ancestry and not other ethnic groups or epidemiologic 
populations. TCGA and the International Cancer Genome Consortium (ICGC) reported 
sequencing for cohorts of HNSCC patients in the United States and India, respectively (1, 67). In 
the TCGA cohort, the majority of these patients were white (242/279, 86.7%), with only 25/279 
(9.0%) black. Different mutational profiles were evidenced between black and white HPV-
negative patients (Figure 1-3). For instance, black patients have significantly higher rates of 
BIRC2/3 amplification compared to white HNSCC patients in this study (25.0% vs 4.3%, p < 
0.001). Although they do not reach statistical significance, blacks also trend toward decreased 
EGFR (4.2% vs 13.5%, p = 0.19) and increased FGFR1 (16.7% vs 9.1%, p = 0.24) amplification. 
Other genetic aberrations were similar between ethnic groups (68, 69).  
ICGC data also noted distinct differences in genomic aberrations in Indian patients with 
oral cancer of the gingivo-buccal region (67). When compared to white American HNSCC 




(p = 0.0365) amplification, PIK3CA activation by mutation or amplification (p = 0.0027) and 
CDKN2A deletion (p = 0.0045) (Figure 1-3). As identified in previous studies of HNSCC, the 
authors observed frequent copy number alterations or mutations in TP53, FAT1, CASP8, HRAS 
and NOTCH1 in the Indian HNSCC patients (70). Interestingly, the ICGC study also identified 
five genes (USP9X, MLL4, ARID2, UNC13C and TRPM3) and three pathways (Wnt signaling, 
dorso-ventral axis formation and axon guidance) previously not associated with HNSCC in 
TCGA. These events may be specific to this epidemiologic sub-group. For example, mutations in 
TRPM3 were identified in 5/50 (10%) Indian ICGC patients, but only 4/208 (1.9%) white and 
1/25 (4%) black HPV-negative TCGA patients. USP9X was more frequently mutated or deleted 
in Indian (7/37, 18.9%) than in white (23/208, 11.1%) or black (1/25, 4%) HPV-negative patients 
(68, 69) although this difference did not reach significance using the Chi-square test with Yate’s 
correction (p = 0.2837). Furthermore, the frequency of copy number alteration or mutation of 
FAT1, FAT3, and FAT4 were increased in the Indian ICGC cohort (67).  
While there have been few other in-depth genomic studies of large ethnic or 
epidemiologic cohorts, unique mutational profiles are likely to exist in other global populations. 
Vettore et al. recently performed targeted deep sequencing on a cohort of 60 patients treated in 
Singapore and found that mutation frequencies for TP53, CDKN2A, and NOTCH1 were 
infrequent compared to other studies. While TP53 and CDKN2A represent the first and third 
most commonly mutated genes in the overall TCGA HNSCC cohort, mutations in these genes, 
respectively, were present in only 23/60 (38.3%) and 3/60 (5%) of Asian patients. Furthermore, 
NOTCH1 mutation was identified in significantly fewer Asian patients (3/60, 5%) than white 
HPV-negative TCGA patients (41/208, 14.6%) (p = 0.012). Conversely, DST, RNF213, COL6A6 




that could reveal additional trends in other epidemiologic populations, therefore, are clearly 
warranted.  
 The mutational loads were similar between white and black cohorts in TCGA (Figure 
1-4) and Indian patients in ICGC data (mean total number of mutations: 112.79 +/- 19.25) (67). 
Copy number alterations, however, were increased in black as compared to white patients 
(0.3342 vs 0.2560, p = 0.0443) (Figure 1-5). When subsites were considered individually, trends 
between ethnic cohorts were apparent for copy number alterations in oropharyngeal tumors 
(however only 2 black patients compared to 8 white) and were also observed for tumors of the 
oral cavity (0.2884 vs 0.2174, p = 0.17). These comparisons are limited by the small number of 
black patients included in this analysis and may be due to sample bias. 
 
Worldwide rates of established HNSCC molecular events 
 Currently, EGFR, PIK3CA, NOTCH pathway and TP53 genes are among the most 
frequently mutated in HNSCC. As these genes have long been associated with HNSCC 
pathogenesis, several smaller cohort studies have been published assessing the rates of genomic 
events for these genes in various ethnic and epidemiologic populations. Understanding which 
populations have unique genetic landscapes may aid in selecting the most informative 
populations for immediate NGS analysis. Unfortunately, a relatively small number of studies 
have sequenced HPV-positive HNSCCs in international studies. Thus, we will separately address 





Epidermal Growth Factor Receptor (EGFR) 
 It has been recognized for nearly 30 years that EGFR is overexpressed in the majority of 
HNSCC tumors (71). The effects of EGFR activation in squamous cells may be pleiotropic: not 
only can changes in receptor signaling affect the Ras-MAPK, PI3K-AKT-PTEN, and/or 
phospholipase C pathways, but they may also activate other receptors by ligand-independent 
dimerization. Consistent with the prevalence of EGFR protein overexpression and demonstrating 
its importance, EGFR-targeted antibody, cetuximab, is currently the only FDA-approved 
targeted therapy for HNSCC and has been shown to improve overall survival of patients (72, 73). 
A meta-analysis of 37 studies by Keren et al. examined EGFR levels in surgically resected 
primary tumor samples and identified 1948/3346 (57.8%) cases with high protein expression. 
The majority of patients were from Europe, with some cohorts also from the US and east Asia; 
overexpression was frequently and consistently noted in Austrian, Spanish, and Dutch cohorts, 
while it was infrequent in Swedish, French, and Italian populations (74). High levels of EGFR 
expression may also be more common in Sudan, where 126/150 (84%) head and neck cancer 
cases displayed overexpression by IHC analysis (75). 
Despite frequent overexpression of EGFR, rates of genetic aberration (by amplification or 
mutation) are relatively low (14.3% in TCGA) (1) and a small number of studies have assessed 
EGFR genomic aberrations in individual populations. For example, 3/41 (7.3%) Korean patients, 
most of whom had larynx cancer, displayed a mutation in the kinase domain of EGFR (76), but 
similar mutations were much less commonly observed in Caucasian or Spanish patients (77-79). 
One TCGA patient displayed truncating EGFRvIII mutation, which was previously detected by 
Sok et al. in 14/33 (42.4%) HNSCCs along with wild type EGFR and was correlated with 




somewhat infrequent, this pathway as a whole is often aberrantly expressed. For example, 31/60 
(52%) Indian patients with buccal-gingival cancer displayed mutations in the EGFR pathway, 
and 46/208 (22.1%) of the TCGA cohort displayed amplification of EGFR family members 
(EGFR, ERBB2-4, EGF, NRG1-4, EREG, AREG, TFGA, BTC, and HBEGF) (1, 81). An 
improved understanding of the genetic and/or biochemical mechanisms driving EGFR 
overexpression in HNSCC will be necessary before extending the assessment of EGFR 
mechanisms globally. However, as global cohorts are being prioritized for genetic studies, 
populations such as Swedish and Italian, which have been associated with lower overall rates of 
EGFR overexpression, may show the largest variation in genomic landscape to those HNSCCs 
already sequenced.  
Catalytic Subunit of Phosphotidylinositol 3-kinase (PIK3CA) 
 The PI3K-AKT-PTEN pathway has been identified as the most frequently mutated or 
amplified oncogenic pathway in HNSCCs in the TCGA cohort (1, 82). Mutations and/or 
amplifications in PIK3CA, the gene encoding the catalytic subunit of phosphotidylinositol 3-
kinase (PI3K), are the most common alterations in this pathway and are observed in 36.9% of the 
TCGA HNSCC cohort (68, 69). These aberrations lead to increased cell growth and viability, 
may drive tumor progression, and are more commonly observed in advanced stage disease as 
reviewed elsewhere (83, 84). PIK3CA mutation or amplification is also more frequent in HPV-
positive tumors, including in the TCGA cohort (56% HPV-positive vs 34% HPV-negative) (1, 
82, 85). Loss of function of PTEN also results in failure to “turn off” PI3K signaling and is 
observed in an additional 10% of HNSCC patients (86). 
Rates of PIK3CA aberration have been assessed in various global cohorts (87-92) and are 




patients in a German HNSCC cohort as well as 3/115 (2.3%) and 6/50 (12%) individuals in two 
independent Japanese groups (88, 90, 93). Alternatively, Redon et al. noted 6/9 (66.6%) of 
French HNSCC patients have increased copy number (94). PIK3CA mutation is generally less 
common than gene amplification. Somatic mutations, commonly including “hotspot” amino acid 
changes to the kinase (H1047R) or helical (E545K, E542K) domains, occur in 20.8% of the 
TCGA cohort, which is consistent with rates of ~10-20% in other studies (87-89). PIK3CA 
mutation rates greater than 10% were noted in cohorts from Thailand (6/58), India (2/19), and 
Israel (4/37) (88, 89, 92). Surprisingly, a complete lack of PIK3CA mutations in the helical or 
kinase domains (exons 9 and 20) were observed in populations of 18 Vietnamese, 33 German, 
and 86 Greek patients as detected by PCR (89-91). This may be due to increased activation of 
HRAS, which signals upstream of PIK3CA, in these epidemiologic sub-groups (95). Due to the 
variation in PIK3CA mutation rates between 1/35 (2.9%) and 5/24 (20.8%) in US patient 
populations (87, 96) and the relatively small number of HNSCC tumor samples that have been 
sequenced worldwide, additional cohort studies are warranted to further consider potential 
associations between rates of genetic aberration and patient ethnicity or epidemiologic-risk. 
NOTCH pathway genes 
In 2011, sequencing-based analysis of HNSCC tumors led to the discovery of 
inactivating NOTCH pathway alterations as the third most common molecular event in the 
disease (1, 68, 70, 96). In fact, mutations in one gene from this pathway, NOTCH1, were 
observed in ~15% of samples in addition to less frequent mutations of the NOTCH2 (~5%) and 
NOTCH3 (~4%) genes, with rare copy number alterations reported. Soon after these reports were 
published, and in contrast to the prevalent loss-of-function mutations, copy number increases and 




a small subset of predominantly white HNSCCs (97). Importantly, the functional role of both the 
activating and inactivating alterations have yet to be fully characterized.  These alterations have 
been reviewed elsewhere (98), but they are suggested to regulate squamous cell differentiation in 
multiple model systems. Consistent with this notion, many HNSCCs are characterized by 
recurrent mutations in the TP63, IRF6 or MED1 genes, which have also been suggested to 
regulate squamous differentiation, supporting a functional importance of this pathway for 
HNSCC pathogenesis (70).  
While the discovery of NOTCH pathway alterations is still relatively new, several studies 
have assessed the frequencies of molecular events globally. These have demonstrated that 22/51 
(43.1%) Chinese oral cavity HNSCC tumors harbored NOTCH1 alterations, with at least half 
predicted to activate function (99), while only 8/84 (9.5%) Japanese oral cavity HNSCCs had 
mutations that were all predicted to inactivate NOTCH1 activity (100). In another cohort of 
Asian patients with tongue cancer, NOTCH1 mutations occurred infrequently but alterations in 
other NOTCH pathway genes (i.e. AR, ARNT, EP300, CREBBP, JAK2, JAK3, NCOA1, 
NOTCH2, NOTCH3, and PARP1) were common (19/60, 32%) and correlated with disease 
survival (81). While much larger cohort studies are needed, the preliminary published data 
indicates that activating NOTCH pathway alterations may be much more common in Chinese 
HNSCCs than in patients represented in the Indian ICGC and TCGA HNSCC projects.  
The Tumor Suppressor Protein, TP53 
 The p53 protein functions as a master regulator of the interplay between the cell cycle 
and apoptosis and is the most frequently deregulated tumor suppressor in HNSCC. In fact, the 
function and role of p53 in HNSCC have been reviewed extensively due to the high frequency of 




commonly inactivated by mutation or deletion (103), while the HPV oncoproteins inactivate p53 
by biochemical mechanisms in HPV-positive HNSCC. Thus, because TP53 is usually wild type 
in HPV-positive HNSCCs, we will restrict the review of genetic events for this gene to oral 
cavity and larynx HNSCCs, which are historically largely HPV-negative. At these organ sites, 
TP53 mutation often correlates with poorer survival (104) and has been associated with exposure 
to tobacco or betel quid (103). Consequently, we may expect to find different rates of TP53 
disruption in different epidemiologic subgroups if the gene is related to these risk factors, or may 
observe high rates across all populations if inactivation is generally required for squamous 
pathogenesis.  
 In the TCGA data set, TP53 mutation was observed in 129/160 (80.6%) HPV-negative 
tumors of the oral cavity (1, 68, 69). In tongue cancer samples from an Asian cohort, TP53 was 
the most frequently mutated gene (as in TCGA), but was mutated in only 23/60 (38.3%) cases. 
Relatively low rates of TP53 mutation are consistent across multiple studies of oral cavity cancer 
in Asian patients (81, 105, 106). Cohorts of Icelandic and American never-smokers also 
displayed lower oral cancer TP53 mutation rates (107, 108), while rates in Brazil and India were 
more consistent with those in the HPV-negative TCGA cohort (67, 109, 110). Global mutation 
rates for oral cavity and larynx HNSCC are summarized in Table 1-2 and Table 1-3, 
respectively. In the studies published thus far, TP53 mutation rates for laryngeal cancers are 
generally moderately higher than those in oral cavity cancer and also vary by geographic region. 
For example, in the TCGA cohort, 64/72 (88.9%) HPV-negative patients with laryngeal cancer 
display TP53 mutation (1, 68, 69). Most other countries also have mutation rates of 50% or 




these metadata are indicative of a relationship between inactivation and carcinogen exposure as 
opposed to specific pathogenic requirements.  
 Consistent with this observation, several groups have attempted to model the predictive 
value of individual TP53 mutations in different epidemiologic populations. For example, Ren et 
al. performed a meta-analysis to assess HNSCC risk and Arg72Pro TP53 mutation across various 
tumor sites in Asian and Caucasian cohorts. They found that this mutation was associated with 
increased risk of nasopharyngeal cancer, but not oral cancer, for homozygous, heterozygous and 
dominant model mutation comparisons in Caucasian cohorts but only homozygous mutations in 
Asian patients (114). Given the frequency and complexity of TP53 aberration, further studies on 
the distinct role of this gene in specific epidemiological populations will be critical to developing 
an improved understanding of HNSCC pathogenesis. 
 
Future Directions 
Ultimately, additional sequencing of various epidemiologic sub-groups will need to be 
performed to understand the distribution of molecular events on a global scale. This work should 
also assess the correlations of disruptive genomic events with worldwide incidence, mortality, 
and particularly survival differences, which have not previously been taken into account. There 
is also a significant void of sequencing data in African populations in particular. Sequencing of 
these groups may identify both common and unique drivers for HNSCC between various 
cohorts. Studies of African populations are extremely important due to the high rate of 
HIV/AIDS patients in the region. We still have very limited knowledge of the pathogenesis or 
molecular distribution of HNSCCs in immunocompromised patients such as those who have 




be necessary to determine the extent to which other environmental and genetic factors affect the 
incidence and severity of HNSCC both between and within epidemiologic sub-groups. 
HPV-positive oropharyngeal squamous cell carcinoma now displays greater incidence 
than invasive cervical cancer (36). While HPV vaccines have the potential to reduce the overall 
number of tumors caused by this virus, many populations around the world are incompletely 
vaccinated and it is unknown how many people encountered HPV before having the opportunity 
to be vaccinated. Thus, given the increasing rates of HPV in the US and abroad as well as wide 
variation between cohorts, there is a clear and urgent need for both epidemiologic data and 
sequencing analysis on HPV-positive tumors, especially those that are associated with additional 
risk factors. Fortunately, patients in the US with HPV-positive tumors are generally younger and 
have improved prognosis since HPV-positive tumors are more sensitive to chemoradiation (115). 
Despite this fact, some HPV-positive tumors are highly aggressive and rapidly lethal, and there 
are no established biomarkers that can identify patients that would respond to more aggressive 
therapy. Future studies are needed to more fully elucidate the specific differences between HPV-
positive patients from different geographic regions, cultural backgrounds, and genders using 
careful genetic analysis in the context of understanding the lethality of each tumor. These efforts 
are important as they may enable the development of biomarkers for the most aggressive forms 
of this epidemic subset of HNSCCs. 
The heterogeneity of HNSCC has been clearly observed in previous studies and is 
dependent on tumor genetics and exposure to various risk factors including the use of tobacco, 
alcohol, and betel quid, HPV infection, and others. This variation is noted between not only 
between patients but also within individual tumors and between local, nodal, and distant tumor 




genetics will be valuable in establishing personalized medicine protocols first for clinical trials 
and then for individualized treatment plans. At this point, however, studies have not assessed the 
genetic heterogeneity found in individual tumors on a large scale. It is possible that different 
causal or associated factors driving HNSCC pathogenesis will lead to different levels of genetic 
heterogeneity within a tumor. As recurrence from targeted therapy can arise from individual cells 
with pre-existing resistant mutations, understanding the degree of heterogeneity in tumors from 
different epidemiologic subgroups may have a substantial impact on the choice of targeted 
therapy in each population.  
Consequently, further sequencing analysis of patients will likely allow for more effective 
use of targeted therapies in countries where NGS analysis is readily available. Unfortunately, 
while precision-guided targeted antibodies and small molecule inhibitors display great promise 
in the future of cancer treatment, their use is currently limited by several disadvantages, 
including high cost and complex infusion regimens. Thus, while genetic studies are perhaps most 
feasible in high income countries, understanding the contribution of epidemiological factors to 
HNSCC development and progression through various genetic pathways may enable treatments 
to be more effectively selected for patients. For example, understanding the high frequency 
genetic events in each region may restrict the number of biomarker tests needed to identify tumor 
drivers, and may enable clinicians to predict whether more or less aggressive therapy is needed 
based on those markers.  
 In the future, the hope is that access to healthcare resources and infrastructure will be 
enhanced globally so that patients have access to the best possible personalized therapy. In the 
meantime, we must think critically about the cost-benefit of biomarker-guided medicine in 




NGS. Analyzing populations with unique epidemiologic and/or biomarker characteristics may be 
the first step to both enhancing our understanding globally and designing interventional protocols 
adapted to regional differences in health care resources and tumor genetics. We are in an exciting 
era of sequencing-guided personalized medicine in the US, and our challenge moving forward is 
to take the discoveries and lessons from these early personalized medicine trials, incorporate 
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Figure 1-1. Age-standardized head and neck cancer incidence rates by sex and subsite for 
various global cohorts 
Incidence rates per 100,000 for males and females in various global cohorts with cancers of the 
oral cavity, oropharynx, or other head and neck sites. Raw incidences, references, and more 
detailed descriptions of each study can be found in Table 1-1. 
* indicates that incidence for oropharyngeal cancer was not reported. † indicates that incidence 






Figure 1-2. Adjusted cervical HPV infection prevalence among women with normal 
cytology and oropharyngeal cancer incidence among men by geographic region (55, 58) 
HPV prevalence includes infection with both low and high risk viral strains and was adjusted 
based on patient age, year of study, sample type, HPV screening method, and viral strain(s). 
Oropharyngeal cancer incidence given for a representative country within each region: Slovakia 
(Eastern Europe), Brazil (South America), Thailand (Southeastern Asia), Japan (Eastern Asia), 
Denmark (Northern Europe), Netherlands (Western Europe), Spain (Southern Europe), India 






Figure 1-3. Prevalence of copy number alterations and/or mutation for various genes in 
HPV-negative black and white patients in the TCGA HNSCC cohort, Indian patients in the 
ICGC HNSCC cohort, and Asian patients in the Vettore cohort (1, 66, 80) 
Prevalence of key genetic aberrations in 24 black and 208 white HPV-negative patients (TCGA 
HNSCC cohort), 37 HPV-negative Indian patients (ICGC HNSCC cohort), and 60 Asian patients 
of unidentified HPV status (Vettore cohort). NOTCH1 mutation prevalence only is reported for 
the Asian cohort.  
* indicates significant differences between white and black TCGA cohorts. † indicates 
significant differences between white TCGA and Indian ICGC cohorts. ‡ indicates significant 








Figure 1-4. Total mutation load in black and white patients in the TCGA HNSCC cohort 
Mutation rates were determined based on data from 24 black and 208 white HPV-negative 







Figure 1-5. Copy number alterations in black and white patients in the TCGA HNSCC 
cohort 
Aberration rates were determined based on data from 24 black and 208 white HPV-negative 






Figure 1-6. Global variation in frequency of PIK3CA aberration in oral cancer 
Frequency of PIK3CA amplification (A) and mutation (B) in oral cancer cohorts from countries 
worldwide. Based on data from Murugan et al. (94) and review of more recent literature, as 






Table 1-1. Age-standardized head and neck cancer incidence rates by sex and subsite for 
various global cohorts 
(16) Incidence rates per 100,000 for adult (age > 15 years) males and females in various global 
cohorts with cancers of the oral cavity, oropharynx, or other head and neck sites from 1998-
2002. Other HNSCC sites include the pyriform sinus, hypopharnyx, lip/oral cavity/pharynx not 
otherwise specified, and larynx.  
(118) Incidence rates per 100,000 for adult males and females in Zimbabwe from 1996-2000. 
Other HNSCC site incidence is the sum of the nasopharyngeal and laryngeal cancer incidence.  
(119) Incidence rates per 100,000 for males and females of all ages in Australia with cancer of 
the lip and oral cavity or oropharynx from 1982-2008. 
(120) Incidence rates per 100,000 for males and females of all ages in Guilan, Iran from 2008-
2009 with cancers of the lip and oral cavity or pharynx and tonsil from 2008-2009. 
* indicates incidence not available 
 
 Oral Cavity Oropharynx Other Sites  
Country Male Female Male Female Male Female Reference 
Belarus 8.93 0.73 4.75 0.23 18.93 0.34 (16) 
UK 5.18 2.75 2.13 0.65 7.74 1.69 (16) 
France 15.25 3.12 9.43 1.48 22.69 1.7 (16) 
Italy 6.08 2.41 2.8 0.57 14.36 1.08 (16) 
China (Hong Kong) 4.72 2.38 1.25 0.26 16.19 0.61 (16) 
India (Mumbai) 15.49 8.12 2.82 0.61 16.66 2.89 (16) 
Philippines 5.3 3.97 0.93 0.62 9.81 0.55 (16) 
Iran (Guilan) 1.91 1.25 1.49 0.67 * * (120) 
Jews 2.64 1.59 0.57 0.18 7.09 1.16 (16) 
Canada 5.7 2.92 2.36 0.7 7.39 1.44 (16) 
US (Black) 9.65 3.31 4.93 0.95 15.81 3.5 (16) 
US (White) 7.16 3.41 2.9 0.73 8.31 2.07 (16) 
Costa Rica 2.69 0.73 1.07 * 5.95 0.42 (16) 
Brazil 12.73 2.66 4.56 * 16.12 1.73 (16) 
Zimbabwe 6.4 1.2 * * 1.6 1.5 (118)   






Table 1-2. TP53 mutation rates in geographical cohorts with oral cavity cancer 
Country Site TP53 Mutation Frequency Reference 
US (TCGA) Oral cavity 129/160 (80.6%) (67) 
Asia Tongue 23/60 (38.3%) (80) 
Asia Tongue 7/66 (10.6%) (104) 
Asia Oral cavity 31/112 (27.7%) (105) 
Taiwan Oral cavity 26/79 (32.9%) (103) 
India Gingivo-buccal 31/50 (62%) (66) 
US (never-smoker) Oral cavity 10/61 (16.4%) (107) 
Iceland Oral cavity 11/52 (21.1%) (106) 
Brazil Oral cavity 15/30 (15%) (108) 






Table 1-3. TP53 mutation rates in geographical cohorts with larynx cancer 
Country Site TP53 Mutation Frequency Reference 
US HPV-negative (TCGA) Larynx 64/72 (88.9%) (67) 
China Larynx 22/64 (34.4%) (110) 
Italy Larynx 62/82 (75.6%) (115) 
Italy Larynx 36/81 (44.4%) (116) 
Denmark Larynx (supraglottic) 87/158 (55.1%) (117) 
South Africa Larynx 11/44 (25%) (111) 
Brazil Larynx 3/7 (42.9%) (108) 
Brazil Larynx/hypopharynx 49/58 (69.0%) (112) 






Table 1-4. Raw data for frequency of PIK3CA aberration in oral cancer used to generate 
Figure 1-6 
Bold text indicates amplification of chromosomal locus 3q26 (as opposed to PIK3CA) 
* indicates that both amplification of PIK3CA and chromosomal locus 3q26 were reported 
(PIK3CA amplification rate was used to generate Figure 1-6.) 
For countries with more than one value for PIK3CA mutation or amplification, an average was 
used to generate the Figure 1-6. 
 
 Amplification  Mutation  
Country No. amp Total % * No. mut Total % Ref 
Japan 3 115 2.6%  3 115 2.6% (94) 
US 14 31 45.2%  2 31 6.5% (94) 
Israel     4 37 10.8% (94) 
US     6 74 8.1% (94) 
US     3 120 2.5% (94) 
Taiwan 40 82 48.8%     (94) 
US     1 35 2.9% (94) 
Greece     0 86 0% (94) 
Spain 9 24 37.5%     (94) 
Vietnam     0 18 0% (94) 
India     2 19 10.5% (94) 
US     5 24 20.8% (94) 
UK 56 68 82.4%     (94) 
Germany 7 12 58.3%     (94) 
Germany 3 33 9.1% * 0 33 0% (94) 
Japan 6 50 12%  2 50 4% (94) 
Thailand 12 58 20.7%  6 58 10.3% (94) 
US     4 38 10.5% (94) 
Taiwan 21 25 84%     (94) 
Germany 85 280 30.4%     (94) 
Spain 43 117 36.8%     (94) 
UK 34 45 75.6%     (94) 
US 34 49 69.4%     (94) 
Germany 4 7 57.1%     (94) 
US 50 75 66.7%     (94) 
Germany 26 44 59.1%     (94) 
France 6 9 66.7% *    (94) 
Japan 29 32 90.6%     (94) 
Japan 7 11 63.6%     (94) 
Germany 26 30 86.7%     (94) 






US 10 13 76.9%     (94) 
India     2 50 4.0% (121) 
Taiwan     9 50 18% (122) 
Taiwan     58 345 16.8% (123) 
US     45 279 16.1% (124) 
India     2 50 4% (66) 
Italy     2 61 3.3% (125) 
Singapore     3 66 4.5% (104) 
Asia     5 60 8.3% (80) 
Taiwan     11 79 13.9% (103) 
Asia     5 123 4.1% (105) 
US 44 279 15.8%     (124) 
Italy 6 64 9.4%     (125) 
South Korea 7 7 100%     (126) 
India 0 50 0%     (66) 
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Chapter 2 : Differential Compensation Mechanisms Define Resistance to 
PI3K Inhibitors in PIK3CA Amplified HNSCC 2 
Abstract 
Objective: Recent sequencing studies of head and neck squamous cell carcinomas (HNSCCs) 
have identified the phosphatidylinositol 3-kinase (PI3K) pathway as the most frequently mutated, 
oncogenic pathway in this cancer type.  Despite the frequency of activating PIK3CA genomic 
alterations (the gene encoding the catalytic subunit of PI3K), targeted inhibitors of PI3K have 
not shown clinical efficacy as monotherapies.  We hypothesized that co-dependent pathways, 
including the Ras-MEK-ERK pathway, may still be functional in the presence of PI3K inhibitors 
and might serve as mediators of this resistance. 
Methods: We assessed the hypothesis using cell viability assays via resazurin and trypan blue 
exclusion assays and Western blot to characterize Ras-MEK-ERK pathway activity.   
Study Design: We evaluated this hypothesis in six PIK3CA-amplified, PI3K inhibitor-resistant 
HNSCC cell lines following treatment with pan and alpha-isoform selective PI3K inhibitors 
(BKM120 and HS-173 respectively). We also tested the effect of combination treatment with 
PI3K inhibitor HS-173 and MEK inhibitor trametinib or EGFR inhibitor gefitinib.  
 Results: Our results displayed maintenance of Ras-MEK-ERK pathway activity in 4 of 6 
HNSCC cell lines after PI3K inhibitor treatment. We also found that UM-SCC-69 and UM-SCC-
                                               
2 This chapter was published in Otorhinolaryngology-head and neck surgery and completed in collaboration with 




108 cells display synergistic responses to dual therapy with HS-173 and either trametinib or 
gefitinib.  
Conclusion: This study suggests that inhibition of the PI3K and Ras-MEK-ERK pathways might 
be effective in some HNSCC patients; however, it also prompts the study of additional resistance 






Head and neck squamous cell carcinoma (HNSCC) is the sixth most common form of 
cancer by incidence worldwide and represents ~3% of cancer cases in the United States.  Common 
modalities used to treat HNSCC patients include surgery, radiation, and cytotoxic chemotherapy.  
Despite the use of these regimens, however, patient prognosis is poor and recurrence and 
metastasis are very common.  Five year survival rates for HNSCC are only 40-50% and have 
remained unchanged for many years (Massano et al. 2006). 
 An increased understanding of the genetic alterations in HNSCC may guide the use of 
targeted therapies and improve patient survival (Ludwig et al. 2016).  Recent sequencing studies 
have identified mutations and copy number changes in genes within a number of cellular pathways 
in HNSCCs. These genetic changes may contribute to cancer development or progression, and 
learning more about them will guide personalized medicine protocols for this cancer type, which 
seek to match patients with an effective treatment option given the specific genetic signature of 
their disease (Birkeland and Brenner 2015; Birkeland et al. 2015a; Birkeland et al. 2015b; Tillman 
BN 2015).  Among the most comprehensive genetic analyses of HNSCCs is the The Cancer 
Genome Atlas (TCGA) dataset, which profiles somatic mutations and copy number alterations in 
279 HNSCC patients.  This study and others have identified the phosphatidylinositol 3-kinase 
(PI3K) pathway as the most frequently mutated, oncogenic targetable pathway in this cancer type 
(Comprehensive genomic characterization of head and neck squamous cell carcinomas  2015; Lui 
et al. 2013).  Of the genes in the PI3K pathway, PIK3CA, which encodes the catalytic subunit and 
alpha isoform of PI3K, is the most frequently altered.  Activating mutation and/or amplification 
of this gene were observed in 36.9% of the TCGA HNSCC cohort (Comprehensive genomic 




increased cell growth and viability, may drive tumor progression, and are more commonly 
observed in advanced stage disease (Isaacsson Velho et al. 2015; Osaki et al. 2004).   
Inhibitors of PI3K have been developed and tested in clinical trials for HNSCC as well as 
other cancer types.  Despite frequent activation of the PI3K pathway and its importance in HNSCC; 
however, these therapies have shown limited efficacy in unmatched clinical trials to date.  In one 
recent trial, for example, HNSCC patients were given docetaxel alone or in combination with PX-
866, an oral pan-PI3K inhibitor.  The addition of PX-866 did not improve progression free survival 
in this cohort (Jimeno et al. 2015). 
 Resistance to treatment with PI3K inhibitors is poorly understood, although some data has 
suggested that these compounds are more effective in patients with alterations in PIK3CA or loss 
of PTEN.  (PTEN is a tumor suppressor gene that acts as a “brake” on PI3K function and is 
inactivated in 10% of HNSCC patients according to TCGA data.)  While an analysis of early 
clinical trials for PI3K inhibitors showed that PI3K altered patients were more responsive to PI3K 
inhibitors than patients without PIK3CA mutation or PTEN loss, this study also indicated only an 
18% overall response rate within the PI3K altered molecular subgroup (Janku et al. 2014).  These 
findings suggest that important resistance mechanisms to PI3K inhibitors are frequently present, 
even in PI3K altered HNSCCs.  
 PI3K inhibitor resistance may be due to activation of a compensatory pathway, which cells 
utilize to grow and divide even in the absence of PI3K signaling.  The Ras-MEK-ERK pathway, 
as an important contributor to cell proliferation and growth, is a likely candidate for codependence 
in cases of PI3K inhibitor resistance.  Previous studies have demonstrated that PI3K and MEK 
inhibitors are synergistic in some HNSCCs (Mazumdar et al. 2014; Mohan et al. 2015; Wirtz et al. 




et al. 2010; Xing and Hogge 2013).  In addition, based on preclinical evidence and frequent genetic 
alterations in HNSCC, trials for pan PI3K inhibitor BKM120 and alpha-isoform specific PI3K 
inhibitor BYL719 are ongoing (examples include: NCT02537223, NCT02051751 and 
NCT01602315).  These agents are being tested in patients not only as monotherapies but also in 
combination with anti-EGFR antibody cetuximab.  Inhibiting a receptor tyrosine kinase such as 
EGFR blocks Ras-MEK-ERK signaling and has shown efficacy in other cancer models (Serra et 
al. 2011).  However, the specific patients that are responsive to mono- and combination therapies 
cannot currently be identified—each patient’s tumor has a unique genetic signature and there is 
currently a lack of useful biomarkers to stratify patients and predict responses to treatment with 
PI3K inhibitor combination therapies.  
In this study, we explore the sensitivity of several models with PIK3CA genetic alterations 
to combination therapies being considered for HNSCC personalized medicine trials. We sought to 
identify the relationships between drug sensitivity and resistance mechanisms in these models in 
order to begin to understand what percentages of patients would respond to each proposed 
combination therapy. We examined activation of the Ras-MEK-ERK pathway as a mechanism for 
resistance to PI3K inhibitors in PI3K altered HNSCC.  To do this, we tested six HNSCC cell lines, 
each of which displayed both amplification of PIK3CA and resistance to PI3K inhibitor 
monotherapy treatment, for compensation through this pathway in the presence of PI3K inhibitors.  
 
Materials and Methods 
Cell Culture 
UM-SCC cells (University of Michigan) are derived from human head and neck squamous cell 




(vol/vol) CO2 as previously described (Brenner et al. 2010). Cells were cultured in DMEM with 
10% FBS, 1X Pen/Strep, 1X NEAA. Details of DNA copy number analysis are being submitted 
as a separate manuscript. All cell lines were confirmed to contain wild type PIK3CA as 
previously reported from Nimblegen V2 exome capture based experiments (Liu et al. 2013).  
Chemicals 
BKM120, HS-173, trametinib, and gefitinib were purchased from Selleck Chemicals.  All 
compounds were initially dissolved in 100% DMSO to 10 mM and then diluted to the indicated 
concentrations for studies in vitro. 
Western Blotting 
Cells at 70-80% confluency were treated with DMSO or inhibitor(s) for six hours prior to 
harvesting and lysing in radioimmunoprecipitation assay buffer. Ten micrograms of each cell 
harvest was used, and standard Western blot protocols were followed as previously described 
(Birkeland et al. 2016). Primary antibodies against pERK1/2 (Thr202/Tyr204) (1:1000, catalog 
No. 4370; Cell Signaling Technology), ERK (1:1000, catalog No. 4695; Cell Signaling 
Technology), pAKT (Ser473) (1:1000, catalog No. 4060; Cell Signaling Technology), AKT 
(1:1000, catalog No. 4685; Cell Signaling Technology), and HSP90 (1:2000, catalog No. 4877; 
Cell Signaling Technology) were incubated overnight at 4°C or for 1 hour at room temperature, 
followed by a goat anti-rabbit horseradish peroxidase (catalog No. 111-035-045; Jackson 
ImmunoResearch) secondary antibody at room temperature for 1 hour. The blots were then 
visualized with chemiluminescence and imaged. 300dpi or greater images were retained from all 




Trypan Blue Assay 
To test for cell membrane integrity and access cell viability, 32,000 cells per well were seeded 
into 24-well cell culture plates.  After 24 hours, cells were exposed to DMSO or inhibitor in a 
multipoint dose-response.  After 72 hour exposure, cells were disaggregated in 50 uL of medium. 
10 uL of the suspension was mixed with 10 uL of trypan blue (0.4% Invitorgen) and viability and 
total cell count were measured using Countess Automated Cell Counter  (Invitrogen). 
Resazurin Assay 
To study relative cell viability, 2,000 cells per well were seeded in 384-well microplates using a 
Multiflo liquid handling dispensing system.  After 24 hours, cells were treated with inhibitor or 
DMSO in a 10-point two-fold dilution series in quadruplicate.  96-well plates were prepared with 
inhibitors in 200X concentration and then diluted to 10X concentration in media in a second 96-
well plate using the Agilent Bravo Automated Liquid Handling Platform and VWorks 
Automation Control Software.  These inhibitors were then used to treat the cells with the desired 
compound concentration, again using liquid handling robotics.  Cells were stained with resazurin 
(Sigma) in PBS for 12-24 hours before fluorescent signal intensity was quantified.  
Quantification occured 72 hours after treatment using the Cytation3 fluorescence plate reader at 
excitation and emission wavelengths of 540 and 612 nM, respectively. 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 6 software.  Unpaired, two-tailed 
Student’s t-tests were conducted to compare total cell counts following DMSO and 1 µM 
trametinib treatment from trypan blue exclusion assays with p<0.05 considered statistically 
significant.  For resazurin assays, IC50 values were determined from the mean and standard 






PIK3CA Alteration in HNSCC Cell Lines 
We first identified a panel of cell lines that displayed amplification of PIK3CA to comprise our 
HNSCC panel.  Copy number amplification for the six cell lines ranged from 2.67 to 6, with 
UM-SCC-69 and -108 exhibiting the highest level of amplification with 6 and 4 copies of 
PIK3CA, respectively.  UM-SCC-47 and -14A had lower levels of PIK3CA amplification, each 
with 2.67 copies of the gene as shown in Figure 2-1A.  None of the six cell lines displayed 
mutations in PIK3CA (Liu et al. 2013).  
PIK3CA Amplified HNSCC Sensitivity to PI3K Inhibitors 
 To then determine the sensitivity of the PIK3CA amplified HNSCC cell lines in our panel 
to PI3K inhibition, we used a resazurin cell viability assay to determine the IC50 value for each 
cell line in response to alpha-isoform specific PI3K inhibitor HS-173 and the pan PI3K inhibitor 
BKM120.  We identified similar sensitivity to these agents, consistent with common alterations in 
PIK3CA and the important role of the alpha isoform in HNSCC.  UM-SCC-1 cells were the most 
sensitive, with IC50 less than 1 µM for both inhibitors.  UM-SCC-108 displayed the greatest 
resistance to a PI3K inhibitor, with an IC50 close to 25 µM for HS-173 (Figure 2-1, Figure 2-2). 
Despite the moderate responses to these treatments, IC50 values of these magnitudes are indicative 
of at least partial PI3K inhibitor resistance, suggesting the opportunity to assess combination 




PI3K inhibitor resistant HNSCC cell lines display differential activation of the Ras-MEK-ERK 
pathway 
Thus, to learn more about the mechanisms of resistance of PI3K inhibitors in HNSCC, we 
first examined the activation of downstream PI3K and Ras-MEK-ERK pathway members after 
PI3K inhibitor treatment in each of the cell lines in our panel.  We hypothesized that Ras-MEK-
ERK pathway activity would be maintained if the pathway represents an important compensatory 
mechanism.  We treated each cell line with 5 µM HS-173 or BKM120 and used Western blotting 
to assess phosphorylated and total levels of Akt and ERK (Figure 2-1B-G).  In each cell line, Akt 
phosphorylation was reduced after treatment with HS-173 or BKM120, consistent with the effect 
of these drugs on downstream members of the PI3K pathway.  In the UM-SCC-1 and UM-SCC-
47 cells, phosphorylation of ERK was also reduced by 5 µM PI3K inhibitor treatment (Figure 2-1B, 
C).  In the other four cell lines, ERK phosphorylation was maintained (Figure 2-1D-G).  This 
maintenance of Ras-MEK-ERK pathway activity suggests that this pathway may be a co-
dependent with the PI3K pathway in the UM-SCC-14A, 69, 92, and 108 cells. 
Potential Synergy of PI3K and MEK Inhibitors in HNSCC 
 To explore the hypothesis that MEK signaling maintains viability in the presence of 
PIK3CA inhibition in some models, we then tested the combination of PI3K inhibitor HS-173 and 
MEK inhibitor trametinib in the panel of HNSCC cells.  If Ras-MEK-ERK pathway activation is 
a mechanism of resistance to PI3K inhibitor treatment, adding trametinib as a second inhibitor 
might sensitize the cells to the inhibitors and result in a synergistic reduction in cell viability.  
Using a resazurin cell viability assay, we observed at least additive effects of these two agents in 
UM-SCC-69 and UM-SCC-108 cells (Figure 2-3).   Lack of benefit from the combination with 




downstream Ras-MEK-ERK pathway activity, as 5 µM treatment resulted in complete inhibition 
of ERK phosphorylation via Western blotting (Figure 2-3, insets).  We also performed trypan blue 
exclusion assays to examine the effect of this drug concentration on absolute cell viability in the 
two cell lines in which PI3K and MEK inhibitors displayed at least additive effects (Figure 2-4). 
Trypan blue dye assays demonstrated that while trametinib monotherapy inhibited cell 
proliferation, it did not reduce cell viability (p<0.05).  Combining PI3K and MEK inhibitors led 
to further reductions in cell viability. 
Potential Synergy of PI3K and EGFR Inhibitors in HNSCC 
Ras-MEK-ERK pathway activity can also be inhibited more broadly using an agent 
targeted against a receptor tyrosine kinase such as the epidermal growth factor receptor (EGFR).  
EGFR is frequently amplified in HNSCC and cetuximab, a monoclonal EGFR antibody is the only 
FDA-approved targeted therapy for this cancer type and several trials are exploring this 
combination clinically.  We hypothesized that blocking EGFR and the downstream Ras-MEK-
ERK pathway in combination with PI3K might be a more effective treatment than using a PI3K 
and MEK inhibitor combination in some models.  To explore this possibility, we treated the cell 
lines displaying Ras-MEK-ERK pathway activity after PI3K inhibitor treatment (UM-SCC-14A, 
69, 92, and 108) with HS-173 in combination with gefitinib, a small molecule inhibitor of EGFR.  
Results of a resazurin cell viability assay for HS-173 in combination with gefitinib again indicated 
potential synergy in UM-SCC-69 and UM-SCC-108, but not UM-SCC-14A and UM-SCC-92 
(Figure 2-5).  We also treated these four cell lines with vehicle, 1 µM gefitnib, 1 µM HS-173, or a 
combination of the inhibitors at 1 µM each.  Western blot analysis of each cell line indicated that 
ERK phosphorylation was reduced by gefitinib treatment and Akt phosphorylation was reduced 




downstream members of the Ras-MEK-ERK and PI3K pathways, respectively.  Treatment with 
both drugs led to decreased phosphorylation of both ERK and Akt, indicating that this combination 
caused the inhibition of expected targets (Figure 2-6). 
 
Discussion  
 In summary, our PIK3CA amplified HNSCC cell lines show intermediate to strong 
resistance to PI3K inhibitors suggesting that matched PI3K targeted therapies may not be 
effective as monotherapies in this cancer type.  While some of the more sensitive UM-SCC cell 
lines in our panel display similar sensitivity to PI3K inhibitors as compared to PIK3CA mutant or 
PTEN deleted cancer cell lines with IC50 of approximately 1 µM (Koul et al. 2012; Mueller et al. 
2012), other resistant models (particularly UM-SCC-92) have IC50 values closer those of 
fibroblast cells.  This data is consistent with a phase 1/2 study of PX-866 and docetaxel in 
patients with solid tumors (NCT01204099), in which only a few HNSCC patients with PIK3CA 
amplification responded to the monotherapy despite pharmacodynamics experiments showing on 
target effect of the drug (Jimeno et al. 2015). As many groups have postulated that compensation 
occurs through either EGFR signaling or directly though alternative pathways activating Ras-
MEK-ERK signaling, we also assessed response to dual inhibitor therapies targeting PIK3CA 
and EGFR or MEK/ERK signaling. These experiments showed 2/6 (33%) of the cell lines 
displayed additive to synergistic effects of alpha-isoform specific PI3K inhibitor HS-173 and 
MEK inhibitor trametinib or EGFR inhibitor gefitinib; there was no benefit of the addition of the 
Ras-MEK-ERK inhibitor in the other models. This data is promising and supports the preclinical 
data for combination trials simultaneously inhibiting both of these pathways (Mazumdar et al. 




response in a subset of tumors, but also suggests that additional unknown compensatory 
mechanisms are driving PIK3CA inhibitor resistance in other HNSCCs.    
Thus, the data presented here suggest that multiple different pathways drive PI3K inhibitor 
resistance and additional work is needed to understand the frequencies with which each pathway 
is utilized and the biomarkers predicting which combination therapy would most benefit individual 
patients. While we didn’t fully assess all combinations that have been suggested in the literature, 
our data provides the foundation for future studies in HNSCC that leverage unbiased approaches. 
Further testing of additional HNSCC cell lines, might identify other PIK3CA amplified models 
with more significant responses to PI3K monotherapy or to combinations that are advancing in 
clinical trials. Likewise, systematic discovery based approaches to identify novel combinations 
that inhibit the growth of models resistant to both the Ras-MEK-ERK + PI3K and EGFR + PI3K 
therapies are needed to understand the additional pathways driving resistance.  These studies might 
also improve cell kill in an even more complex therapeutic setting (e.g. tri-therapy or cycled di-
therapies). For example, exploring other PIK3CA amplified or mutated HNSCC models might 
allow us to stratify responses based on additional genetic alterations in the PI3K, Ras-MEK-ERK, 
and other cellular pathways. We could then assess genetics biomarkers (personalized medicine) to 
predict which patients might be most and least sensitive to a specific PI3K-based combination 
regimen.  Indeed, focusing on developing therapies for the most highly recurrent compensatory 
pathways may be one approach to improving therapy.   
We have entered an exciting time in the HNSCC field. Several institutions have initiated 
personalized medicine protocols, such as the MiOTOseq trial, which aim to characterize the 
molecular genetics of every consenting HNSCC patient that enters the clinic. These studies are 




enrollment of HNSCC patients on appropriate interventional trials. As noted above, personalized 
trials have increased the overall survival of patients with HNSCC (Chau et al. 2016; Tsimberidou 
et al. 2014), but the overall rates of improvement have been underwhelming. As the field moves 
forward, we need to begin to understand how HNSCCs respond to matched targeted therapies in 
order to take the next step towards improving overall response. Here, we focused on understanding 
the combinations of resistance pathways to inhibitors of the most recurrently altered oncogenic 
pathway in HNSCC. Our data indicates a complex and differential response to matched therapy; 
it also suggests the value of future work utilizing unbiased approaches to nominate co-dependent 
pathways driving this resistance.  Developing an improved understanding of resistance to matched 
therapies in HNSCC as well as the frequencies with which each resistance mechanism is observed 
represents one key step to improving the overall survival of patients enrolling in personalized 






Figure 2-1. Cell viability and Ras-MEK-ERK activity in response to PI3K inhibition.  
IC50 via resazurin assay (A) and Western blot analysis of PI3K and Ras-MEK-ERK pathway 
activation in UM-SCC-1 (B), 47 (C), 14A (D), 69 (E), 92 (F), and 108 (G) following treatment 





Figure 2-2. Concentration response curves after PI3K inhibitor treatments in HNSCC cell 
lines and fibroblasts. 
Cell viability for UM-SCC-1, 47, 14A, 69, 92, 108 and fibroblasts after 72 hour treatment with 
increasing concentrations of PI3K inhibitors BKM120 (A) and HS-173 (B), as measured using a 





Figure 2-3. Cell viability responses to co-treatment with HS-173 and trametinib via 
resaurin assays. 
Cell viability via resazurin assay and Ras-MEK-ERK pathway activation via Western blot 
analysis (insets) for UM-SCC-1 (A), 47 (B), 14A (C), 69 (D), 92 (E), and 108 (F) after treatment 





Figure 2-4. Cell viability responses to co-treatment with HS-173 and trametinib via trypan 
blue exclusion assays. 
Live and total UM-SCC-69 (A) and UM-SCC-108 (B) cells after 72 hour treatment with 







Figure 2-5. Cell viability responses to co-treatment with HS-173 and gefitinib via resaurin 
assays. 
Cell viability for UM-SCC-14A (A), -69 (B), -92 (C), and -108 (D) after 72 hour treatment with 






Figure 2-6. Western blot analysis following co-treatment with HS-173 and gefitinib. 
Western blot analysis of downstream PI3K and RAS-MEK-ERK pathway activation in UM-
SCC-14A (A), -69 (B), -92 (C), and -108 (D) following 6 hour treatment with 1 µM gefitinib 
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Chapter 3 : Rationale for Using Irreversible EGFR Inhibitors in Combination 
with PI3K Inhibitors for Advanced Head and Neck Squamous Cell 
Carcinoma3 
Abstract 
Head and neck squamous cell carcinoma (HNSCC) is a common and debilitating form of cancer 
characterized by poor patient outcomes and low survival rates. In HNSCC, genetic aberrations in 
PI3K and EGFR pathway genes are common, and small molecules targeting these pathways have 
shown modest effects as monotherapies in patients.  While emerging preclinical data support the 
combined use of PI3K and EGFR inhibitors in HNSCC, in-human studies have displayed limited 
clinical success so far.  Here, we examined the responses of a large panel of patient-derived 
HNSCC cell lines to various combinations of PI3K and EGFR inhibitors, including EGFR agents 
with varying specificity and mechanistic characteristics.  We confirmed the efficacy of PI3K and 
EGFR combination therapies, observing synergy with alpha isoform selective PI3K inhibitor HS-
173 and irreversible EGFR/ERBB2 dual inhibitor afatinib in the majority of models tested.  
Surprisingly, however, our results demonstrated only modest improvement in response to HS-
173 with reversible EGFR inhibitor gefitinib.  This difference in efficacy was not explained by 
differences in ERBB target selectivity between afatinib and gefitinib; despite effectively 
disrupting ERBB2 phosphorylation, the addition of ERBB2 inhibitor CP-724714 failed to 
                                               
3 This chapter was published in Molecular Pharmacology and completed in collaboration with the following 
authors: Elizabeth Leonard, Chloe Matovina, Micah Harris, Gabrielle Herbst, Aditi Kulkarni, Jingyi Zhai, Hui Jiang, 




enhance the effect of HS-173 gefitinib dual-therapy.  Accordingly, while irreversible ERBB 
inhibitors showed strong synergistic activity with HS-173 in our models, we observed that none 
of the reversible ERBB inhibitors were synergistic.  Therefore, our results suggest that the ERBB 
inhibitor mechanism of action may be critical for enhanced synergy with PI3K inhibitors in 
HNSCC patients and motivate further preclinical studies for ERBB and PI3K combination 
therapies. 
Introduction 
Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common 
form of cancer by incidence worldwide and is often associated with either high alcohol and 
tobacco use or infection with high-risk human papilloma virus (HPV) (1, 2). The disease has 5-
year survival rates of less than 50% for HPV negative tumors and around 80% for HPV positive 
tumors, and we believe that overall survival for patients will be improved by advancing novel 
therapeutic approaches that target aberrations common to different subsets of HNSCC tumors (3, 
4). Furthermore, the development of effective rational combination therapies may be critical for 
overcoming common resistance mechanisms that emerge following targeted monotherapy. We 
believe this approach may have utility for both adapting clinical paradigms with 
adjuvant/neoadjuvant agents as well as advancing personalized medicine approaches through the 
development of rational combination therapies for the most prominent molecular alterations in 
HNSCC.  
Of the potential targetable molecular alterations common to HNSCC, the 
phosphoinositide-3 kinase (PI3K) pathway is disrupted through genomic amplifications or 
activating point mutations in >30% of tumors (5-8) and the epidermal growth factor receptor 




already been advanced individually in HNSCC. For example, in a recent phase II trial, pan-PI3K 
inhibitor BKM120 (buparlisib) with paclitaxel improved survival as compared to paclitaxel and 
placebo in recurrent and metastatic HNSCC patients (10), and EGFR antibody cetuximab is 
currently in clinical use after demonstrating improved outcomes in combination with 
radiotherapy or cisplatin (11, 12). Thus, while PI3K and EGFR targeting therapies have been 
used with some clinical success, response rates are still relatively low and innate or acquired 
resistance mechanisms appear to be widespread (8, 10-14).  
Preclinical data indicate that dual-therapies directed against both PI3K and EGFR 
pathways might improve responses in HNSCC (8, 15-20). Given these promising data, several 
clinical trials assessing the combination have been opened in HNSCC, most of which use the 
EGFR targeting antibody cetuximab in combination with various inhibitors of PI3K (e.g. 
NCT01816984, NCT2282371, NCT02822482). Unfortunately, however, one recently completed 
study showed no significant improvement in patient survival with the addition of pan-PI3K 
inhibitor PX-866 to cetuximab (21). These surprising data suggested that a deeper understanding 
of the molecular mechanisms of action that drive response to PI3K and EGFR therapies is 
necessary to fully interpret the results of these trials. 
Here, due to the early reported disparity between in vitro and clinical trial results, we 
conducted further studies characterizing the responses to various classes of PI3K and EGFR dual 
therapies in HNSCC. We used a panel of genetically diverse HNSCC cell lines to examine 
responses to combinations of PI3K and EGFR inhibitors; in doing so, we sought to assess 
patterns of response that might translate to future clinical trial design and/or serve as a guide for 





Materials and Methods 
Cell Culture 
Cells were cultured in a humidified incubator at 37°C with 5% (vol/vol) CO2. UM-SCC 
cells (University of Michigan) and Cal-33 cells (a kind gift from Dr. Anthony Nichols) were 
previously derived from HNSCC patient tumor samples and cultured in DMEM with 10% FBS, 
1X Pen/Strep, 1X NEAA (22). HSC-2, HSC-4 (both from Japanese Collection of Research 
Bioresources through Sekisui XenoTech, Kansas City, KS) and Detroit 562 (American Type 
Culture Collection, Manassas, VA) cells were cultured in EMEM with 10% FBS, 1X Pen/Strep.  
All cell lines were genotyped to confirm authenticity and were mycoplasma negative. 
Details of DNA copy number analysis are published elsewhere (23). All UM-SCC cell 
lines were confirmed to contain PIK3CA as previously reported from Nimblegen V2 exome 
capture based experiments (24).  Cal-33, HSC-2 and HSC-4 copy number data were obtained 
from the publicly available canSAR database (25, 26).  EGFR mutation status and/or copy 
number was similarly assessed using data from Nimblegen V2 exome capture based experiments 
(24) for UM-SCC cell lines, the canSAR database for HSC-2, HSC-4, and Cal-33 (25, 26), and 
previously published work for Detroit 562 (20). 
Genomic DNA Purification 
Cells from models with PIK3CA mutations (Cal-33, HSC-2, HSC-4, Detroit 562, UM-SCC-43, 
UM-SCC-19, UM-SCC-85) were harvested and washed in PBS, then frozen at -20°C.  The 
thawed cell pellet was re-suspended in 700 µL of Nuclei Lysis Solution (Promega, Madison, WI) 
for one hour at 55°C.  Then, 200 µL of Protein Precipitation Solution (Promega) was added to 
the sample, which was mixed and placed on ice for at least five minutes before being centrifuged 




600 µL of isopropanol and centrifuged at 13,000 RPM for one minute.  After aspirating the 
resulting supernatant, the DNA pellet was washed in 200 µL of 70% ethanol, dried, and re-
suspended in 30-50 µL of nuclease-free water. 
Sanger Sequencing 
Genomic DNA was amplified using PCR with Platinum Taq DNA Polymerase High Fidelity 
(Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions, and the primers with 
sequences listed in Figure 3-1.  After being inserted into the pCR8 vector system or processed 
using the Qiagen QIAquick PCR purification kit, PCR products were submitted for Sanger 
sequencing at the University of Michigan DNA Sequencing Core on the 3730XL DNA 
Sequencer (Applied Biosystems, Foster City, CA) as described elsewhere (27).  Sequences were 
aligned using the DNASTAR Lasergene software suite. 
Chemicals 
All compounds (BYL719, HS-173, BKM120, afatinib, gefitinib, erlotinib, BMS-599626, 
AEE788, TAK-285, CUDC-101, and dacomitinib) were purchased from Selleck Chemicals 
(Houston, TX).  Each inhibitor was initially dissolved in 100% sterile dimethyl sulfoxide 
(DMSO) to 10 mM and then diluted in media to the indicated concentrations for studies in vitro.  
Table 3-1 gives the chemical name for each inhibitor used here. 
Resazurin Cell Viability Assay 
Resazurin cell viability assays were performed as described previously (8, 28, 29). To study 
relative cell viability, 2,000 cells per well (for all cell lines except HSC-2, for which the cell 
density was reduced to 1,000 cells per well due to large cell size and rapid growth rate) were 
seeded (in 50 µL volume) in 384-well microplates using a Biotek (Winooski, VT) Multiflo liquid 




Inhibitors were prepared by hand from 10 mM stocks at 200X concentration in a 96 well plate, 
then diluted 10X concentration in media in a second 96-well plate using the Agilent (Santa Clara, 
CA) Bravo Automated Liquid Handling Platform and VWorks Automation Control Software.  
The intermediate plate with inhibitors in media was used to treat the cells with the desired 
compound concentration, again using liquid handling robotics, such that cells were treated with 
complete media containing 0.5% inhibitor or DMSO in a 10-point two-fold dilution series.  Each 
treatment was administered in quadruplicate. Cells were stained with 10 μL of 440 μM resazurin 
(Sigma, St Louis, MO) dissolved in serum-free media for 12-24 hours before fluorescent signal 
intensity was quantified. Quantification occurred after 72 hour treatment using the Biotek 
Cytation3 fluorescence plate reader at excitation and emission wavelengths of 540 and 612 nm, 
respectively.  Data were plotted using Prism 7 and fit with concentration response curves using 
the log(inhibitor) vs. response -- Variable slope model with four parameters (IC50, top, bottom, 
and Hill slope) allowed to vary.   
Annexin V Apoptosis Assay 
To study Annexin V presentation, 115,000 Detroit 562 cells or 100,000 UM-SCC-59 cells per 
well were seeded in six-well plates.  After 24 hours, media was aspirated and replaced with 3 mL 
of fresh, complete media.  1 mL of media containing DMSO or inhibitor(s) was added to each 
well.  Cells were cultured for 72 hours, at which time, media was collected from each well.  Each 
well was then washed in PBS, which was also collected.  Finally, cells were trypsinized and 
added to the suspension.  Samples were then centrifuged, washed once with PBS, and counted 
using the Countess Automated Cell Counter (Invitrogen).  100,000 cells per sample were stained 
with Annexin V FITC and PI using the Dead Cell Apoptosis Kit (ThermoFisher, Waltman, MA) 




each sample.  Samples were incubated at room temperature in the dark for 15 minutes and 
analyzed using the Bio-Rad ZE5 or MoFlo Astrios EQ Cell Sorter at the University of Michigan 
Flow Cytometry Core.  
Western Blotting 
Cells at 70-80% confluency were treated with DMSO or inhibitor prior to harvesting and lysing 
in radioimmunoprecipitation assay buffer (catalog No. 89900; ThermoFisher) containing 1% NP-
40 and 0.1% SDS. 8-20 micrograms of each cell harvest were used, and standard Western blot 
protocols were followed as previously described (30). Primary antibodies (described in detail in 
Table 3-2) were incubated overnight at 4°C or for at least one hour at room temperature, 
followed by a goat anti-rabbit horseradish peroxidase (catalog No. 111-035-045; Jackson 
ImmunoResearch, West Grove, PA) secondary antibody at room temperature for one hour as 
described elsewhere (31). The blots were then visualized with chemiluminescence and imaged. 
300dpi or greater images were digitally retained from all Westerns and representative blots are 
shown.  ImageJ software was used to quantify protein expression and compare treatment 
responses. 
Synergy Analysis 
The effects of combination treatments were analyzed with Combenefit software (32) using the 
highest single agent (HSA) model (33-37).  For each cell line and pair of inhibitors, the number 
of concentration combinations with scores greater than 20 were counted.  These counts were 
averaged across at least two (and as many as five) independent replicates for each experiment.  
Experiments having more than eight concentration combinations with scores greater than 20 
were considered additive or synergistic.  We compared the number of concentration 




as HS-173 and gefitinib (gefitinib combination score).  Cell lines were considered more 
responsive to the afatinib combination if the afatinib combination score exceeded the gefitinib 
combination score by eight or more. 
Statistical Analysis  
To determine if statistically significant differences occurred with combination treatments, a two-
way ANOVA was performed in R to compare the natural logarithm of the percentage of living 
cells following vehicle, HS-173, gefitinib or afatinib, or combination treatment. Specifically, this 
test was performed using type III analysis with the “Anova” function from the “car” package.  The 
interaction between HS-173 and gefitinib or afatinib treatment indication was tested by F-test for 
the synergy effect of drug combination. In total, four separate tests on drug combination (HS-173 
combined with gefitinib or afatinib for UM-SCC-59 and Detroit 562 cell lines) were performed 
simultaneously, so Bonferroni correction was used to adjust p-values. 
 
Results 
Subsets of HNSCCs Respond to PI3K + EGFR Inhibitor Combination Therapies 
To first probe the co-dependence of HNSCC cell lines to PI3K and EGFR pathway 
inhibitors, we compared the response of a small panel of models to the PI3Ka inhibitor HS-173 
(38, 39) and irreversible pan-EGFR/ERBB2 inhibitor afatinib (40) as monotherapies and in 
combination.  We selected HS-173 as the PI3K inhibitor as it was the most effective and isoform 
selective small molecule in our panel of cell lines.  Afatinib was used as the ERBB inhibitor; this 
drug was approved by the FDA in 2016 as a first-line treatment for patients with non-small cell 
lung cancer whose tumors harbored mutations in EGFR.  It has also displayed efficacy in 




(NCT01824823, NCT01415674, NCT01427478, NCT02979977). PI3K and ERBB inhibitor 
combination experiments were performed in four models with PIK3CA mutations (HSC-2, HSC-
4, Detroit 562 and Cal-33, Figure 3-1) and one with high-level PIK3CA amplification (UM-
SCC-59, 5 wild type copies) using a resazurin cell viability assay after 72 hour drug treatment 
and then validated by annexin V apoptosis assay (below).  Our studies showed variable 
responses by cell line.  
HSC-2, HSC-4 and Detroit 562 display a hotspot PIK3CA mutation (indicating activation 
of and likely dependence on the PI3K signaling pathway) but have limited responses to HS-173 
and other PI3K inhibitors as monotherapies with IC50 close to or exceeding 1 µM.  In these three 
cell lines, we observed that the addition of afatinib to HS-173 resulted in dose-dependent 
improvements in the efficacy of PI3K inhibition (Figure 3-2A-C). These results represented 
drug synergy using the HSA model.  This effect was also observed when pan-PI3K inhibitor 
BKM120 and another PI3Ka inhibitor, BYL719, were titrated with afatinib (Figure 3-3A-B), 
but not when p110b inhibitor TGX-221 was tested in combination (Figure 3-3C) suggesting that 
the synergistic dose combination response specifically requires inhibition of PI3Ka.  Similarly, 
titrating afatinib into constant concentrations of HS-173 or BKM120 resulted in synergistic 
responses in combination-responsive PIK3CA mutant cell lines HSC-4 and Detroit 562 (Figure 
3-4).  In contrast, the data also demonstrated that one of the PIK3CA mutant HNSCC cell lines, 
Cal-33, as well as the PIK3CA amplified cell line, UM-SCC-59, showed little combination 
benefit (Figure 3-2D-E), suggesting that these models depend on alternative survival pathways.  
 After establishing that subsets of HNSCCs responded synergistically to HS-173 and 
afatinib, we examined the downstream signals in the PI3K and EGFR pathways in order to 




responsive models (HSC-2 and Detroit 562) and one combination non-responsive model (Cal-
33). Thus, following a 6-hour treatment with vehicle (DMSO), HS-173 monotherapy, afatinib 
monotherapy, or HS-173 and afatinib combination therapy, we evaluated EGFR and ERBB2 
phosphorylation as well as effector signaling through AKT, MEK and ERK (Figure 3-5).  As 
expected, afatinib monotherapy was sufficient to inhibit EGFR and ERBB2 phosphorylation.  
While the degree to which afatinib reduced ERBB2 phosphorylation in lysates from treated 
Detroit 562 cells was fairly minimal here, more robust effects on ERBB2 phosphorylation are 
visible after shorter treatment times (likely due to transient effects on receptor phosphorylation, 
see Figure 3-8C below). Downstream of these effects on EGFR and ERBB2 signaling, ERK and 
MEK phosphorylation are similarly decreased in non-responsive Cal-33 and responsive HSC-2 
cell lines.  Detroit 562 cells display minimal changes in MEK phosphorylation following 
treatment at this dose and time point, yet ERK phosphorylation is reduced somewhat.  AKT 
phosphorylation, used as a readout of primarily PI3K but also EGFR pathway activity, was 
reduced in HS-173 monotherapy treated samples in each cell line.  In the responsive HSC-2 cell 
line, a further reduction in AKT phosphorylation was evidenced with the addition of afatinib to 
HS-173.  Thus, in both non-responsive and responsive models, inhibition of PI3K’s downstream 
signaling through AKT and inhibition of ERBB signaling both at the receptor level and 
downstream through MEK and ERK was achieved (Figure 3-5).  This indicates that the 
combination effect was not limited to models with reductions in effector signaling.   
Responses to PI3K + EGFR Inhibition Vary Based on Inhibitor Type 
 We further investigated the role of ERBB inhibition in HS-173 and afatinib combination 
response by testing PI3Ka inhibitor HS-173 in combination with reversible EGFR inhibitor 




viability experiments performed as above displayed a much less marked effect with HS-173 and 
gefitinib as compared to co-treatment with HS-173 and afatinib (Figure 3-6A-B).  These effects 
were confirmed using an orthogonal annexin V apoptosis assay. For example, in the Detroit 562 
cell line (synergistically responsive to HS-173 and afatinib), we observed higher levels of FITC 
positive (apoptotic) cells following di-therapy compared to what would be expected from 
additive effects of HS-173 and afatinib monotherapies (adjusted p-value = 0.009, two-way 
ANOVA).  Importantly, no significant change in cell death was seen in the non-synergistically 
responsive UM-SCC-59 model (adjusted p-value = 1, two-way ANOVA), and HS-173 
combinations with gefitinib were ineffective in both cell lines (adjusted p-values = 1, two-way 
ANOVA) (Figure 3-7).  These data suggested a significant difference in the ability of gefitinib 
and afatinib to induce synergistic cell kill in our models.  
 Given this surprising observation, we expanded our original analyses on 5 cell lines to a 
larger panel of HNSCC models.  Here, we selected an additional nine models with genetic 
characteristics of tumors most likely to receive PI3K or EGFR inhibitors in a precision medicine 
setting, including those with either PIK3CA mutations or high-level gene amplifications (greater 
than four copies).  As evidence of this, additivity between HS-173 and gefitinib was only 
observed in 4/14 (29%) of models.  
Importantly, much more significant “further benefit,” which we define as including 
multiple synergistic dose combinations, was observed with HS-173 and afatinib combination 
therapy in 8/14 (57%) of models (Figure 3-8A). Of the four models that demonstrated additivity 
with gefitinib, three received further benefit with afatinib. The in vitro models that failed to 
display robust improvements in response to HS-173 with the addition of afatinib included Cal-33 




(Figure 3-8A).  Interestingly, Cal-33, UM-SCC-19, UM-SCC-43, and UM-SCC-85, like some of 
the combination-responsive models discussed above, display activating mutations in PIK3CA 
(Figure 3-1). Cal-33 and UM-SCC-85 cells were among the most sensitive to PI3K inhibitor 
monotherapies, while UM-SCC-59 (with high-level amplification of wild-type PIK3CA) is one 
of the most resistant.  Thus, neither PIK3CA mutation nor responsiveness to PI3K inhibitor 
monotherapy is a good predictor of responsiveness to HS-173 and afatinib co-treatment.  
Likewise, at least when considered as single variables, PIK3CA copy number (Figure 3-8A), 
EGFR copy number (Figure 3-8A), and ERBB protein expression (Figure 3-8B) are also poor 
indicators of combination response. Although mutations in EGFR have been shown to be closely 
linked to responses to EGFR inhibitors (41-46), the cell lines used here did not display such 
variants.  Thus, neither sensitivity nor resistance to EGFR inhibitor monotherapies or 
combination therapies can be explained by the presence of L858R or T790M/C797S mutations, 
respectively. After our resazurin assay determined that the HS-173 and gefitinib combination 
was largely ineffective as compared to HS-173 and afatinib, we tested the combination of HS-
173 and afatinib in UM-SCC-110 and patient-matched fibroblasts and demonstrated the inability 
of combination therapy to drive cell death in normal fibroblasts (Figure 3-9).  
Together, these data strongly suggest important differences between afatinib- and 
gefitinib-based combinations in our model system.  Given the differences between the inhibitors, 
we hypothesized that the greater effectiveness with afatinib over gefitinib may be due to 1) a 
broader spectrum of ERBB family member inhibition, and/or 2) irreversible as opposed to 
reversible inhibition of EGFR. To begin testing this hypothesis using combination responsive 
Detroit 562 cells, we performed a resazurin cell viability assay in which we compared the effects 




This demonstrated that CP-724714 was unable to add to HS-173 and gefitinib in this assay and 
the total effect of this tri-therapy combination remained much less substantial than the effect of 
HS-173 and afatinib.  This result suggested the possibility that ERBB2 inhibition did not account 
for the differences between inhibitors or that CP-724714 could not sufficiently inhibit ERBB2 
signaling in our system. 
 Consequently, to validate that the doses of CP-724714 used here could sufficiently inhibit 
ERBB2 signaling, we performed Western blot analysis on lysates harvested from Detroit 562 
cells following CP-724714 or afatinib treatment.  At doses equivalent to or less than those used 
in resazurin cell viability assays, we observed that both CP-724714 and afatinib treatment 
resulted in robust inhibition of ERBB2 phosphorylation after 15 or 60 minutes (Figure 3-6B).  
We also examined lysates from HSC-2 cells following 2 hour treatment with each mono- or di-
therapy (Figure 3-6C).  This demonstrated decreased EGFR phosphorylation in gefitinib and 
afatinib treated samples, with a slightly greater loss of EGFR phosphorylation with afatinib than 
gefitinib.  Phosphorylation of ERK, GAB1, and MEK, downstream of EGFR, were similar for 
gefitinib and afatinib treatments; in addition, co-treatment with HS-173 and gefitinib or afatinib 
did not reduce downstream ERBB signals beyond those levels seen with gefitinib and afatinib 
monotherapy treatments.  Phosphorylation of PI3K pathway effector AKT was appropriately 
inhibited upon HS-173 treatment, but PDK1 and GSK3b phosphorylation remained unchanged.  
Together, these data suggest that ERBB2 inhibition alone may not be sufficient to explain 
differences between the gefitinib and afatinib combinations and therefore warrant further 
evaluation of differences between reversible and irreversible ERBB inhibitor combinations.   
 Thus, using a resazurin cell viability assay, we tested HS-173 in combination with three 




ERBB targeting agents (TAK285, CUDC-101, and dacomitinib) in HSC-2 and Detroit 562 cells.  
While we observed that 0/4 (0%) reversible ERBB inhibitors displayed synergistic dose 
combinations in either cell line, 3/4 (75%) and 4/4 (100%) irreversible ERBB targeting drugs 
had synergistic dose combinations with HS-173 in Detroit 562 and HSC-2 cells, respectively 
(Table 3-3, Figure 3-10). These data add support to the hypothesis that irreversible inhibition of 
EGFR and/or its ERBB family members may be important for achieving the most significant 
growth inhibition with PI3K and ERBB inhibitor combinations.   
Discussion  
Our data are consistent with previous studies showing the benefit of PI3K and EGFR 
inhibitor combination therapies (8, 15-20) and also extend that work by discovering that PI3K 
inhibitors are much more effective in combination with irreversible than reversible EGFR 
inhibitors in HNSCC.  In prior work comparing classes of EGFR targeting monotherapies in this 
cancer type, preclinical data demonstrated that irreversible EGFR inhibitors are superior to other 
EGFR targeting agents, including cetuximab (16, 47) and reversible inhibitor gefitinib (48). 
Similarly, previous work has shown that the addition of ERBB2 targeting antibodies pertuzumab 
(49) or trastuzumab (50) to gefitinib enhances its efficacy in HNSCC cell lines; however, our 
findings demonstrated that the broader specificity of irreversible inhibitors alone cannot explain 
these differences in sensitivity, as administering ERBB2 inhibitor CP-724714 with gefitinib and 
HS-173 did not enhance drug effects (Figure 3-6). Collectively, our data may suggest why 
greater improvements in patient survival following PI3K and EGFR combination therapies have 
not yet been observed in HNSCC and other cancers clinically and support the need for additional 




Of the published HNSCC studies evaluating PI3K and EGFR di-therapies, most have 
been performed with either cetuximab (15, 18, 19) or the reversible EGFR inhibitors (e.g. 
gefitinib, erlotinib) (17, 20). One exception is a recent report from Silva-Oliveira et al. that 
examined responses to PI3K pathway inhibitors (including AKT inhibitor MK-2206) with two 
different irreversible EGFR inhibitors (16).  In this study, pharmacologic inhibition or siRNA 
knockdown of AKT resulted in improved sensitivity to afatinib and allitinib (a second 
irreversible EGFR inhibitor) in HN13 cells (16).  The need to suppress AKT phosphorylation in 
responses to PI3K + EGFR drug combinations is supported by studies of both EGFR targeting 
antibodies (18, 51) and reversible inhibitors (16, 18, 20, 51). Importantly, in lung cancer models, 
irreversible EGFR inhibitors have sustained reductions in EGFR phosphorylation and an 
improved ability to decrease effector AKT phosphorylation as compared to reversible inhibitors 
(52). The inability of reversible EGFR inhibitors to sustain suppression of EGFR and AKT 
phosphorylation has been linked to altered receptor trafficking (53), a mechanism that does not 
affect the activity of irreversible inhibitors. In contrast, we did not observe greater reductions in 
AKT phosphorylation with HS-173 and afatinib than with gefitinib dual-therapy (Figure 3-6C). 
These data suggest that factors other than or in addition to the level of suppression of 
downstream EGFR effector signaling may be responsible for mediating combination benefit 
and/or that specific inhibitor combinations may be required to achieve synergistic cell death 
responses.   
	 Of the emerging novel classes of PI3K and EGFR inhibitors that we evaluated here, 
several are already in advanced clinical development for HNSCC and other cancers as mono- 
and combination therapies. For example, BKM120 improved survival when administered with 
paclitaxel (versus paclitaxel and placebo) in a phase II HNSCC trial (10), and BYL719 
monotherapy recently demonstrated safety in patients with solid tumors (54).  Of the irreversible 
EGFR inhibitors that we evaluated, dacomitinib has shown efficacy beyond that of cetuximab in 
preclinical models (47) and is undergoing evaluation in phase II studies in recurrent and 




indicated for use in lung cancer patients, has also demonstrated similar efficacy to cetuximab 
(55) in HNSCC patients; this result is very promising given that cetuximab was approved for use 
in HNSCC with radiation or cytotoxic chemotherapy after successful phase 3 trials (11, 12).  
Afatinib is currently undergoing evaluation in a variety of treatment paradigms in HNSCC 
(including NCT01824823, NCT01427478, NCT02979977 and NCT01783587) and has also been 
tested in other solid tumor types as part of a combination therapy with inhibitors targeting PLK 
(NCT01206816), Src (NCT01999985), insulin-like growth factor receptor (IGFR) 
(NCT02191891), MEK (NCT02450656), or multiple receptor tyrosine kinases (NCT00998296), 
but not yet with PI3K inhibitors.   
Many irreversible EGFR inhibitors have activity against both wildtype and mutated 
forms of EGFR (including those with T790M and/or C797S resistance mutations), which may 
contribute to their improved clinical efficacy over reversible drugs like gefitinib and erlotinib. 
Thus, the use of irreversible EGFR inhibitors with PI3K inhibitors in HNSCC may lead to more 
durable responses than reversible EGFR inhibitor combinations by eliminating not only EGFR 
mutations but also activation of compensatory signaling through PI3K as critical resistance 
mechanisms.  Nevertheless, these combinations are still limited by other forms of resistance, 
including novel resistance mutations and co-dependent pathways, which will likely develop after 
prolonged exposure to even irreversible EGFR and PI3K inhibitor co-treatments. 
 Collectively, our work motivates the translation of specific PI3K and irreversible EGFR 
dual-therapies into xenograft mouse models and other more clinically relevant systems.  If such 
studies confirm our in vitro findings, clinical trials evaluating these drug combinations will be 
warranted. More broadly, our data also motivate a need to develop additional biomarkers that can 
be used to determine not only if a drug inhibits its target, but also if the drug inhibits pivotal 
downstream effector pathways capable of rescuing cell survival. Indeed, our findings suggest 
that responses may be mediated by complex downstream signaling networks or other yet-
unidentified factors. Developing the next generation of adaptive biomarkers and rationally 
designed matched combination therapies may therefore be one key to improved survival for 








Figure 3-1. Sanger sequencing confirms PIK3CA mutations. 
Sanger sequencing confirmed E545K PIK3CA mutation in UM-SCC-43 and HSC-4 cells and 





Figure 3-2. Responses to HS-173 + afatinib treatment in HNSCC cell lines.  
(A) HSC-2, (B) HSC-4, (C) Detroit 562, (D) Cal-33, and (E) UM-SCC-59 were treated with 
increasing concentrations of PI3Ka inhibitor HS-173 and/or EGFR/ErbB2 inhibitor afatinib for 
72 hours.  Cell viability was measured using a resazurin cell viability assay. Each point is the 




repeated independently at least three times with similar combination effects; representative data 





Figure 3-3. Responses to treatment with afatinib and PI3K inhibitors with varying 
selectivity.  
HSC-2 cells were treated with increasing concentrations of pan-PI3K inhibitor BKM120 (A), 
PI3Ka inhibitor BYL719 (B), or PI3Kb inhibitor TGX-221 (C) and/or EGFR/ERBB2 inhibitor 
afatinib for 72 hours.  Cell viability was measured using a resazurin cell viability assay. Each 
point is the mean and s.d. of quadruplicate determinations from a single experiment.  Each 
experiment was repeated independently at least two times with similar combination effects; 





































































Figure 3-4. Responses to reverse titration of afatinib and PI3K inhibitors. 
Detroit 562 (A, C) and HSC-4 (B, D) cells were treated with increasing concentrations of 
EGFR/ERBB2 inhibitor afatinib and/or pan-PI3K inhibitor BKM120 (A, B) or PI3Ka inhibitor 
HS-173 (C, D) for 72 hours.  Cell viability was measured using a resazurin cell viability assay. 
Each point is the mean and s.d. of quadruplicate determinations from a single experiment.  Each 
experiment was repeated independently two times with similar combination effects; 





Figure 3-5. Signaling responses to HS-173 + afatinib in combination responsive and non-
responsive HNSCC cell lines.  
Western blot analysis of downstream PI3K and RAS-MEK-ERK pathway activation following 
six hour treatment with vehicle (DMSO), EGFR/ERBB2 inhibitor afatinib, PI3Ka inhibitor HS-
173, and combination in Cal-33, Detroit 562 and HSC-2 cell lines.  HSP90 was used as a loading 














































































Figure 3-6. Responses to HS-173 + ERBB inhibitor treatment in PIK3CA mutant HNSCC 
cells.   
(A) HSC-2 cells were treated with increasing concentrations of PI3Ka inhibitor HS-173 and/or 
EGFR inhibitor gefitinib for 72 hours.  Cell viability was measured using a resazurin cell 
viability assay. Each point is the mean and s.d. of quadruplicate determinations from a single 
experiment.  Each experiment was repeated independently at least three times with similar 
combination effects; representative data is shown along with analysis using Combenefit software 
(32). (B) Detroit 562 cells were treated with increasing concentrations of PI3Ka inhibitor HS-
173 and/or EGFR gefitinib, ERBB2 inhibitor CP-724714, and/or EGFR/ERBB2 inhibitor 
afatinib for 72 hours.  Cell viability was measured using a resazurin cell viability assay. Each 
point is the mean and s.d. of quadruplicate determinations from a single experiment.  This 
experiment was repeated independently three times with similar combination effects; 
representative data is shown. (C) Western blot analysis of phosphorylated and total ERBB2 
expression following treatment with vehicle (DMSO) or 15 or 60 minute treatment with either 
ERBB2 specific inhibitor CP-724714 or EGFR/ERBB2 inhibitor afatinib in Detroit 562 cells.  





Figure 3-7. Cell death responses to HS-173 + afatinib treatment in combination responsive 
and non-responsive HNSCC cell lines.  
Combination non-responsive model UM-SCC-59 and combination responsive model Detroit 562 
were treated with vehicle (DMSO), PI3Ka inhibitor HS-173, reversible EGFR inhibitor 
gefitinib, and/or EGFR/ERBB2 irreversible inhibitor afatinib for 72 hours.  Cell viability was 
measured using an annexin V apoptosis assay after cells were stained with FITC and PI.  Data 
shown represents the mean and s.d. from 2-3 independent experiments. ** indicates significance 
with p < 0.01 using two-way ANOVA to compare vehicle, HS-173, afatinib, and combination, as 
described above in Materials and Methods.  Comparisons for HS-173 and gefitinib combinations 
in each cell line and for HS-173 and afatinib combination in UM-SCC-59 were performed, but 





Figure 3-8. Sensitivity of HNSCC Cell Lines to HS-173 and gefitinib or afatinib 
combination treatment.  
(A) Table shows mutation and copy number data for cell lines tested for sensitivity to HS-173 
and gefitinib or afatinib. PIK3CA mutations were confirmed via Sanger sequencing. No cell lines 
displayed mutations in EGFR.  PIK3CA and EGFR copy number were determined using the 
publicly available canSAR database (Bulusu et al., 2014; Halling-Brown et al., 2012) for Cal-33, 
HSC-2 and HSC-4 cells and using Oncomine for UM-SCC cells.  Detroit 562 EGFR copy 
number was reported as previously published (Young et al., 2013).  Combinatorial effects of HS-
173 and gefitinib or afatinib were determined using resazurin cell viability assays after 72 hour 
drug treatment.  Experiments with quadruplicate replicates were performed 2-5 times and 
combination benefit was assessed using Combenefit software (Di Veroli et al., 2016) as 
described above.  4/14 (29%) cell lines displayed additive effects following HS-173 and gefitinib 
co-treatment; 8/14 (57%) of models responded more favorably to combination treatment with 




Western blot analysis for EGFR, ERBB2, and ERBB3. b-actin was used as a loading control. (C) 
Western blot analysis of downstream PI3K and RAS-MEK-ERK pathway activation following 2 
hour treatment with vehicle (DMSO), PI3Ka inhibitor HS-173, reversible EGFR inhibitor 
gefitinib, reversible ERBB2 inhibitor CP-724714, EGFR/ERBB2 inhibitor afatinib, or 
combinations in HSC-2 cells.  HSP90 was used as a loading control.  Representative images are 





Figure 3-9. SCC cells, but not matched fibroblasts, respond to HS-173 and afatinib co-
treatment. 
UM-SCC-110 and matched fibroblasts from the same patient (UM-SCC-110 fibroblasts) were 
treated with vehicle (DMSO), PI3Ka inhibitor HS-173 and/or EGFR/ERBB2 inhibitor afatinib 
for 72 hours.  Cell viability was measured using a resazurin cell viability assay. Data shown is 
the mean and s.d. of duplicate determinations.  





Figure 3-10. Responses to PI3K and reversible or irreversible EGFR inhibitor 
combinations. 
HSC-2 cells were treated with increasing concentrations of PI3Ka inhibitor HS-173 and/or 
reversible EGFR inhibitor erlotinib (A), reversible EGFR/ERBB2 inhibitor BMS-599626, 
irreversible EGFR/ERBB2 inhibitor TAK285, or irreversible EGFR/ERBB2 inhibitor CUDC-
101 (D) for 72 hours.  Cell viability was measured using a resazurin cell viability assay. Each 
point is the mean and s.d. of quadruplicate determinations from a single experiment.  Each 
experiment was repeated independently at least two times with similar combination effects; 
























































































Table 3-1. Chemical Names for Inhibitors Used 
Inhibitor Chemical Name 






















Table 3-2. Primary Antibody Conditions 
Target Supplier Cat. No. Dilution 
pEGFR(Tyr1068) Cell Signaling Technology 3777 1:1000 
EGFR Origene TA312545 1:2000 
pERBB2(Tyr1221/1222) Cell Signaling Technology 2249 1:500 
HER2 Cell Signaling Technology 2165 1:1000 
pMEK(Ser217/221) Cell Signaling Technology 9121 1:1000 
MEK1/2 Cell Signaling Technology 8727 1:1000 
pERK1/2(Thr202/Tyr204) Cell Signaling Technology 4370 1:1000 
ERK1/2 Cell Signaling Technology 4695 1:1000 
pAKT(Ser473) Cell Signaling Technology 4060 1:1000 
AKT Cell Signaling Technology 4685 1:1000 
HSP90 Cell Signaling Technology 4877 1:2000 





Table 3-3. Combinatorial Effects of PI3K + ERBB Inhibitors in HNSCC Cell Lines.  
Combinatorial effects of PI3Ka inhibitor HS-173 and reversible or irreversible ERBB targeting 
agents in HSC-2 and Detroit 562 HNSCC cell lines.  Synergy was assessed using Combenefit 
software (32).  Synergy was not observed for PI3Ka inhibitor HS-173 with any reversible 
inhibitor in either cell line.  4/4 and 3/4 irreversible EGFR inhibitors were synergistic with HS-









Gefitinib EGFR Reversible No No 
Erlotinib EGFR Reversible No No 
BMS-566924 EGFR/ERBB2 Reversible No No 
CP-724714 ERBB2 Reversible No No 
Afatinib EGFR/ERBB2 Irreversible Yes Yes 
TAK-285 EGFR/ERBB2 Irreversible Yes No 
CUDC-101 EGFR/ERBB2/HDAC Irreversible Yes Yes 
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Chapter 4 : Pik3ca Mutation and Notch1 Loss Accelerate Tumor Formation 
in a Transgenic Model of Head and Neck Squamous Cell Carcinoma 
Abstract 
 Head and neck squamous cell carcinoma (HNSCC) is characterized by a heterogeneous 
set of genetic alterations; these aberrations translate into a host of functional changes, which 
contribute to the aggressive nature of this disease and make the prediction of effective treatment 
paradigms difficult.  Two of the most commonly dysregulated pathways in this cancer type 
include the phosphatidylinositol 3-kinase (PI3K) and NOTCH pathways.  Both activation of 
PI3K and loss of NOTCH signaling have been shown to play oncogenic roles in HNSCC and 
have been studied using an array of preclinical models.  Here, we examined the interplay 
between PI3K and NOTCH signaling in vitro and in vivo.  We generated HNSCC cell lines with 
knockout of PIK3CA or NOTCH1 using CRISPR/Cas9 techniques.  UM-SCC-47 cells with 
PIK3CA partial knockout exhibited altered expression of DLL1, HES2, as well as genes involved 
in epithelial to mesenchymal transition.  We also developed a transgenic mouse model to study 
co-alteration of genes in the PI3K and NOTCH signaling pathways using a tamoxifen-inducible, 
K14-Cre system to overexpress H1047R mutant Pik3ca and/or knockout of Notch1.  Following 
chronic exposure to carcinogen 4-nitroquinoline N-oxide, K14; Notch1c/c; Pik3caH1047R mice 
displayed shorter time to endpoint compared to control mice or those mice with alterations in 
either Notch1 or Pik3ca.  These findings demonstrate the non-overlapping and synergistic 




cross-talk between these pathways; such work could uncover unique molecular features and 





Head and neck squamous cell carcinoma (HNSCC) is a common and deadly form of 
cancer, accounting worldwide for 830,000 new diagnoses and 430,000 deaths per year (1, 2). 
HNSCC tumors are most often found in the epithelial tissue of the oral cavity, larynx, 
oropharynx, and hypopharynx (1).  Their development is commonly associated with a variety of 
environmental risk factors, including excessive consumption of alcohol and/or tobacco and the 
presence of high-risk forms of human papilloma virus (HPV). Prognosis varies widely with 
tumor subsite and stage at presentation as well as with HPV status; the overall 5-year survival 
rate for oral cavity HNSCC patients is approximately 65%, but rates are much lower in cases of 
disease progression (3). Treatments also differ in individual cases depending on the severity and 
progression of the disease: common first-line treatments for early stage cancers include surgery 
or radiation therapy, and more advanced cancers are often treated with postoperative 
concomitant chemo-radiation in combination with cisplatin (1).  
With the ever-increasing ease of performing next-generation sequencing, more and more 
studies have focused on genetic alterations that may be responsible for tumor formation or 
severity. In HNSCC, two of the most commonly altered pathways include the PI3K and Notch 
signaling pathways (4-6).  For example, based on The Cancer Genome Atlas (TCGA) HNSCC 
dataset, approximately two-thirds of HNSCC tumors display genetic aberrations in PI3K 
pathway genes.  Of these alterations, the most frequent and perhaps most notable is PIK3CA 
amplification or mutation, each of which is observed in 15-20% of patients (7-9).   
An array of other studies, including those performed in our laboratory, have also 
demonstrated the presence of alterations in PIK3CA and the potential role for PI3K in HNSCC 




mouse models for altered PI3K signaling, despite the high rate of aberrations documented in 
TCGA.  Common PIK3CA aberrations include mutations in the helical (E542K, E545K) and 
kinase (H1047R) domains of the gene; these specific amino acid changes are known to activate 
PI3K signaling (6, 13-15).  In transgenic mouse models of breast and lung cancer, conditional 
expression of the Pik3caH1047R mutant drives spontaneous adenocarcinomas (16, 17), allowing 
for in vivo trials of targeted therapeutics in these tumor types.  At present, Du et al. have 
described the sole in vivo model of PIK3CA activation in HNSCC, which utilizes the a RU486-
inducible K5 promoter to conditionally overexpress wildtype Pik3ca in the mouse oral cavity and 
tongue.  Pik3ca overexpression alone is insufficient to initiate carcinogenesis in this model, 
though subsequent chronic administration of tobacco analogue 4-NQO in drinking water results 
in the formation of invasive, poorly-differentiated tumors within six months as well as lymph 
node and lung metastases in roughly 40% of animals (18).   
Similarly, deletion of Pten (which opposes PI3K signaling and acts as a tumor 
suppressor) is insufficient to drive in vivo HNSCC formation (19), but 4-NQO treatment of 
Ptenflox/flox; K14-Cre transgenic mice triggers multiple dysplastic and neoplastic lesions of the 
tongue, analogous to field cancerization seen in humans (20). Alternatively, reports of a double 
knockout of transforming growth factor-b (Tgfbr1) and Pten driven by the K14 promoter in a Cre 
recombinase system describe spontaneous formation of invasive SCC of oral epithelia with full 
penetrance (21).  Using this Tgfbr1-Pten knockout strain, promising antitumor efficacy of 
targeted PI3K and mTOR inhibitors has been achieved (22, 23).       
Notch dysfunction, resulting in disruption of signaling pathways involved in embryologic 
differentiation, cellular proliferation, and maintenance of metabolic homeostasis (24), has been 




Notch signaling in cancer is incompletely understood, as evidence has suggested a bimodal role, 
depending on the nature of the alteration (25). Activating mutations in Notch receptors were first 
identified in lymphomas (26), but more recent research in HNSCC has indicated that N-terminal, 
inactivating mutations in NOTCH1 are present in at least 10-15% of tumors and may be a 
playing a tumor suppressive role in this cancer type (4, 5, 7, 27, 28).   
Many previous mouse models have revealed an important but complex role for Notch 
signaling in tumor formation.  Demehri et al. demonstrated, using several genetically engineered 
mouse models (GEMMs) with varying degrees of Notch signaling on the Msx2-Cre background, 
that mouse lifespan and age at spontaneous tumor onset was correlated with alteration severity: 
animals lacking gamma secretase activity did not survive, while those with loss of Notch1 lived 
almost as long as wildtype littermates but developed skin tumors after roughly 1.5 years (29). 
This study also demonstrated that different Notch pathway members could affect survival and 
tumor phenotypes differently; mice without Notch effector Rpbj KO lived tumor-free for 4 
months, while animals with knockout of Notch1-3 also lived for approximately 4 months but 
displayed skin tumors at about 3 months of age (29).  In a separate manuscript, Demehri et al. 
also showed that inactivation of Notch signaling leads to increased susceptibility to chemical 
carcinogenesis (30).  Similarly, Nyman et al. recently demonstrated that transgenic mice 
expressing the dominant negative form of Maml1 (DNMAML1) under the control of a tamoxifen-
inducible K14 Cre displayed increased frequency and multiplicity of oral cancers (27).  This 
effect was enhanced by the co-expression of DnMaml1 with gain-of-function mutant p53R172H 
and especially with HPV oncogenes E6 and E7.  However, in another HPV-driven mouse model 
of oral cavity SCC, both Notch1 overexpression (LSL-KRASG12D/LSL-NICD/iHPV-Luc; K14-




CreERtam) enhanced tumor growth and invasiveness (31).  Taken together, these studies indicate 
that Notch signaling plays a multifaceted role in tumor initiation and that the means by which 
inactivation of this pathway is achieved may critically affect survival and/or tumor burden.  
Additionally, the immune system is an important component of these effects.  Di Piazza et al. 
showed the striking ability of pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) 
to act directly on T-cells and protect against cutaneous carcinomas or, when genetically ablated, 
to promote tumor formation via increased Wnt signaling in K5-driven models of loss of Notch1 
and Notch2 (32). 
While substantial research efforts have investigated individual genetic alterations and 
their related signaling networks (including PI3K and Notch signaling as described above), far 
fewer studies have examined how the presence of multiple mutations or copy number alterations 
in genes from two or more separate pathways might impact HNSCC tumorigenesis and treatment 
response.  Previous work using GEMMs with deficiencies in multiple Notch pathway genes 
suggests that other transgenic models with alterations in additional signaling networks may 
display additive or even synergistic phenotypes as well.  Excitingly, recent work by Sambandam 
et al. indicates that preclinical HNSCC models with inactivation of NOTCH1 may be more 
sensitive to PI3K inhibition, making NOTCH1 loss a potential biomarker for response to these 
targeted therapies (33).  Here, based on these results as well as the frequency of loss-of-function 
NOTCH1 and activating PIK3CA mutations in HNSCC, we developed in vitro models of 
PIK3CA and NOTCH1 knockout and a transgenic mouse model of Notch1 loss and Pik3ca 







UM-SCC cells were maintained in DMEM with 10% FBS, 1X Pen/Strep, 1X NEAA at 37°C and 
5% CO2 (vol/vol).  All cell lines were genotyped to confirm authenticity and were mycoplasma 
negative as described previously (34). 
Generation of CRISPR Cell Lines 
500 µL of lentiviral construct (Sigma Aldrich) with gRNA targeting the first exon of PIK3CA 
(sequence: 5’-GTTCACCTGATGATGGTCG-3’) was added to UM-SCC-47 cells in a six-well 
plate that contained 2.5 mL of complete media with 10 µg/mL polybrene (EMD Millipore, Cat 
No: TR-1003-G).  An additional well was left without virus as a control. After 1-2 weeks, cells 
were exposed to puromycin selection until non-transduced cells died.  As an additional selection 
measure, cells were expanded and sorted for GFP positivity versus non-transduced, wildtype 
cells at the University of Michigan Flow Cytometry Core using the MoFlo Astrios EQ Cell 
Sorter. Cells expressing GFP were expanded and seeded in 10 cm dishes with 500-1000 cells per 
dish to isolate single-cell colonies. When colonies formed on these dishes, colony rings were 
used to isolate, trypsanize, and expand each individual colony to its own well in a 24 well plate. 
When these 24 well plates became confluent, each well was expanded to two wells. One of these 
wells was lysed and harvested to test for PIK3CA or Notch1 expression using Western blot (see 
below), while the other was maintained in culture. 
Genomic DNA Isolation  
Cells were harvested and washed in PBS, then frozen at -20ºC. The pellet was then thawed and 
transferred to 700 µL of Nuclei Lysis Solution (Promega, Madison, WI) for 1 hour at 55ºC. 200 




and centrifuged at 13,000 RPM for two minutes. The supernatant was then transferred to a tube 
containing 600 µL of isopropanol, incubated for 15 minutes, and centrifuged at the same speed 
for another minute. The DNA pellet was washed in 70% ethanol, dried, and re-suspended in 35-
50 µL of nuclease-free water.  
PCR and Sanger Sequencing 
DNA was amplified using PCR with Platinum Taq DNA Polymerase High Fidelity (Invitrogen) 
according to manufacturer’s protocols and with primers that targeted the region of the guide 
RNA for PIK3CA (primer sequences: FWD: 5’-CCTCCACGACCATCATCAGG-3’ and REV: 
5’-TCTTCCCTTTCTGCTTCTGT-3’) or Notch1 (FWD: 5’-CTGGCTTTGTGGTT-3’, REV: 5’- 
GTCCAGGATGTGGCACAAG-3’). PCR products were inserted into the pCR8 vector system 
(ThermoFisher, Cat No: K250020) and transformed into Mach1 competent cells, again according 
to manufacturer’s protocols. Bacteria cultures from individual colonies on LB + spectinomycin 
plates were grown overnight and DNA was isolated using the Qiagen mini-prep protocol (Cat 
No: 27106) according to manufacturer’s protocols. The DNA product was analyzed via Sanger 
sequencing at the University of Michigan DNA Sequencing Core on the 3730XL DNA 
Sequencer (Applied Biosystems). Sequences were aligned using the DNASTAR Lasergene 
software suite. 
Western Blotting 
Cells were grown to 70-80% confluency and lysed in radioimmunoprecipitation assay buffer 
(ThermoFisher, Cat No: 89900) containing 1% NP-40 and 0.1% SDS. 10-50 micrograms of each 
cell harvest were used, and standard western blot protocols were followed as previously 




Table 4-2) were applied overnight at 4°C or for at least one hour at room temperature, followed 
by a goat anti-rabbit horseradish peroxidase (Cat No: 111-035-045; Jackson ImmunoResearch, 
West Grove, PA) secondary antibody at room temperature for one hour as described elsewhere 
(36). The blots were then visualized with chemiluminescence and imaged. Images were digitally 
retained at 300 or greater dpi from all westerns and representative blots are shown. 
 
RNA Isolation and qPCR 
Cells were harvested in Qiazol (Cat No: 79306; Qiagen) and stored at -80°C.  RNA was isolated 
using the Qiagen RNeasy Mini Kit (Cat No: 74106) according to manufacturer’s protocols, and 
then quantified using the Qubit fluorometer (ThermoFisher).  cDNA was synthesized using the 
SuperScript Vilo cDNA Synthesis kit (ThermoFisher, Cat No: 11754250, also using 
manufacturer’s protocols, in the GeneAmp® PCR System 9700 (Applied Biosystems).  qPCR 
analysis for each cDNA sample was performed with Quantitech SYBR green (catalog No: 
204143; Qiagen) on the QuantStudio 5 instrument (ThermoFisher).  Primers were purchased 
from Intregrated DNA Technologies and sequences are listed in Table 4-3. 
Transcriptome and Gene Set Enrichment Analysis  
Transcriptome analysis was performed using Illumina stranded transcriptome library preparation 
kits with 75 nucleotide paired end sequencing to >100x depth on an Illumina HiSEQ4000 for 
UM-SCC-47 and UM-SCC-47 PIK3CA CRISPR cells. No quality issues were identified in the 
analysis. To calculate gene expression in fragments per kilobase million (FPKM), we aligned 
reads using STAR (v2.5.3a) according to the standard two-step alignment process and the 
processed the data with Cufflinks (v2.2.1). Using the FPKM read counts, we then defined gene 




to the control and uploaded the gene sets into GSEA (MIT, Broad) to identify significant overlap 
with Hallmark, KEGG and GO biological process pathways with false discovery rate (FDR) q-
value < 0.05 considered significant.  
Inhibitors 
All inhibitors were purchased from Selleck Chemicals and dissolved in 100% DMSO to 10 mM, 
then diluted to their appropriate concentrations for use in vitro. 
Resazurin Cell Viability Assay 
2000 cells per well were seeded (in 50 µL volume) in 384 well microplates (Grenier, Cat No: 
781091) and allowed to adhere overnight.  The following day, inhibitors were prepared at 200X 
in 96-well plates.  Inhibitors were dissolved in DMSO in a ten-point, two-fold dilution series.  
These inhibitors were then diluted 1:20 into complete media using the Agilent BRAVO Liquid 
Handing system.  Finally, again using this liquid handling equipment, media containing inhibitor 
was added to each well of the cell plate at 1:10.  Treatments were performed for 72 hours.  12-24 
hours prior to the end of the treatment time point, 10 µL of 440 µM resazurin (Sigma, Cat No: R-
7017) was added to each well of the plate.  Signal was measured and quantified using the Biotek 
Cytation3 fluorescence plate reader at excitation and emission wavelengths of 540 and 612 nm, 
respectively.  Using Prism 7, data were plotted and fit with concentration response curves using 
the log(inhibitor) vs. response -- Variable slope model with four parameters (IC50, top, bottom, 
and Hill slope) allowed to vary.                                                                                                                                                                                                                                            
Animal Care 
Animals were housed in a vivarium accredited by the Assessment and Accreditation of 
Laboratory Animal Care at the University of Michigan. Veterinary care was provided by the 




performed according to Institution for Animal Care and Use Committee-approved protocol 
PRO00008316. Mice with Notch1 loss and/or Pik3ca mutation were originally obtained from the 
laboratory of Dr. Sunny Wong.  To generate mice for experiments, we paired one healthy male 
and one healthy female mouse (both mice between the ages of 6 and 30 weeks). Male and female 
littermates were weaned and separated into their respective cages at 3 weeks of age.   
Genotyping  
At 3-4 weeks, ear clips were taken to obtain DNA samples for genotyping. DNA was extracted 
from clips using the Hot Sodium Hydroxide and Tris (HotSHOT) program, in which 75 µL of 
Basic Reagent was added to each sample (1g NaOH, 0.074g EDTA-disodium, adjusted to a 
volume of 1L with ddH2O for a pH of 12). Samples were placed on a 95°C heat block for 20-30 
minutes and on ice for 5 minutes to allow the solution to cool. Once samples were cooled, 75 µL 
of Neutralizing Reagent (6.304g Tris-HCl, adjusted to a volume of 1L with ddH2O for a pH of 5) 
was added to each tube. Samples were kept on ice for genotyping or stored at -20°C overnight. 
PCR was used to obtain the K14, Notch1, and Pik3ca genotypes, using 2x GoTAQ Green PCR 
Master Mix (catalog No: M7122; Promega). Each PCR well contained 3.5 µL ddH20, 5 µL 
GoTAQ Green, 0.5 µL of 20 µM primer mix (for K14, Notch1 or Pik3ca), and 1 µL genomic 
DNA isolated from the ear clip of an individual mouse. PCR products were evaluated using 2% 




At 5 weeks of age, mice with expression of K14 promoter and desired genotypes for Notch1 and 




powder at 12.5 mg/mL in sterile corn oil and vortexed for 2 hours at room temperature prior to 
use. Mice received three intraperitoneal (i.p.) injections of tamoxifen at 50 mg/kg, once daily for 
three days. 
4-Nitroquinoline N-Oxide 
At 6 weeks of age, mice received 5 µg/mL 4-Nitroquinoline-N-oxide (4-NQO) (Sigma, Cat No: 
N8141), a tobacco analogue, via their drinking water. 4-NQO was prepared as described 
previously (18).  4-NQO powder was dissolved at 5 mg/mL in sterile propylene glycol (Sigma, 
Cat No: 4347) and vortexed for at least 2 hours at room temperature.  4-NQO was then diluted 
1:100 in sterile water and filtered using a 0.2 µm filter for a final concentration of 50 µg/L. 
Drinking water containing 4-NQO was administered chronically for 16 weeks, with water 
prepared fresh and changed each week.  
Tumor Monitoring 
Each week, all mice on treatment were weighed and monitored for tumor formation and general 
health. Some mice developed adverse phenotypes and were treated as described in  
Table 4-5.  Mice reached their endpoint based primarily on the basis of 20% weight loss, which 
suggested the presence of oral tumors that made eating and/or drinking difficult. As mice tended 
to gain weight in the 8 weeks following the initiation of 4-NQO administrations, mice were 
sacrificed if they exhibited 20% weight loss compared to the highest recorded weight during this 
time period. After 8 weeks of tumor monitoring, weights were compared to the rolling average 
weight, with 20% weight loss again resulting in sacrifice. Additional mice that died or required 
euthanasia due to signs of poor health prior to the weight loss endpoint were included in the 





After being exposed to 4-NQO and reaching their endpoint, mice were humanely euthanized and 
dissected to look for visible tumor on the cheek, lip, and tongue. Tumors were photographed, 
collected, and fixed using formalin for no more than 72 hours.  Tissues were then processed into 
FFPE blocks by the University of Michigan Rogel Comprehensive Cancer Center Research 
Histology and Immunoperoxidase Laboratory Core.  
Immunohistochemistry 
Immunohistochemistry was performed using standard protocols. Briefly, slides were 
deparaffinized at 58°C for 30 minutes, then rehydrated with xylene and ethanol, followed by a 
wash with deionized water.  Antigen unmasking was performed at temperatures > 90°C for 1 
hour in citrate buffer.  After two washes with PBST, endogenous peroxidase was quenched.  
Following two additional PBST washes, 5% goat serum was used for blocking, and primary 
antibody (see Table 4-4) was applied overnight at 4°C.  Following three PBST washes, 
secondary antibody was applied for 30 minutes at RT, then washed away with PBST.  The 
Vectastain Elite ABC kit was used to add the avidin-biotinylated HRP complex, after which 
slides were washed with PBST three times and water once.  Next, slides were incubated with 
DAB for 2-10 minutes and washed with water again.  Hematoxylin was used as a counterstain, 
followed by another water wash and tissue dehydration using ethanol.  Two xylene washes were 
performed, and slides were mounted.  Slides were scored by a pathologist and representative 
images are shown. 
Statistical Analysis 
We modeled the time to endpoint as a continuous outcome in a linear regression model.  Group 




made with either K14 or K14; Notch1c/c; Pik3caH1047R as the reference group.  Maximum 
likelihood paramer estimates were obtained with p < 0.05 considered statistically significant. 
 
Results 
Co-Alteration of PI3K and Notch Pathways in TCGA 
We queried the HNSCC TCGA dataset to explore the rate of NOTCH and PI3K pathway 
co-alteration in patients with this cancer type.  This analysis identified a majority of patients with 
mutation or copy number changes in one or both pathways.  Of the 505 patients with mutation 
and copy number information available in TCGA, 198 (39.2%) tumors in this dataset had an 
alteration in a NOTCH pathway gene (NOTCH1, NOTCH2, NOTCH3, NOTCH4, MAML1, 
MAML2, MAML3), and 319 (63.2%) tumors had an alteration in the PI3K pathway (PIK3CA, 
PTEN, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, PIK3R6, 
PIK3AP1, PIK3C2A, PIK3C2B, PIK3C2G, PIK3C3, AKT1, AKT2, AKT3, AKT1S1, AKTIP, 
EIF4B, EIF4E, EIF4EBP1, EIF4G1, FKBP1A, MTOR, PDK1, PDK2, RHEB, RPS6KB1) (7-9).  
More than one quarter of patients (142/505, 28.1%) displayed alterations in both the NOTCH 
and PI3K signaling networks, and 26 of these tumors (5.1%) exhibited inactivating Notch1 
alterations (deletion or N-terminal mutation) as well as potentially activating PIK3CA alterations 
(amplification or mutation) (Figure 4-1, Table 4-6).   
Characterization of PIK3CA Knockout HNSCC Cell Line Demonstrates Interplay Between PI3K 
and NOTCH Signaling Pathways 
We set out, therefore, to explore whether the Notch and PI3K signaling networks 
interacted using in vitro genetic knockout models, hypothesizing that alteration of PI3K or Notch 




interested in identifying changes that might occur after long-term depletion of signaling through 
the PI3K p110 alpha isoform.  As noted above, PIK3CA, the gene which encodes this PI3K 
isoform, is frequently altered in HNSCCs, suggesting that it may be a common oncogenic driver.  
To study the consequences of loss of p110a, we used CRISPR-Cas9 technology to knockout 
PIK3CA in patient-derived UM-SCC-47 cells, a widely used model of HPV positive oral 
squamous cell carcinoma.  UM-SCC-47 cells were transduced with a lentiviral construct 
including the Cas9 endonuclease as well as a guide RNA targeting the first exon of PIK3CA.  
Following selection and single-cell cloning, this method generated a daughter cell line with at 
least two unique deletions in regions near the gRNA sequence.  One of these deletions is a loss 
of seven nucleotides, and the second deletion is three nucleotides in length (Figure 4-2).  
Although (1) some wildtype PIK3CA DNA may still be present and (2) three nucleotide 
deletions may allow effective translation of downstream regions of the protein following a single 
missing amino acid, protein expression of p110a was markedly reduced in this model (Figure 
4-3).  A resazurin cell viability assay demonstrated that the UM-SCC-47 CRISPR model 
displayed decreased sensitivity to alpha-isoform selective PI3K inhibitor HS-173 and pan-PI3K 
inhibitor BKM120 (Figure 4-5), further indicating that this model is a functional model of 
PIK3CA knockout.  Growth rates and levels of AKT phosphorylation were similar between 
wildtype and PIK3CA partial knockout cells (Figure 4-4), although pAKT was slightly 
decreased with loss of p110a (as might be expected due to decreased PI3K signaling) (Figure 
4-3).  We observed no significant signaling changes in the Ras-MEK-ERK pathway and no 
compensation through other p110 isoforms in this model (Figure 4-3). 
To continue to explore potential differences between the wildtype UM-SCC-47 and 




to identify 84 genes that were >2 log2-fold increased and 189 that were >2 log2-fold decreased 
in the PIK3CA partial knockout model relative to wild type cells.  Although the upregulated gene 
set was relatively small, gene set enrichment analysis (GSEA) defined significant overlap with 
genes in the interferon and epithelial to mesenchymal transition and TNF alpha via NFKB 
response pathways, consistent with an upregulation of anti-immune survival pathways (Table 
4-7). Interestingly, the PIK3CA partial knockout cell line also displayed a mesenchymal 
morphology compared to UM-SCC-47 wildtype cells (Figure 4-6).  The 189-gene 
downregulated gene set, in contrast, had significant overlap with genes in the mTOR KEGG 
pathway (FDR q < 0.05), confirming that the knockout deregulated known downstream PI3K 
effector pathways. Surprisingly, Go-ontology enrichment analysis with GSEA software 
identified significant enrichments in pathways related to tissue development and epidermal 
differentiation, which contained a few genes in common between the gene sets (Table 4-7). 
These common genes driving the significance of the interaction included DLL1 and two keratins 
(K5 and K14), which are known to be regulated by NOTCH signaling in HNSCC (28, 37, 38).  
Further analysis of the downregulated gene set also identified another known NOTCH effector, 
HES2, as >2 log2-fold decreased between the knockout and wild type models. Decreased 
expression of DLL1 and HES2 was confirmed via qPCR (Figure 4-7).  Taken together, then, the 
GSEA data confirmed that the PIK3CA partial knockout inactivated mTOR signaling, increased 
an anti-immune response, and inhibited NOTCH signaling pathways in this model.  Thus, co-
alterations in PI3K and Notch pathways could lead to deregulation of epidermal differentiation 




Transgenic Mouse Model of Notch1 Loss and H1047R Pik3ca Mutation Displays Accelerated 
Tumor Formation 
Having observed these effects in vitro, we decided to develop an in vivo model to study 
PI3K pathway activation and NOTCH deficiency in HNSCC.  Few previous studies have 
examined the role of aberrant PI3K signaling in transgenic mouse models of HNSCC (18), 
particularly via activating mutation of PIK3CA, and we are unaware of any other models that can 
be used to evaluate simultaneous alteration of these two pathways.  We selected the H1047R 
PIK3CA mutation, one of the “hotspot” alterations in this gene. This mutation is observed in 
many human cancers, including breast, colorectal, lung, and HNSCC tumors and has a known 
role in the activation of PI3K signaling (6, 7, 14, 15).  NOTCH1 has been identified as one of the 
most frequently altered genes in HNSCC tumors (4, 5, 7), and loss of Notch signaling has been 
shown to contribute to tumorigenesis in other transgenic mouse models of this cancer type (27).  
Therefore, our model uses two of the most common genetic alterations in the PI3K and NOTCH 
signaling pathways to mimic PI3K aberrant and/or Notch deficient HNSCCs. 
To develop this model, we used the tamoxifen-inducible, Cre recombinase system to 
drive the expression of transgenes under the control of a K14 promoter.  As K14 is expressed in 
epithelial cells, including those of the oral mucosa, this expression system was a suitable choice 
to study cancers originating in the oral cavity.  Here, we modeled activation of PI3K signaling 
via the expression of H1047R mutant Pik3ca and/or loss of Notch signaling via knockout of the 
first exon of Notch1 in K14 positive cells (Figure 4-8).   
To induce the formation of head and neck tumors in our transgenic mouse model, we 
treated mice with a well-validated chemical carcinogen, 4-Nitroquinoline N-oxide (4-NQO).  




formation of reactive oxygen species that can cause double stranded breaks in DNA (39, 40).  As 
a result, tumors observed following treatment with 4-NQO serve as a model of smoking-induced 
HNSCCs (39, 41-44).  For this study, we administered 4-NQO to mice at 50 ug/mL via chronic 
exposure in drinking water.  Treatments began at six weeks of age and continued for 16 weeks 
(18).   
During 4-NQO treatment as well as afterward, weekly health checks were performed to 
assess the time to endpoint.  When mice reached 20% loss of body weight, we humanely 
euthanized the animals and checked the lip, cheek, and tongue tissue for the presence of any visible 
lesions.  We also included animals requiring euthanasia prior to the 20% loss of body weight 
endpoint if they displayed visible lesions upon sacrifice.  In our current analysis (which may be 
updated with additional animals as further histologic data is generated and statistical tests are 
performed), cohorts of eight or nine animals comprised each of the four genetic backgrounds: K14 
only, K14 with Pik3ca H1047R mutation (K14; Pik3caH1047R), K14 with Notch1 knockout (K14; 
Notch1c/c), and K14 with both Pik3ca mutation and Notch1 knockout (K14; Notch1c/c; 
Pik3caH1047R).  All eight of the mice in the K14; Notch1c/c; Pik3caH1047R group had visible lesions, 
while 5/9 (55.6%) animals in K14; Notch1c/c group, 6/8 (75%) mice in the K14; Pik3caH1047R group, 
and 8/9 (88.9%) mice in the K14 group had visible lesions (Figure 4-9, Table 4-8).  Of these mice, 
each had visible lesions identified in at least one and as many as three anatomic subsites (Figure 
4-9, Table 4-8).  When lesions were present and subsite information was available, the average 
number per mouse was varied by genotype, ranging from an average of 1 lesion per mouse for the 
K14; Notch1c/c group to 2.16 lesions per mouse in the K14; Pik3caH1047R group (Figure 4-9, Table 
4-8).  Consistent with expression driven by K14, dorsal skin tumors were observed in a small 




and within all genotypes except K14; Notch1c/c (Figure 4-9, Table 4-8).  Although mice of each 
genotype developed comparable lesions in this experiment, the time to endpoint was more 
disparate between groups.  Each of the groups with genetic alteration in Pik3ca and/or Notch1 
displayed decreased time to endpoint as compared to K14 only control mice, with the double 
alteration mice also reaching endpoint more quickly than either K14; Notch1c/c or K14; 
Pik3caH1047R animals (Figure 4-10).  This result indicates that Notch1 loss and Pik3ca mutation 
act synergistically in this transgenic model and provides support for the hypothesis that alteration 
of both NOTCH and PI3K pathway genes could substantially affect HNSCC outcomes. 
To more fully characterize the lesions in each of our four transgenic mouse strains (K14, 
K14; Pik3caH1047R, K14; Notch1c/c, and K14; Notch1c/c; Pik3caH1047R), we identified squamous 
cell carcinoma samples from each group and performed immunohistochemistry (Table 4-9, 
Figure 4-11).  While our initial analysis only included one sample per genotype, we identified 
several patterns of interest.  First, p110a was high in all samples, including those without the 
Pik3caH1047R transgene (Figure 4-11).  Similarly, pPDK1(Ser241) and p63 staining was high in 
all samples (Figure 4-11).  While previous western blot analysis of lysates from tumor and 
normal samples from K14; Pik3caH1047R mice indicated confirmed AKT phosphorylation in SCC 
samples (Figure 4-12), pAKT staining by IHC was disparate between groups (Figure 4-11).  
Higher levels of AKT phosphorylation were seen in K14 and K14; Notch1c/c SCCs, perhaps 
driven by high expression of p110a.  Interestingly, CD8 infiltration reciprocated survival data, 
with the greatest infiltration the K14; Notch1c/c; Pik3caH1047R sample, intermediate infiltration in 
K14; Pik3caH1047R and K14; Notch1c/c tumors, and low infiltration in the case of K14 alone 




Notch1c/c; Pik3caH1047R and K14; Pik3caH1047R sample; all three of these, however, displayed 
higher PD-L1 intensity than the tumor from the K14 mouse. 
 
Discussion 
Our results show that both overexpression of H1047R mutant PIK3CA and loss of 
NOTCH1 are pivotal events for HNSCC pathogenesis derived from K14 positive cells. The 
overlapping ability of aberrations in these two pathways to drive HNSCC development and/or 
progression is suggested by the aberration rates in PI3K and NOTCH signaling in HNSCC 
TCGA patient tumors (7) and the altered expression of DLL1, HES2, EMT- and differentiation-
related genes in our cell line model of partial PIK3CA knockout.  Furthermore, we also show in a 
transgenic mouse model that the combining H1047R mutant Pik3ca and Notch1 loss drives a 
more aggressive cancer phenotype, displaying earlier onset of endpoint than disruption of either 
gene individually. This data suggests that although the pathways are clearly linked, mutant 
PIK3CA and NOTCH1-driven pathways are not completely overlapping as disruption of both 
pathways has an additive functional effect on disease pathogenesis.  
The significance of our study is supported by recent work from Sambandam et al., which 
shows that NOTCH1-mutant HNSCC cell lines are highly sensitive to PI3K/mTOR inhibitors 
(33). The discovery of the relationship between these two pathways in cell line and xenograft 
models was reinforced further by their data showing that a PDK1-dependent mechanism drove 
resistance to PI3K inhibitors in NOTCH1 wild type models, but not in NOTCH1 mutant models. 
Interestingly, a previous study in which mice with K5-driven overexpression of wildtype 
PIK3CA were treated with 4-NQO for 16 weeks demonstrated a strong correlation of aggressive 




significantly higher p110α and PDK1 protein expression (18).  Although NOTCH status was not 
specifically tested in the 4-NQO-treated K5-PIK3CA mice, we might hypothesize, based on the 
data on Samdandam et al. (33), that NOTCH alterations were not present.  Our model, however, 
does not recapitulate this evidence for PDK1’s role in PI3K signaling: immunohistochemistry 
data, although limited to a small number of animals with validated SCC, suggests that there is no 
difference in PDK1 expression in tumors from K14 only, K14; Notch1c/c, and K14; Notch1c/c; 
Pik3caH1047R mice.  Rather, all stains from 4-NQO-induced SCC tumors displayed strong staining 
covering most of the tumor area.  Less intense staining was observed in normal tissues, epithelial 
dysplasias, and spontaneous SCCs (no 4-NQO treatment).  These results suggest that another 
mechanism, outside of high PDK1 expression, mediates the effects of PI3K signaling in this 
model.  Additional immunohistochemical data suggests that this effect is not mediated by 
activation of canonical downstream PI3K effector AKT or by expression of p63.  Alternatively, 
CD8 infiltration was highest in the K14; Notch1c/c; Pik3caH1047R SCC sample, which may 
indicate an important role for the immune system in this model.  In light of this, it is interesting 
to note that PDL1 staining was most intense in mice with alterations in Pik3ca and/or Notch1.  
While the results require validation in additional tumor specimens, these data suggest that T-cell 
exhaustion may be observed in animals with more significant tumor burden and earlier tumor 
onset.  Further studies are needed to assess the presence of other markers of T-cell exhaustion, 
such as CTLA-4 and Tim-3.  If validated, the state of these T-cells could contribute to 
accelerated tumor formation in K14; Notch1c/c; Pik3caH1047R mice as the immune system fails to 
efficiently recognize and eliminate foreign tumor cells.  A role for PI3K signaling in immune 




expression of interferon alpha and gamma signaling pathways in GSEA analysis of our PIK3CA 
partial knockout cell model (Table 4-7). 
Alternatively, the presence of the H1047R Pik3ca mutation in our transgenic mouse 
model presents a second possible factor that could contribute to the lack of PDK1-dependence.  
The differential mechanisms downstream of mutant and wildtype PIK3CA are not well-
understood; it is possible that activation of this oncogene via mutation, amplification, or 
overexpression promotes signaling through differential or other currently unidentified pathways.  
These differences are difficult to compare in vitro as many cell lines exhibit additional copies of 
the 3q chromosome (10), which may be a side-effect of the changes necessary for tumor cells to 
survive outside of the host environment (46) and it is unclear how many copies of this gene are 
necessary for functional alterations in PI3K signaling.  Previous studies assessing PIK3CA 
amplification and overexpression have indicated that either may predict poor prognosis for 
HNSCC patients, while mutation status does not stratify outcomes (47). Similar studies have also 
proposed mechanisms including inactivation of YAP, a member of the Hippo signaling pathway, 
as an additional downstream PI3K target responsible for changes in tumor progression (48).  
Despite the potential for alternative effector signaling in our PIK3CA mutant model and 
the one with wildtype PIK3CA overexpression developed by Du et al. (18), the time to tumor 
formation appears similar.  While this evidence may suggest that PIK3CA mutation does not 
further induce tumor formation as compared to PIK3CA overexpression alone, these results are 
difficult to compare due to confounding factors including the specific genetic driver of PIK3CA 
overexpression (K14 vs K5) and the specificity of each endpoint protocol.  It would be 




replaced by wildtype Pik3ca to more definitively compare the effects of PI3K activation via 
mutation rather than overexpression alone.   
In summary, our results here provide evidence for differential but coordinating effects of 
signaling through the PI3K and NOTCH pathways.  We demonstrate that these alterations are 
clinically relevant through our analysis of genetic data from patients in the HNSCC TCGA 
cohort and explore their mechanistic function using cell line knockout models lacking PIK3CA 
or NOTCH1.  Our in vitro studies reveal alterations in gene expression related to epithelial to 
mesenchymal transition and keratinocyte differentiation.  Finally, we used a Cre-inducible, K14-
driven transgenic mouse model displaying two of the most common alterations in these signaling 
pathways, Pik3ca mutation and Notch1 loss, in order to assess the tumorigenic potential of 
changes in one or both of these genes.  We showed that the co-alteration of PI3K and Notch 
signaling accelerated tumor formation, displaying at least additive effects when compared to 
changes in just one of these pathways.  Together, these findings suggest that PI3K-altered, 
NOTCH-deficient tumors may represent a unique and targetable subset of HNSCCs.  While 
restoring the loss of NOTCH signaling will be difficult to achieve clinically and come with other 
toxicities due to the bimodal role of this pathway, PI3K inhibitors may have greater efficacy in 
individuals with inactivating mutations or deletion of NOTCH1, especially when observed with 
activation of PIK3CA.  Studies to evaluate this hypothesis are ongoing; we eager await the 
results of a clinical trial to determine the efficacy of PI3K/mTOR inhibitor bimeralisib in 
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Figure 4-1. Venn diagram for co-alteration of PI3K and NOTCH genes in TCGA HNSCC 
cohort. 
TCGA HNSCC patients with available mutation copy number data (n = 505) data were evaluated 
for the presence of indicated genetic changes.  Pathway or gene alterations included all mutations 
and gene deletion or amplification (two additional copies).  NOTCH1 inactivating mutations 
occurred before amino acid 1440.  PIK3CA mutations included any nonsynonymous mutations 




























Figure 4-2. Sanger sequencing for UM-SCC-47 wildtype and PIK3CA partial knockout 
cells. 
Schematic of sanger sequencing results from UM-SCC-47 PIK3CA partial knockout, showing 3 
bp deletion and 7 bp deletion in PIK3CA. Low levels of wildtype PIK3CA DNA may remain.  






Figure 4-3. Western blot analysis of UM-SCC-47 wildtype and PIK3CA partial knockout 
cells. 
Protein expression of pAKT(Ser473), AKT, and pEGFR(Y1068) was reduced in UM-SCC-47 
PIK3CA partial knockout compared to wildtype cells, while other PI3K isoforms and effectors 





Figure 4-4. Growth rates for UM-SCC-47 wildtype and PIK3CA partial knockout cells. 
Cells were cultured for the indicated periods of time and stained with resazurin for 24 hours.  
Wildtype and PIK3CA partial knockout cells displayed similar rates of proliferation. 
  






























Figure 4-5. UM-SCC-47 PIK3CA partial knockout cells display reduced sensitivity to PI3K 
inhibition as compared to wildtype UM-SCC-47 control cells. 
Cells were treated with increasing concentrations of pan-PI3K inhibitor BKM120 and alpha-



































Figure 4-6. Images of UM-SCC-47 wildtype and PIK3CA partial knockout cells. 
UM-SCC-47 PIK3CA partial knockout cells displayed a more mesenchymal morphology than 






Figure 4-7. qPCR validation of differential DLL1 and HES2 Gene Expression in UM-SCC-
47 PIK3CA partial knockout cells. 
Log2 fold change in mRNA expression of DLL1 and HES2 in UM-SCC-47 PIK3CA partial 







































Figure 4-8. Schema for K14; Pik3ca; Notch1 mouse model. 
Mutant Pik3ca and loss of Notch1 were expressed under the control of a K14-driven Cre 
recombinase.  Mice were administered tamoxifen to induce transgene expression and chronically 
treated with 4-NQO in their drinking water for 16 weeks.  We monitored tumor formation and 
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Figure 4-9. Representative images of tumors observed in transgenic mice following 4-NQO 
exposure. 
Tumor images at time of euthanasia in K14; Notch1c/c; Pik3caH1047R, K14, Notch1c/c, K14; 








Figure 4-10. Time to endpoint in transgenic mice with loss of Notch1 or overexpression of 
mutant Pik3ca. 
Time to endpoint (20% loss of body weight and/or visible lesion upon euthanasia) for mice with 






























Figure 4-11. Representative staining for transgenic mice. 
Images of slides from K14; Pik3caH1047R squamous cell carcinoma samples stained with (A) 












Figure 4-12. Western blot analysis of PI3K, EGFR, and downstream effectors in 
Pik3caH1047R mouse tissue.   
p110a is overexpressed in K14; Pik3caH1047R mouse tissues, and pAKT(Ser473) and PTEN are 
increased in tumor tissue.  There is little change in protein expression for EGFR or downstream 






Figure 4-13. CD8 IHC in transgenic mouse SCC tumors. 
Representative images of CD8 staining in transgenic mouse SCC tumors.  Dense intralesional 
infiltration was observed in K14; Pik3caH1047R; Notch1c/c tissues, moderate intralesional 






Table 4-1. PCR primers, protocols, and product sizes for genotyping. 
Target Rosa26Pik3ca Notch1 Generic Cre 
Primers  
(5’ to 3’ sequences)  
Mutant: GCG AAG 
AGT TTG TCC TCA 
ACC  
Common: AAA GTC 
GCT CTG AGT TGT 
TAT 
Reverse: GGA GCG 
GGA GAA ATG GAT 
ATG 
Forward: CCA ACT 
GCA CTC TTC CAG 
TAA TCG AAG 
Reverse: TGC CTC 
AGT TCA AAC ACA 
AGA TAC GAG GGG 
Forward: CAT 
GCT TCA TCG 
TCG GTC C 
Reverse: GAT 
CAT CAG CTA 
CAC CAG AG 
PCR Program 94°C for 4 min 
40 cycles:  
   94°C  for 30 sec 
   58°C  for 30 sec 
   72°C  for 1 min   
72°C  for 10 min 
94°C for 4 min    
35 cycles:                                               
   94°C  for 30 sec 
   56°C  for 30 sec 
   72°C  for 1 min  
72°C  for 10 min 
94°C for 4 min    
35 cycles:                                               
   94°C  for 30 sec 
   56°C  for 30 sec 
   72°C  for 1 min  
72°C  for 10 min 
Product Size Wild type allele: 650 bp 
Mutant allele: 340 bp 
Wild type allele: 478 bp 






Table 4-2. Primary antibody conditions for western blot analysis. 
Target Supplier Cat. No. Dilution 
p110a Cell Signaling Technology 4249 1:1000 
pEGFR(Tyr1068) Cell Signaling Technology 3777 1:1000 
EGFR Origene TA312545 1:2000 
p-p70 S6 kinase (Thr389) Cell Signaling Technology 9234 1:500 
p70 S6 kinase  Cell Signaling Technology 2708 1:1000 
pMEK(Ser217/221) Cell Signaling Technology 9121 1:1000 
MEK1/2 Cell Signaling Technology 8727 1:1000 
pERK1/2(Thr202/Tyr204) Cell Signaling Technology 4370 1:1000 
ERK1/2 Cell Signaling Technology 4695 1:1000 
pAKT(Ser473) Cell Signaling Technology 4060 1:1000 
AKT Cell Signaling Technology 4685 1:1000 
HSP90 Cell Signaling Technology 4877 1:2000 






Table 4-3. qPCR primer sequences. 
Primer  Sequence (5’ to 3’) 
HES2 F: CATCAACCAGAGCCTGAG 
R: CACGGTCATTTCCAGGAC 
DLL1 F: ACTATAACCTCGTGCAGGACC,                                                                                                           
R: TCAGATGCTTCTCCACCCCTG 
β-actin  F: 5’-AAGTGTGACGTGGACATCCG-3’ 
R:5’-GATGTGACAGCTCCCCACAC-3’ 
HPRT F: 5’-AGATGGTCAAGGTCGCAAGC-3’ 
R: 5’-ATGACACAAACATGATTCAAATCCC-3’ 
RPL19 F: 5’-CCGCTTACCTATGCCCATGT-3’ 
R: 5’-AAATCGCCAATGCCAACTCC-3’ 




Table 4-4. Primary antibody conditions for IHC. 
Target Supplier Cat. No. Dilution 
pAKT(Ser473) Cell Signaling Technologies 4060 1:50 
pPDK1(Ser241) Abcam ab52893 1:100 
CD8 Abcam ab203035 1:200 
PDL1 Cell Signaling Technologies 64988 1:200 
p110a Cell Signaling Technologies 4249 1:50 
p63 Proteintech 12143-1-AP1 1:200 
 
 
Table 4-5. Adverse phenotypes noted in transgenic mice with Notch1 and/or Pik3ca 
alterations and corresponding treatments. 
Phenotype Genotype Affected Treatment 
Eye Lesions K14; Notch1c/c and K14; Notch1c/c; Pik3caH1047R Ophthalmic ointment, applied daily 
Long Nails K14; Notch1c/c and K14; Notch1c/c; Pik3caH1047R Trimming 
Swollen Lymph Nodes K14; Notch1c/+; Pik3caH1047R Close monitoring by veterinary staff 
Swollen Feet K14; Notch1c/+; Pik3caH1047R None 




Table 4-6. Co-alteration of PI3K and NOTCH genes in TCGA HNSCC cohort. 
Number (and percent) of patients (n = 505) with the presence (1) or absence (0) of the indicated 
PI3K and NOTCH pathway alteration in TCGA HNSCC cohort (7-9). 































































































Table 4-7. GSEA in UM-SCC-47 wildtype and PIK3CA partial knockout cells. 
Gene set enrichment analysis was performed with genes differentially expressed between UM-
SCC-47 wildtype and PIK3CA partial knockout cells to identify significant overlap with 
Hallmark, KEGG and GO biological process pathways. Differentially expressed genes were 
defined as those >2-log2 fold upregulated or downregulated in the knockout model relative to the 
wildtype control. Gene Set Name is the pathway enriched, # of Genes in Gene Set is the number 
of genes in the GSEA pathway being tested, and # Genes in Overlap is the number of 
differentially expressed genes in the indicated gene set. 
Gene Set Name 
# Genes in 
Gene Set 
(K) 
# Genes in 
Overlap 
(k) 
k/K p-value FDR q-value 
Hallmark_Interferon_ 
Alpha_Response 97 5 0.0515 9.06E-07 4.19E-05 
Hallmark_Interferon_ 
Gamma_Response 200 6 0.03 1.68E-06 4.19E-05 
Hallmark_Epithelial_ 
Mesenchymal_Transition 200 5 0.025 3.09E-05 3.86E-04 
Hallmark_TNFA 





Table 4-8. Lesion subsite information for transgenic mice. 
For each genotype, the total number of mice as well as the number of mice with lesions is shown.  
In cases where lesion subsite information was known, the number of mice with lip, tongue, 
cheek, and skin lesions is listed along with the total number of lesions per group and the average 
number of lesions per animal. Total lesions and lesions per mouse are calculated based on the 
animals having lesions with known subsites. 






Mice in Group 8 9 8 9 
Mice with Lesion 8 5 7 8 
Mice with Lesion Subsite Known 7 3 6 8 
Mice with Lip Lesion 3 0 4 0 
Mice with Tongue Lesion 2 3 6 8 
Mice with Cheek Lesion 3 0 3 3 
Mice with Skin Lesion 2 1 0 0 
Total Lesions 10 4 13 11 






Table 4-9. IHC scoring summary for transgenic mouse squamous cell carcinoma samples. 
Scores for SCC samples from transgenic mice.  For intensity, 1 indicates weak staining, 2 
indicates moderate staining, and 3 indicates strong staining.  For area, 1 indicates 0-25% of 
stained cells, 2 indicates 25-50% of stained cells, 3 indicates 50-75% of stained cells, and 4 
indicates 75-100% of stained cells.  For CD8, 1 indicates poor intralesional infiltration, 2 
indicates moderate intralesional infiltration, and 3 indicates dense intralesional infiltration. 
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Chapter 5 : Small Molecule Profiling Identifies Novel PI3K inhibitor 
Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma 
Abstract 
 High-throughput, small molecule profiling studies have provided important advances in 
drug development, including in the identification and optimization of targeted therapies for 
various cancer types.   Given the limitations of these treatments, which often display inadequate 
efficacy as monotherapies due to both intrinsic and acquired resistance, novel approaches are 
needed to improve clinical responses.  Here, we sought to improve the effects of targeted 
phosphatidylinositol 3-kinase (PI3K) inhibitors in head and neck squamous cell carcinoma 
(HNSCC) by using these agents in combination with other small molecules inhibiting pathways 
that might be responsible for drug resistance.  To do so, we developed and optimized a 
combinatorial screening approach that utilized a resazurin cell viability assay.  This assay was 
used to test a library of >1400 clinically-relevant small molecule inhibitors alone and in 
combination with two PI3K inhibitors in ten patient-derived HNSCC cell lines, 
generating >150K data points characterizing the landscape of combinatorial PI3K inhibitor 
responses in HNSCC and potentially other PI3K-driven cancer types.  Our results demonstrated 
that dual treatment with inhibitors of PI3K and several upstream RTKs resulted in synergistic 
responses, but that combinations targeting downstream PI3K effectors were less effective.  We 
more fully characterized the phenotypic effects of one of our most effective drug pairs, PI3K and 




cycle in a diverse panel of cell lines.  We also further investigated the role of ALK and IGF-1R in 
PI3K inhibitor responses using CRISPR/Cas9 approaches and demonstrated using a kinase 
knockout library that genetic knockout of ALK or IGF-1R can result in sensitivity to PI3K 
inhibitor treatment.  Finally, PI3K inhibitor pictilisib and ALK/IGF-1R inhibitor brigatinib were 
tested in a xenograft model, and combination treatment resulted in a synergistic reduction in 
tumor volume.  Based on the efficacy of PI3K and ALK/IGF-1R inhibitor co-treatments, our 
findings motivate further pre-clinical evaluation of these therapies and offer a dataset that might 
provide improved treatment options and better prognoses for patients with HNSCC and other 
cancer types. 
Introduction 
In recent years, targeted therapies have shown promise as effective treatment options for 
cancer patients; however, significant challenges in target identification and patient selection 
remain and limit the optimal uses of these cancer therapeutics.  Previously, unbiased small 
molecule profiling studies have provided an efficient means by which to prioritize leads for 
further validation and in doing so have successfully delivered solutions for many shortcomings 
of targeted therapy treatments.  The generation of large screening datasets has effectively aided 
the optimization of compounds with activity against established targets, the design of additional 
molecules to alter previously understudied drug targets, and the identification of biomarkers to 
guide personalized medicine protocols (1-7).   In spite of these advances, both innate and 
acquired mechanisms of resistance to these targeted inhibitors impede the durability of patient 
responses and present a major, ongoing concern.  One potential means of overcoming resistance 
is using two or more targeted agents simultaneously; such combination treatments may inhibit 




tumor cells and deliver improved responses.  Here, we sought to address the problem of 
resistance to targeted therapy using high throughput screening techniques.  Using a specific drug 
class and tumor type, our study seeks to demonstrate the validity of this approach.  Specifically, 
we generated >150,000 data points using small molecule combinations to identify and target 
factors driving resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in head and neck 
squamous cell carcinoma (HNSCC).  
HNSCC has long been characterized by poor responses to treatment, and survival 
statistics remain dire today.  This form of cancer is the sixth most common by incidence 
worldwide (8) and affects 830,000 new patients each year (9, 10).  HNSCCs occur in various 
sites of the upper aerodigestive tract, including the oral cavity, larynx, oropharynx and 
hypopharynx.  Many HNSCC cases can be attributed to the excessive use of tobacco and/or 
alcohol or to infection with high-risk strains of human papilloma virus (HPV).  While surgery, 
radiation, and cytotoxic chemotherapy are the most frequently used treatments for HNSCC 
patients, recurrence and metastasis remain widespread.  Furthermore, despite the FDA approval 
of epidermal growth factor receptor (EGFR) antibody cetuximab and immunotherapy 
(programmed death (PD)-1 checkpoint blockade via pembrolizumab and nivolumab) (11-15), 
response rates remain low and patient selection is an ongoing challenge.  The identification of 
additional drug targets and biomarkers for response is therefore an area of unmet and urgent need 
in this cancer type.  
Sequencing studies have provided insight into other targeted therapies that may prove 
effective in HNSCC.  Of these, inhibitors of PI3K are one promising option, given that genes in 
the PI3K pathway are altered via mutation or copy number alteration in as many as 2/3 of 




shown underwhelming efficacy and/or limiting toxicity for these agents in head and neck cancer 
patients (19, 20).  One of the most promising of these studies, a recent phase 2 trial of buparlisib 
(BKM120) in recurrent and metastatic HNSCC, demonstrated that this PI3K inhibitor provided 
benefit beyond that achieved with standard-of-care paclitaxel in a subset of recurrent/metastatic 
head and neck cancer patients; nevertheless, the majority of PI3K inhibitor-treated patients were 
non-responsive (20). In light of these findings, we proposed that the addition of other inhibitors 
to PI3K pathway targeting drugs might improve responses.  Some PI3K inhibitor combination 
trials are ongoing in HNSCC, but these have to date not improved progression-free, overall 
response rate, or overall survival (21), and the trials have been limited to agents targeting PI3K 
and EGFR (eg: NCT01816984, NCT2282371, NCT02822482) or PI3K and CDK4/6 
(NCT03065062). 
 In order to better define the landscape of resistance to PI3K inhibitors in HNSCC and 
prioritize additional combination inhibitors for evaluation in future clinical studies, we tested a 
library of small molecule inhibitors in a diverse panel of PI3K aberrant HNSCC cell lines as 
single agents and combinations with PI3K inhibitors.  In doing so, we sought to uncover both 
expected and unexpected synergistic drug pairs, which could be validated and advanced in 
additional HNSCC models.  As a whole, we present here a wealth of data regarding responses to 
mono- and dual-therapy treatments and provide as a resource that might inform future clinical 







Cells were cultured in a humidified incubator at 37°C with 5% (vol/vol) CO2. UM-SCC cells 
(University of Michigan) and Cal-33 cells (a kind gift from Dr. Anthony Nichols) were 
previously derived from HNSCC patient tumor samples and cultured in DMEM with 10% FBS, 
1X Pen/Strep, 1X NEAA (22). HSC-2, HSC-4 (both from Japanese Collection of Research 
Bioresources) and Detroit 562 (from American Type Culture Collection) cells were cultured in 
EMEM with 10% FBS, 1X Pen/Strep.  All cell lines were genotyped to confirm authenticity, as 
described previously (22), and were tested to confirm lack of mycoplasma contamination. 
For small molecule profiling studies (both in experiments using the Selleckchem inhibitor library 
and in the secondary validation screen), low-passage cell lines were frozen in large aliquots (5-
10 million cells each).  After aliquots were thawed, in order to minimize genetic drift over 
extended periods of time in culture, cells were passaged five or fewer times before fresh stocks 
were obtained and used.  A single lot of FBS was used for all small molecule profiling and 
reverse-format validation experiments. 
Details of DNA copy number analysis for UM-SCC cell lines are published elsewhere (23).  All 
UM-SCC cell lines were confirmed to contain PIK3CA as previously reported (24).  Cal-33, 
HSC-2, and HSC-4 copy number data were obtained from the publicly available canSAR 
database (25, 26).  PIK3CA alterations were previously confirmed via Sanger sequencing (27). 
Chemicals 
All compounds, including inhibitor libraries using in small molecule profiling, were purchased 
from Selleck Chemicals.  For small molecule profiling, the Selleckchem inhibitor library 




five or fewer freeze-thaw cycles before being retired from use.  All other compounds were 
initially dissolved in 100% sterile DMSO to 10 mM and then diluted in media to the indicated 
concentrations for studies in vitro.   
Resazurin Cell Viability Assay 
To study relative cell viability, 2,000 cells per well (for all cell lines except HSC-2, for which the 
cell density was reduced to 1,000 cells per well due to large cell size and rapid growth rate) were 
seeded (in 50 µL volume) in 384-well microplates using a Multiflo liquid handling dispensing 
system. The following day, cells were treated with complete media containing inhibitor or 
DMSO using the Agilent Bravo Automated Liquid Handling Platform and VWorks Automation 
Control Software.  For small molecule profiling studies, the Selleckchem inhibitor library 
(Appendix 1) was diluted 20X into complete media (3 µL inhibitor into 60 µL media) and mixed 
well, for a final concentration of 500 µM.  A second intermediate plate was generated by 
transferring 14 µL of 500 µM inhibitor in media to into the first quadrant of a 384 deep well 
plate (Axygen, Cat No: 14-222-227), which contained 90 µL of complete media in quadrants 1 
and 3 and 70 µL of complete media in quadrants 2 and 4. 30 µL from the first quadrant was 
transferred, and 10 µL from the first quadrant was transferred to the third quadrant .  For the final 
dilution, 30 µL of inhibitor in media from the third quadrant was added to the fourth quadrant.  
Following each transfer, ten pipetting cycles were performed to ensure complete and thorough 
mixing of the inhibitor with the media.  This intermediate plate was then diluted 10X onto cells 
to achieve final drug concentrations of approximately 5, 1.5, 0.5, and 0.15 µM.  Each well of 
cells was also treated with media containing DMSO (positive control wells and monotherapy 
plates) or PI3K inhibitor (combination plates) using the Multiflo liquid handling dispensing 




AKT phosphorylation and cell viability after treatment (data not shown) and are listed in Table 
5-1.  For all other resazurin experiments (including secondary validation screens), cells were 
treated with 0.5% inhibitor or DMSO in a 10-point two-fold dilution series in quadruplicate. To 
accomplish this, 96-well plates were prepared with inhibitors in 200X concentration and then 
diluted to 10X concentration in media in a second 96-well plate. These inhibitors were then used 
to treat the cells with the desired compound concentration, again using liquid handling robotics. 
In all cases, cells were stained with 10 μL of 440 μM resazurin (Sigma) dissolved in serum-free 
media for 12-24 hours before fluorescent signal intensity was quantified. Quantification occurred 
after 72 hour treatment using the Cytation3 fluorescence plate reader at excitation and emission 
wavelengths of 540 and 612 nm, respectively.  To generate concentration response curves, data 
were plotted in Prism 8 using the log(inhibitor) vs. response -- Variable slope model with four 
parameters (IC50, top, bottom, and Hill slope) allowed to vary.   
Trypan Blue Dye Exclusion Assay 
To test for cell membrane integrity and access cell viability, 24,000 cells per well were seeded 
into 24-well cell culture plates. The following day, cells were exposed to DMSO or inhibitor in a 
multipoint dose-response. After 72 hour exposure, cells were trypsinized, pelleted, and 
resuspended in in 50 μL of medium. 10 μL of the suspension was mixed with 10 μL of trypan 
blue dye (0.4% Invitrogen) and viability was measured using Countess Automated Cell Counter 
(Invitrogen). Both total cell number and percent viability were recorded for the assay.  
Annexin V Apoptosis Assay 
To study Annexin V presentation, 100,000 cells per well (for all cell lines except Detroit 562, for 
which the cell density was increased to 115,000 cells per well as used in previous studies (27)) 




complete media and 1 mL of media containing DMSO or inhibitor(s).  Cells were cultured for 72 
hours.  At this time point, media was collected from each well.  Each well was then washed in 
PBS, which was also collected.  Finally, cells were trypsinized and added to the suspension.  
Samples were then centrifuged, washed once with PBS, and counted using the Countess 
Automated Cell Counter (Invitrogen).  50,000 cells per sample were stained with Annexin V 
FITC and PI using the Dead Cell Apoptosis Kit (Cat No: V13241; ThermoFisher) according to 
manufacturer’s instructions. 2.5 µL of Annexin V FITC and 2.5 µL of PI were added to each 
sample.  Samples were incubated at room temperature in the dark for 15 minutes and analyzed 
using the Bio-Rad ZE5 Cell Sorter at the University of Michigan Flow Cytometry Core.  
Cell Cycle Analysis 
To perform cell cycle analysis, 300,000 Detroit 562 cells per well or 350,000 HSC-4 cells per 
well were seeded in six-well plates.  After 24 hours, media was aspirated and replaced with 2 mL 
of complete media containing DMSO or inhibitor(s).  Cells were cultured for 24 hours, and 10 
µM EdU was added to each well during the final hour of treatment.  At the 24 hour time point, 
media was aspirated from each well.  Each well was then washed in PBS.  Finally, cells were 
trypsinized and collected.  Samples were then centrifuged and washed once with 1% BSA in 
PBS (Invitrogen).  Each sample was fixed, permeabilized, and stained using the Click-it EdU 
Flow Cytometry Assay kit (Cat No: C10425, ThermoFisher) according to manufacturer’s 
instructions. Cells were resuspended in 500 µL of FxCycle PI/Rnase Staining Solution (Cat No: 
F10797; Invitrogen) and analyzed using the Bio-Rad ZE5 Cell Sorter at the University of 





Cells at 70-80% confluency were treated with DMSO or inhibitor prior to harvesting and lysing 
in radioimmunoprecipitation assay buffer (Cat No. 89900; ThermoFisher) containing 1% NP-40 
and 0.1% SDS. 8-50 micrograms of each cell harvest was used, and standard western blot 
protocols were followed as previously described (28). Primary antibodies (described in detail in  
Table 5-2) were incubated overnight at 4°C or for at least 1 hour at room temperature, followed 
by a goat anti-rabbit horseradish peroxidase (Cat No. 111-035-045; Jackson ImmunoResearch) 
secondary antibody at room temperature for 1 hour as described (29). The blots were then 
visualized with chemiluminescence and imaged. 300dpi or greater images were digitally retained 
from all westerns and representative blots are shown. 
Combination Inhibitor Response Analysis 
To compare effects of inhibitors from our small molecule library as monotherapies and in 
combination with PI3K inhibitors, we developed a scoring scheme to rank the inhibitors based 
on their effects in each cell line.  This score (S) was calculated from the difference in relative 
viability between the monotherapy and combination therapy treatment at each concentration of 
library inhibitor using the formula: 
𝑆 = #max	(0, 𝑠𝑖𝑔𝑛(𝑠/)𝑠/1 + 𝑠𝑖𝑔𝑛(𝑠1)𝑠11 + 𝑠𝑖𝑔𝑛(𝑠3)𝑠31 + 𝑠𝑖𝑔𝑛(𝑠4)𝑠41) 
 
where s1, s2, s3, and s4 are the scores (i.e. absolute difference) of the four doses and sign(si) is the 
sign (+1 for positive numbers and -1 for negative numbers) of si. 
In order to eliminate effects of non-biological responses, we added two additional 
qualifications: (1) for monotherapies, if treatment with a higher concentration of library inhibitor 




concentration, and (2) for combinations, if a lower concentration of library inhibitor resulted in 
an unexpected lower viability, the viability will be set as that with the adjacent higher 
concentration.  These qualifications minimize the effect of any non-biological responses on the 
score and/or rank of an inhibitor.  Any score less than zero (indicating that combination 
treatment increased cell viability as compared to monotherapy) was set as zero.  Separate scores 
were generated to assess the effect of PI3K inhibitor combination with each PI3K targeting agent 
(HS-173 or BKM120).  These scores were combined to generate a score evaluating effects 






where sH and sB represent the scores for HS-173 (H) and BKM120 (B) in the individual cell 
lines.   
To prioritize inhibitors tested in secondary validation screening, compounds from the 
validation set were categorized into three groups based on their effect in combination with HS-
173.  The first group of inhibitors did not decrease cell viability as monotherapy over the 
concentration range tested and did not improve the efficacy of HS-173, thus representing false 
positives from the profiling experiment and/or combinations with effects specific to cell lines 
that were not tested in validation screens.  The second group of inhibitors had some efficacy as 
monotherapies and improved the response to HS-173.  However, the combination effects were 
additive and/or not dose-dependent.  The final group of inhibitors represented compounds that 
appeared synergistic with HS-173, improving the effect of PI3K inhibitor monotherapy in a 




 Synergy scores across multiple cell lines were combined as a weighted average to 
evaluate the recurrence of potentially synergistic combination effects across various HNSCC 
models.  To calculate this recurrence score, PI3K inhibitor synergy scores from individual cell 
lines were used in the following equation, analogous to the one above for evaluating the effects 
of combinations with BKM120 and HS-173: 
𝑆 = (√




where s1H, s1B, s2H, s2B, …, s10H, and s10B represent the combined scores for erlotinib (H) and 
gefitinib (B) in the individual cell lines.   
 The relative combination effects of HS-173 and the top inhibitors from the validation 
screen (AZD3463, entrectinib, TAE226 and PCI-24781) were compared using the scores 
generated by Chalice Bioinformatics software (Horizon Discovery Group) using the Loewe 
model of synergy (30-32).  Chalice software was also used to evaluate the effect of various PI3K 
and RTK inhibitors in Figure 5-5, Figure 5-6, Figure 5-7, and Figure 5-8.  Combenefit 
software (33) was used to generate synergy plots, also using the Loewe model of synergy.  For 
Figure 5-14, an R script was written (modeled after the Chalice software and Loewe synergy 
model) to assess the combination effect of any dual-therapy.  This program will be made 
available at a later date as further optimization is currently being performed. 
Heatmaps 
Unsupervised hierarchical clustering was performed using Multiple Experiment Viewer (MEV) 
to order responses by cell line-PI3K inhibitor combinations in Figure 5-5.  Heatmaps were 




Kinase Library Preparation 
UM-SCC-108 cells were transduced with the Human Kinase Lentiviral CRISPR Pool (Sigma 
Aldrich HKCRISPR). Conditions for transduction were established for a multiplicity of infection 
(MOI) of 30%. After 7 days of puromycin selection, the cells were expanded and seeded per 
treatment. To preserve at least 300x coverage, 3 million cells per treatment were needed. 
Triplicate pools of cells were treated with DMSO, 0.25 µM HS-173 or 0.25 µM BKM120.  
Inhibitors were applied for three days, then cells were cultured in media without drug for three 
days.  This treatment was applied for two cycles and at the end of the second cycle, DNA was 
extracted from the remaining cells using Gentra Puregene Cell Kit (Qiagen).  
To preserve coverage of the Kinase Library, 12 µg of DNA was used to PCR amplify the gRNA 
sequence using the Herculase ii Fusion DNA Polymerase (Agilent, Cat No: 600675). 2 reactions 
with 6 µg input DNA was amplified with the following primers: 
PCR #1 Forward : AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG 
PCR #2 Reverse: CTCGATTAATTAAGGTTGCTCACTTGTCGACTAATGC 
The two reactions were then combined, and 5 µL were used to set up the second round of PCR 
reactions, using the following primers: 
PCR #2 Forward: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
T(1-9bp stagger)AAGTAGAGtcttgtggaaaggacgaaacaccg 






Uppercase sequence represents Illumina adapters. The forward primer has the TruSeq Universal 
Adapter, and the reverse primer consists of Illumina P7, 8bp index, and multiplexing PCR primer 
2.0. The underlined sequence represents an 8bp barcode. Lowercase letters are the priming sites 
for the lentiviral construct. 
The PCR products were gel extracted and purified using Gel Extraction PCR Purification Kit 
(Qiagen). Samples were then submitted to the University of Michigan DNA Sequencing Core for 
sequencing with Illumina MiSeq V3 Kit. 
Analysis of Kinase CRISPR Library 
Reads were demultiplexed by barcode and then mapped to the corresponding reference library 
using an in-house python script. gRNA counts were input into Model-based Analysis of 
Genome-wide CRISPR/Cas9 knockouts (MAGeCK, v0.5.2) (34). MAGeCK algorithms 
calculated significant gRNAs and genes, and genes with an α-RRA score of ≤ 0.05 were 
considered significantly depleted. 
RNA Isolation and qPCR 
Cells were harvested in Qiazol (Cat No: 79306; Qiagen) and stored at -80°C.  RNA was isolated 
using the Qiagen RNeasy Mini Kit (Cat No: 74106) according to manufacturer’s protocols, and 
then quantified using the Qubit fluorometer (ThermoFisher).  cDNA was synthesized using the 
SuperScript Vilo cDNA Synthesis kit (Cat No: 11754250; ThermoFisher), also using 
manufacturer’s protocols, in the GeneAmp® PCR System 9700 (Applied Biosystems).  qPCR 
analysis for each cDNA sample was performed with Quantitech SYBR green (Cat No: 204143; 
Qiagen) on the QuantStudio instrument (ThermoFisher).  Primers were purchased from 




Table 5-3. Analysis was performed using QuantStudio Design &Analysis Software v1.3.1 
software (ThermoFisher) and Microsoft Excel. Changes in cycle times were compared to the 
geomean of three housekeeping genes (b-actin, HPRT, and RPL19).  Triplicate determinations 
for each sample were compared to controls.   
Generation of CRISPR Knockout Cell Lines 
HSC-4 cells were seeded in six-well plates and transfected with TrueCut Cas9 Protein v2 and 
gRNA using Lipofectamine™ CRISPRMAX™ Transfection Reagent (Invitrogen) using 
manufacturer’s protocols.  For ALK and IGF-1R, respectively, the following crRNA sequences 
were obtained from ThermoFisher and used: 5’-GCTCCGAGGAGGAT-3’ and 5’-
TCACGGTCATTACC-3’.  Cells were expanded and isolated as clones using single-cell 
dilution. 
Genomic DNA Isolation  
Cells were harvested and washed in PBS, then frozen at -20ºC. The pellet was then thawed and 
transferred to 700 µL of Nuclei Lysis Solution (Promega) for 1 hour at 55ºC. 200 µL of Protein 
Precipitation Solution (Promega) was added to the sample, which was then mixed and 
centrifuged at 13,000 RPM for two minutes. The supernatant was then transferred to a tube 
containing 600 µL of isopropanol, incubated for 15 minutes, and centrifuged at the same speed 
for another minute. The DNA pellet was washed in 70% ethanol, dried, and re-suspended in 35-
50 µL of nuclease-free water.  
PCR and Sanger Sequencing 
DNA from HSC-4 knockout cells was amplified using PCR with Platinum Taq DNA Polymerase 
High Fidelity (Invitrogen) according to manufacturer’s protocols and with primers that targeted 




CGACGCAACCCTCCAAGAT-3’ and REV: 5’-AGGAGGCCGTTTACTACT-3’) or IGF-1R 
(primer sequences: FWD: 5’-CGACATCCGCAACGACTATC-3’ and REV: 5’- 
GAGGTTGGGGAAGAGGTCTC -3’). PCR products were inserted into the pCR8 vector system 
(Cat No: K250020, ThermoFisher) and transformed into Mach1 competent cells, again according 
to manufacturer’s protocols. Bacteria cultures from individual colonies on LB + spectinomycin 
plates were grown overnight and DNA was isolated using the Qiagen mini-prep protocol (Cat 
No: 27106) according to manufacturer’s protocols. The DNA product was analyzed via Sanger 
sequencing at the University of Michigan DNA Sequencing Core on the 3730XL DNA 
Sequencer (Applied Biosystems). Sequences were aligned using the DNASTAR Lasergene 
software suite. 
Xenografts 
Animals were housed in a vivarium accredited by the Assessment and Accreditation of 
Laboratory Animal Care at the University of Michigan. Veterinary care was provided by the 
University of Michigan Unit for Laboratory Animal Medicine (ULAM), and all procedures were 
performed according to Institution for Animal Care and Use Committee-approved protocol 
PRO00008065.  Athymic nude mice (both male and female, 1-3 months old) were 
subcutaneously injected with 2 million UM-SCC-108 cells per flank. After allowing tumors to 
become palpable (~1 week following injection), treatment with vehicle (10% NMP, 90% 
PEG300), pictilisib (100 mg/kg), brigatinib (50 mg/kg), or combination was administered via 
oral gavage in 200 µL per 20 g mouse three times per week for three weeks. Inhibitors were 
prepared fresh or used after storage at 4°C for no more than 1 week. To improve inhibitor 
solubility in vehicle, sonication was used for at least 5 cycles of 20 sec at 50% amplitude and 10-




calipers and calculated using the formula width x length 2 x pi/6) were recorded 2-3 times per 
week. General health was monitored with euthanasia required upon loss of 20% body weight (as 
compared to highest weight recorded), the presence of ulceration exceeding half the surface area 
of the tumor, tumor length greater than 20 mm, or tumor volume greater than 3000 mm3. 
Statistical Analysis 
To determine if statistically significant differences occurred with combination treatments in trypan 
blue dye exclusion and annexin V apoptosis assays, a two-way ANOVA was performed in R to 
compare the natural logarithm of the percentage of living cells following vehicle, PI3K inhibitor 
monotherapy, RTK monotherapy, or combination treatment. Specifically, this test was performed 
using type III analysis with the “Anova” function from the “car” package.  Bonferroni correction 
was used to adjust p-values. 
For comparisons of tumor volumes in xenograft studies, an unpaired, t-test was used to compare 
the average tumor volume for mice from each group using Prism 8 software. 
 
Results 
To identify potential mechanisms of resistance to PI3K inhibitor monotherapies in 
HNSCC, we tested a library of small molecule inhibitors in combination with vehicle (DMSO) 
or low concentrations of two PI3K inhibitors in a diverse panel of patient-derived HNSCC cell 
lines (Appendix 1).  To select PI3K inhibitors for these studies, we performed preliminary 
experiments, which demonstrated that pan and p110a selective pharmacologic agents were more 
effective than those directed against p110b, g, and d (Figure 5-1), consistent with the fact that 
activating aberrations in PIK3CA are more frequent than alterations in other PI3K pathway gene 




37) to extend progression free and overall survival in recurrent and metastatic HNSCC (20, 38), 
we chose this inhibitor for use in combination studies.  HS-173 was the most effective selective 
p110a inhibitor in our preliminary data, and as such was chosen as the second combinatory PI3K 
inhibitor (39, 40).  Concentrations for these inhibitors were selected such that they inhibited 
viability (relative to vehicle-treated controls) by no more than 25% yet demonstrated reduced 
downstream signaling (assessed based on decreased AKT phosphorylation at the Ser473 residue 
following drug treatment, data not shown)  (Table 5-1).   
The ten cell lines used in this study were chosen to represent clinical HNSCC cases that 
would be nominated for biomarker-driven trials of PI3K inhibitor combinations.  Each cell line 
model displayed genetic alteration in PIK3CA: four harbored PIK3CA mutations (HSC-2, HSC-
4, Detroit 562, and UM-SCC-43), while the others had amplification of wild type PIK3CA with 
an average copy number anywhere between 2.67 (UM-SCC-55) to 6 (UM-SCC-69) copies of 
this gene (23, 27).  As HPV negative and oral cavity HNSCCs represent those patients with the 
poorest clinical prognosis (41), most of the selected cell lines also displayed lack of high risk 
HPV strains and were derived from oral cavity subsites.  UM-SCC-104, which is HPV positive, 
and Detroit 562, which was derived from a metastatic pharynx cancer, are the only exceptions. 
The small molecule library used for these profiling experiments included 1406 inhibitors, 
most of which are FDA-approved or in clinical development for cancer or other diseases.  
Inhibitors were classified into 23 pathways based on their molecular targets (Appendix 1, 
Figure 5-2) and were used to treat cells for 72 hours before viability was measured using a 
resazurin cell viability assay.  The initial phase of our small molecule profiling studies generated 
more than 150,000 data points characterizing nearly 15,000 drug-cell line pairs.  Each of these 




approximately 0.15 to 5 µM.  Each inhibitor was used as a single agent and in combination with 
the two PI3K inhibitors, and results were quantified using a synergy score for each PI3K 
inhibitor combination (HS-173 score, BKM120 score) or the collective effect of both PI3K 
inhibitor combinations (PI3K inhibitor score) (Figure 5-5A, also see Materials and Methods for 
further details on scoring schemes). Clustering of these scores by cell line (Figure 5-5A) 
revealed that HS-173 and BKM120 scores for 9/10 (90%) of models grouped together, as would 
be expected.  Cell lines with mutations in PIK3CA clustered in two groups—Detroit 562, UM-
SCC-43, and HSC-2 HS-173 scores aligned together, while HSC-4 and HSC-2 BKM120 scores 
clustered in a separate group.  PIK3CA copy number and gene expression did not seem to affect 
clustering. 
In order to nominate potentially synergistic PI3K inhibitor combinations from these 
profiling experiments, we selected 96 inhibitors from our 1406-member library (Appendix 1) 
and tested them in a validation screen.  These agents were chosen based on two main factors: (1) 
magnitude of synergy score and (2) recurrence of potential synergistic effects across cell line 
models.  To quantitatively compare these two factors for each inhibitor, we developed a 
“recurrent synergy score”, which combined the HS-173 score and BKM120 score for each of the 
ten cell lines into a single metric of potential synergy with PI3K inhibitors.  Based on this 
summary score, the second most effective PI3K inhibitor combination therapy in our screen was 
irreversible EGFR/ERBB2 inhibitor afatinib.  This was strong initial validation for our approach, 
as previous work from our laboratory and other groups has demonstrated the important role of 
the epidermal growth factor receptor (EGFR) in PI3K inhibitor resistance in HNSCC (27, 42-
48).  Additional combinations with potential synergy include those inhibiting both PI3K and 




kinase, Bcl-2, histone deacetylase complex (HDAC), and focal adhesion kinase (FAK).  Other 
inhibitors with high recurrent synergy scores were included in the validation set to increase the 
overall diversity of the combinations that we considered: together, these 96 inhibitors included 
drugs directed against more than 75 different target genes. 
Each of the inhibitors in the validation set was tested using a reverse-format approach:  
instead of titrating library inhibitors against a single concentration of PI3K inhibitor as in the 
original screen, four-point concentration response curves were generated for p110a-selective 
inhibitor HS-173 as a monotherapy and with four concentrations of each inhibitor from the 
validation set (Figure 5-3).  These experiments were performed in PIK3CA mutant models HSC-
2, HSC-4, and Detroit 562 and validated using positive control combination HS-173 + afatinib 
and negative control combination HS-173 + AZD4547 (Figure 5-4) (27).  Each inhibitor from 
the validation set, based on its effect with HS-173, was then manually placed in one of three 
groups (no combination effect, additive, or synergistic).  Approximately 25% of the inhibitors in 
the validation set were confirmed as potentially synergistic in one or more of these three models 
using the reverse-format screen.  Of the potentially synergistic inhibitors, five pathways were 
further prioritized with 1-3 inhibitors considered for each pathway: ALK (tested using ALK/IGF-
1R inhibitor AZD3463 and ALK/Ros1/Trk inhibitor entrectinib), JAK (AZ960, AT9263, and 
TG-101348), IGF-1R (BMS-754807 and ADW541), FAK (PF-566271 and TAE226), and 
HDAC (PCI-24781).  Of these ten compounds, AZD3463, entrectinib, TAE226, and PCI-24781 
showed the greatest efficacy in combination with HS-173 in HSC-2, HSC-4, and Detroit 562 
cells and as such were characterized in a large panel of HNSCC cell lines, including models with 
variation in genetic characteristics, gene expression profiles, and HPV status (Figure 5-5C, 




the Loewe synergy model (32).  A subset of cell lines displayed synergistic responses to each 
PI3K inhibitor combination, while others responded additively or did not respond to mono- or 
dual-therapy.  In general, these responses did not correlate with PIK3CA mutation status or 
expression level (Figure 5-5C, Figure 5-7); in this dataset, Chalice score was significantly 
higher for HS-173 and TAE226 combination treatment in cell lines with PIK3CA mutations 
(Figure 5-5Ciii), but this association was lost on further analysis with independent PI3K and 
FAK inhibitor combinations (Figure 5-14).  
Using a PIK3CA amplified model with a CRISPR kinome library available in our lab, we 
then set out to complement our small molecule profiling approach by identifying genes that, 
when knocked out, conferred sensitivity to PI3K inhibitor monotherapy.  UM-SCC-108 cells had 
been previously transduced with the Human Kinase CRISPR Knockout Library, which contains 
gRNAs targeting 684 kinases with approximately nine gRNAs per gene.  We treated the UM-
SCC-108 kinome knockout library cells with DMSO, 0.25 µM HS-173, or 0.5 µM BKM120 for 
14 days and sequenced the remaining cells.  We then used the MAGeCK algorithm to identify 
gRNAs and genes that were significantly depleted in HS-173 or BKM120-treated samples 
relative to controls.  This analysis identified 118 gRNAs that were significantly depleted (p-value 
≤ 0.05) in the BKM120-treated population and 124 gRNAs that were significantly depleted in 
the HS-173-treated population.  Of these, 21 gRNAs overlapped between the two PI3K inhibitor 
treatments.  Consistent with other studies, knockout of AXL and ERBB3 increased sensitivity to 
PI3K inhibition (31, 49, 50).  In support of our small molecule profiling results, which 
demonstrated that UM-SCC-108 cells were synergistically responsive to PI3K and ALK/IGF-1R 
inhibitors, ALK knockout cells were significantly depleted after BKM120 treatment (p = 0.014) 




Given the efficacy of HS-173 in combination with AZD3463 or entrectinib in several 
HNSCC models and the results of the kinase knockout screen, we next performed further 
experiments to validate and characterize the potential role for ALK and/or IGF-1R signaling as a 
mechanism of resistance to PI3K inhibitor treatment.  ALK fusions play an important oncogenic 
role in other cancer types, including lung cancer and neuroblastoma (51-55); to date, the clinical 
use of ALK inhibitors has been primarily limited to ALK-fusion positive patients of these cancer 
types.  On the other hand, ALK fusions are rarely observed in HNSCC (~1%) (56), and ALK 
inhibitors have not been used effectively as monotherapies in cases lacking these fusions.  
Recent preclinical data suggests that co-targeting ALK and EGFR may be effective in some 
HNSCCs (57, 58), but the combined effect of PI3K and ALK inhibition has not been examined 
in cancers at this anatomic site.  To investigate the co-dependence of PI3K and ALK in HNSCC, 
we first determined the responses of three HPV negative, PIK3CA mutant cell lines (HSC-2, 
HSC-4, and Detroit 562) to a panel of PI3K and ALK inhibitors in various combinations (Figure 
5-8).  We observed responses that were additive to synergistic with HS-173, BKM120 and 
pictilisib (59) in combination with inhibitors targeting ALK and/or IGF-1R (AZD3463, 
entrectinib, crizotinib, TAE684, BMS-754807, and brigatinib).  Synergistic responses were not 
observed with p110b inhibitor TGX-221 , demonstrating the specific role of PI3K’s alpha 
isoform in synergistic responses.  Similarly, replacing ALK/IGF-1R inhibitors with Trk inhibitor 
PF-06273340 or FGFR inhibitor BGJ398 did not recapitulate synergistic responses in any of the 
models, suggesting a need to inhibit ALK/IGF-1R. 
We then expanded our analysis to cell lines with amplification of wildtype PIK3CA or 
HPV positivity.  Using trypan blue exclusion assays, we tested the effect of PI3K inhibitor 




monotherapy (brigatinib), and each PI3K and ALK inhibitor combination.  Pictilisib and 
brigatinib combinations caused a significant reduction in the percentage of living cells in all 
models, with BKM120 combinations trending toward statistical significance (Figure 5-8B, see 
Table 5-5 for p-values by two-way ANOVA).  Next, annexin V apoptosis assays were used to 
determine the percent of FITC positive cells in HSC-4, Detroit 562, UM-SCC-103 and UM-
SCC-69 after vehicle, PI3K inhibitor monotherapy, ALK inhibitor monotherapy, or dual-therapy.  
For each cell line, pictilisib and brigatinib combination-treated cells displayed significantly 
higher levels of FITC positivity than monotherapies (Figure 5-8C).  BKM120 and brigatinib 
combinations trended toward synergistic responses, while TGX-221 and brigatinib combinations, 
as expected, resulted in levels of apoptosis that were comparable to monotherapies (Table 5-6).  
Apoptotic responses were confirmed using western blot for caspase and PARP cleavage in the 
same four cell lines (Figure 5-8D, Figure 5-9).  Similarly, cell death by apoptosis was observed 
with HS-173 and AZD3463 combinations (Figure 5-10).  Synergistic drug combinations also 
affected the cell cycle in PIK3CA mutant HSC-4 cells, resulting in a reduction in the percentage 
of cells going through S-phase (as measured using EdU positivity) (Figure 5-8E).   
Because brigatinib has been reported to inhibit not only ALK but also other targets (most 
notably IGF-1R (60), we took a genetic approach to determine whether ALK, IGF-1R, or both 
were contributing to combination responses in HSC-4 cells.  We hypothesized that loss of the 
critical mediator of response would sensitize cells to treatment with PI3K inhibitor monotherapy.  
Using CRISPR/Cas9, we generated and characterized genetic knockouts of ALK and IGF-1R 
(Figure 5-11A, Figure 5-12).  No dramatic differences were noted in sensitivity to PI3K 
inhibition in the ALK or IGF-1R knockout cell lines as compared to those seen in wildtype HSC-




5-11B).  RNA sequencing is currently being performed to evaluate differences in gene 
expression between wildtype and knockout cell lines and identify additional mediators of PI3K 
inhibitor resistance.  qPCR experiments for a small panel of genes did not demonstrate 
significant differences in mRNA levels for AKT1, PDK1, IGF-1R, or PIK3CA between HSC-4 
wildtype and ALK knockout or HSC-4 wildtype and IGF-1R knockout cells (Figure 5-13).  ALK 
gene expression was ~4-fold lower in IGF-1R knockout cells; however, this decrease does not 
suggest that ALK signaling is preventing PI3K inhibitor sensitivity in the IGF-1R knockout 
model. 
We next sought to validate other potentially synergistic combinations and compare them 
to PI3K + ALK inhibitor dual-therapies.  To do this, we first tested a subset of the molecular 
pathways that might mediate resistance to PI3K inhibitor treatment based on our small molecule 
profiling experiments.  Again using resazurin cell viability experiments, we tested inhibitors of 
each proposed compensatory pathway in combination with pictilisib.  In most cases, we used two 
inhibitors of each pathway to eliminate effects that might be specific to a single RTK inhibitor 
and not to a class of inhibitors with a common target.  These combinations were evaluated in six 
HNSCC cell lines: two cell lines with PIK3CA mutations (HSC-4 and Detroit 562) and four with 
amplification of wildtype PIK3CA (HPV negative: UM-SCC-108 and UM-SCC-59, HPV 
positive: UM-SCC-47 and UM-SCC-104).  Synergistic effects were again quantified based on 
the Loewe model of synergy (Figure 5-14) (32), which demonstrated that ALK, IGF-1R, 
AURKA, FAK, FGFR, and/or HDAC inhibition might also enhance cell death when combined 
with PI3K inhibitor treatment.  For some RTK targets, including those involving FGFR and FAK 
inhibitors, one of two similar RTK-targeting agents was more synergistic in combination with 




ponatinib and TAE226 (61, 62), and was also observed using orthogonal western blot analyses.  
Ponatinib and pictilisib co-treatment led to PARP cleavage in HSC-4 cells, while more specific 
FGFR inhibitors BGJ398 and AZD4547 did not result in the same level of apoptosis when used 
in combination with pictilisib (Figure 5-16).  Using this same approach to detect apoptotic 
responses, we confirmed the results of our resazurin cell viability assays by showing that 
combinations of pictilisib and ALK inhibitor brigatinib, IGF-1R inhibitor ADW742, FAK 
inhibitor TAE226, FGFR inhibitor ponatinib, and aurora kinase inhibitor ENMD-2076 lead to 
increased expression of cleaved PARP in HSC-4 and UM-SCC-108 following 24 hour treatment 
(Figure 5-15).  Similar effects for RTK inhibitor combinations were seen in a larger panel of cell 
lines, including UM-SCC-116, which does not display aberration in PIK3CA via mutation or 
copy number amplification (Figure 5-15).     
After evaluating this panel of primarily upstream RTK inhibitors in combination with 
pictilisib, we wanted to determine if the synergistic combinations effects that we observed were 
mediated by rescue of a downstream pathway.  We hypothesized that if such a downstream 
effector (for example, AKT) was responsible for resistance to PI3K inhibition, then an inhibitor 
specifically targeting this effector would display synergy in combination with a PI3K inhibitor.  
To test this, we again used a panel of HNSCC cell lines including three with PIK3CA mutant cell 
lines (HSC-4, Detroit 562, and HSC-2) and three with amplification of wildtype PIK3CA (HPV 
negative: UM-SCC-103, HPV positive: UM-SCC-47 and UM-SCC-104) and treated each with 
PI3K inhibitor BKM120 in combination with an inhibitor of a pathway downstream of PI3K or 
other RTKs.  These combinations included BKM120 and ALK/Ros1 inhibitor brigatinib 
(positive control for PI3K + RTK synergy), AKT inhibitor MK-2206, mTOR inhibitor 




observed with pictilisib and AKT inhibitor combinations, BKM120 and MK-2206 combination 
did not display synergy when used together.  Similar results were observed for mTOR, PDK1, 
and JAK inhibitors in HSC-4 cells (Figure 5-17).  This was confirmed using western blot 
analysis, which showed that co-treatment with BKM120 and brigatinib, but not other inhibitors, 
induced PARP cleavage (Figure 5-18).  Responses in other cell lines recapitulated these effects, 
with only JAK inhibition providing greater reduction in cell viability than monotherapies in a 
subset of cell lines (Figure 5-19).  Given that JAK inhibitors ruxolitinib and tofacinib were not 
synergistic with pictilisib (Figure 5-14), the effects of TG-101348 may be drug-specific and 
mediated by additional effects to inhibit FLT3 or bromodomains (61).  
Finally, we assessed the efficacy of PI3K and ALK inhibitor combinations in vivo using a 
xenograft model of UM-SCC-108.  Following the establishment of tumors, we treated mice with 
vehicle, monotherapy, or combination therapy.  We performed pharmacodynamic experiments to 
assess drug-indcued changes on a molecular level.  As expected, pictilisib reduced AKT 
phosphorylation after 1 hour treatment, both as a single agent and dual-therapy (Figure 5-20).  
Additionally, after 6 hour treatment, pictilisib alone or in combination with brigatinib induced 
the expression of apoptotic markers cleaved caspase 3 and cleaved PARP (Figure 5-21).  We 
then administered vehicle, monotherapy, and dual-therapy three times per week for three weeks 
to assess the effects of pictilisib and brigatinib on tumor growth.  We compared the average 
tumor volume for mice in each of the treatment arms, noting no significant difference in tumor 
volume between vehicle- and brigatinib-treated mice (p = 0.11, unpaired t-test).  In contrast, 
pictilisib monotherapy slowed tumor growth as compared to vehicle (p = 0.0013, unpaired t-test), 
and the addition of brigatinib to pictilisib treatment resulted in a further significant reduction in 




unpaired t-tests) (Figure 5-22); this indicated a synergistic response.  Minimal toxicity was 
observed, as all mice maintained their body weight over the course of the treatment period 
(Figure 5-23), which suggests that such combinations might also display limited side-effect 
profiles if administered in human patients.  After three weeks of treatment, given the surprisingly 
strong anti-tumor effect of this combination, we continued to administer pictilisib or combination 
to a subset of the mice in these two experimental groups to assess differences in time to endpoint 
between these two groups.  Although only five mice were included in each arm of this study, 
three of the five combination-treated mice lived two or more weeks beyond the date when all 
pictilisib animals reached their tumor endpoint (Figure 5-24).  As a whole, these results confirm 
the synergy of pictilisib and brigatinib in vivo and suggest that this combination may provide 
significant tumor growth delay despite the development of acquired resistance. 
 
Discussion 
Previous publications have demonstrated preclinical and clinical rationale for PI3K 
inhibitor treatment in HNSCC (20, 35, 63) and suggested combinatorial approaches to improve 
responses to such therapies (27, 31, 43, 49, 50).  Here, by performing high throughput 
combinatorial studies of PI3K inhibitor responses, we provide rationale for dual-therapy 
approaches as well as nominate novel drug pairs for evaluation using in vitro and in vivo models 
of HNSCC.  One of these combination treatments involves co-treatment with PI3K and ALK-
targeting agents; together, these inhibitors, such as pictilisib and brigatinib, induce apoptosis in a 
diverse panel of HNSCC cell lines and delay tumor growth in a mouse model. 
The mechanistic link between PI3K and ALK in HNSCC is incompletely understood.  




models, demonstrating that ALK signaling may play a critical role in this cancer type despite the 
lack of ALK gene fusions or amplifications observed in other types of tumors (57, 58).  Our 
HSC-4 ALK knockout cell line is more responsive than wildtype HSC-4 cells to AKT inhibitor 
GDC-0068 (Figure 5-11).  Interestingly, Gonzales et al. noted that EGFR + ALK inhibitor 
combination treatments provide further reductions in AKT phosphorylation compared to 
monotherapies (57).  One possibility, then, is that further inhibiting AKT, which is downstream 
of both EGFR and PI3K, mediates response to ALK inhibitor treatment.  However, our data 
indicates that pictilisib monotherapy, at concentrations that are insufficient to induce apoptosis, 
sufficiently blocks AKT phosphorylation at the serine 473 residue after six and 24 hour treatment 
periods (data not shown).  While this suggests that other signals may also be critically important, 
we have not considered the maintenance of AKT inactivation, other AKT phosphorylation sites, 
or total AKT protein levels.  Additionally, it remains to be determined if ALK + AKT inhibitor 
combinations have greater than additive effects. 
In fact, the sensitivity of ALK knockout cells to AKT inhibition is somewhat surprising 
as our studies using a set of PI3K combinations that inhibit upstream RTK and downstream 
effectors demonstrated that the RTK inhibitor combinations (including those targeting IGF-1R, 
FAK, AURKA, and others) produced responses similar to PI3K + ALK inhibitor therapies.  Such 
responses, however, were not observed with PI3K + AKT, mTOR, BCL-2, or PDK1 inhibitors.  
This could be due to the contributions of multiple RTKs to PI3K inhibitor resistance, with each 
RTK playing a partial, albeit critical, role.  Furthermore, these RTK inhibitors are not perfectly 
selective and might have activity against more than one critical resistance mechanism.  In these 
cases, synergistic responses may require tamping down multiple RTKs and their overlapping 




increased potential for toxicity, “off-target” effects may actually increase the efficacy of some of 
these agents in HNSCC and other cancer types and act as a means of suppressing pathways that 
would otherwise mediate tumor progression or recurrence.  For example, ponatinib has been 
described as an inhibitor of BCR-ABL, FGFR, SRC, MEK, JUN, and other signaling pathways 
(64, 65), but has a striking effect with pictilisib in UM-SCC-59 cells, a model previously 
characterized as fairly non-responsive to PI3K inhibitor alone (27).  Consistent with this, 
pictilisib and ponatinib co-treatment induced apoptosis in HSC-4 cells, while other FGFR 
inhibitor combinations were less effective (Figure 5-16).  Similarly, brigatinib’s effects may not 
be solely due to its inhibition of ALK signaling, but also due to inhibition of IGF-1R or even 
EGFR signaling (66).  Such findings highlight the ongoing challenges of developing safer 
inhibitors that display broad-spectrum kinase activity. 
An additional challenge not addressed in our study is the selection of patients most likely 
to respond to any specific PI3K inhibitor therapy.  Our results indicate that pictilisib and 
brigatinib, as well as other PI3K inhibitor combinations, are capable of inducing apoptosis in cell 
lines with disparate PIK3CA mutation status, copy number, and expression levels (Figure 5-7, 
Figure 5-15).  HPV status is also not a stratifying factor.  These results, unfortunately, are in line 
with other studies that have demonstrated similar difficulty in predicting PI3K inhibitor 
responses (27, 67, 68) and suggest that other or multiple factors, including not only mutations 
and copy number changes, but also protein or mRNA transcript levels (69, 70), may be important 
mediators of response.  One recent paper suggested that NOTCH1 mutation status may predict 
responses to PI3K inhibitor monotherapy (63), but combinatorial responses, involving a larger 
host of factors (both drug-related and otherwise), will likely only make patient selection more 




to PI3K inhibitor combinations, additional cell line and mouse models of HNSCC will need to be 
tested. 
Taken as a whole, this work provides a rich dataset examining resistance to targeted PI3K 
inhibitors and demonstrates the successful use of drug pairs to inhibit PI3K and co-dependent 
signaling networks in HNSCC.  For the first time, we report the synergy of PI3K and ALK 
inhibitors in cancers without ALK fusions, giving additional support to the role for ALK 
signaling in HNSCC specifically.  Further studies of other novel combinations are warranted; 
similar experiments could also be performed with other agents or in additional cancer types.  
Using these approaches to better understand sensitivity and resistance to targeted therapy may be 
instrumental in improving outcomes for HNSCC and other cancer patients. 
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Figure 5-1. Response of HNSCC and MCF-7 cell lines to PI3K inhibitor monotherapies.  
HNSCC and MCF-7 breast cancer cell lines were treated with increasing concentrations of PI3K 
inhibitors for 72 hours.  MCF-7 was used as a model known to have high sensitivity to PI3K 
inhibitors (71).  Cell viability was measured using a resazurin cell viability assay, and IC50 
values were determined as described in Materials and Methods. X denotes resistance with IC50 
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Figure 5-2. Schematic for high throughput combinatorial screen.   
An inhibitor library with 1406 compounds targeting a diverse set of cellular pathways (see 
Appendix 1) was used to treat ten HNSCC cell lines.  Inhibitors from the library were applied at 
four concentrations as monotherapies and in combination with low concentrations of PI3K 
inhibitors HS-173 and BKM120.  Potentially synergistic compounds were tested using a 
validation assay where HS-173 was titrated into constant concentrations of 96 promising 
inhibitors from initial screening.  Inhibitors with synergy upon repeat testing were tested in a 
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Figure 5-3. Schematic for validation screening.  
(A) Cells were treated first with DMSO or titrations of HS-173 as shown.  (B) Validation 
inhibitors were added such that each combination was tested in quadruplicate for four 
concentrations of HS-173 and four concentrations of each validation inhibitor.  Resazurin cell 
viability experiments were performed to assess responses after 72 hours and prioritize inhibitors 





Figure 5-4. Synergistic and non-synergistic PI3K inhibitor combinations for optimization 
of reverse-format validation screen.  
HSC-2, Detroit 562, and HSC-4 cells were treated with PI3K inhibitor HS-173 and/or (A) 
negative control FGFR inhibitor AZD4547 or (B) positive control EGFR/HER2 inhibitor afatinib 
for 72 hours.  Cell viability was measured using a resazurin cell viability assay.  Mean +/- SD for 
quadruplicate determinations from a single representative experiment are shown. 


























































































Figure 5-5. Workflow for small molecule profiling and selection of promising inhibitor 
combinations.   
(A) HNSCC cell lines were treated with a small molecule inhibitor library (Appendix 1) as 
monotherapies and in combination with low concentrations of two PI3K inhibitors. A heat map 
was generated based on statistical scoring for each inhibitor and evaluation of the recurrence of 
effect across the HNSCC cell line panel as described in Materials and Methods above.  Cell lines 
were arranged using unsupervised hierarchical clustering.  (B) Magnification of top-scoring 
inhibitors from (A), which are potentially synergistic with PI3K inhibitors. (C) Validation of top-
scoring, recurrent PI3K inhibitor combinations using resazurin cell viability assays in a diverse 
panel of HNSCC cell lines with quantification using Chalice score (Horizon Discovery).  






Figure 5-6. Responses to validated PI3K inhibitor combinations in a diverse panel of 
HNSCC cell lines.   
HS-173 and AZD3463, entrectinib, TAE226, or PCI-24781 were administered to HNSCC cell 
lines with varying genetic status and HPV status (UM-SCC-47, UM-SCC-104, UD-SCC-2, and 
UM-SCC-105 are HPV positive) as monotherapies and in combination.  Experimental conditions 
mimicked those shown below in Figure 5-8A with PI3K inhibitor titrated into four constant 
concentrations of combination inhibitor.  UM-SCC-105 and UM-SCC-55 cells were treated with 
AZD3463 and PCI-24781 combinations at 10X lower concentrations than other cell lines due to 
incrased sensitivity to these agents when administered as monotherapies.  Experiments were 
performed at least twice with quantification using Chalice score (Horizon Discovery).  Average 




























































































































Figure 5-7. PIK3CA gene expression level does not predict response to PI3K inhibitor 
treatment.   
HS-173 and AZD3463, entrectinib, TAE226, or PCI-24781 were administered to HNSCC cell 
lines and results were quantified using Chalice score (Horizon Discovery).  RNA sequencing 
















































































































































































Figure 5-8. Orthogonal assays confirm cell death, apoptosis, and cell cycle arrest following 




(A) HSC-2, HSC-4, and Detroit 562 cells were treated with increasing concentrations of PI3K 
inhibitors and/or RTK inhibitors as indicated in the table for 72 hours.  Cell viability was 
measured using a resazurin cell viability assay as shown in representative images.  Synergy of 
each combination was evaluated using Chalice score (Horizon Discovery).  Each combination 
experiment was performed at least twice in all three cell lines, with average Chalice scores used 
to create a heat map. Representative concentration response curves for HSC-4 and Detroit 562 
cells after treatment with PI3K inhibitor pictilisib and ALK inhibitor brigatinib are shown along 
with analysis using Combenefit software (33).  (B) HNSCC cells were treated with vehicle 
(DMSO), PI3K alpha/delta-isoform inhibitor pictilisib (0.5 µM for UM-SCC-69 and UM-SCC-
104, 1 µM for Detroit 562, UM-SCC-103, and UM-SCC-47, 2.5 µM for HSC-4), pan-PI3K 
inhibitor BKM120 (1 µM for Detroit 562, UM-SCC-69, UM-SCC-103, UM-SCC-47, and UM-
SCC-104, 2.5 µM for HSC-4), PI3K beta-isoform inhibitor TGX-221 (5 µM), and/or ALK 
inhibitor brigatinib (0.25 µM for UM-SCC-69, 0.5 µM for UM-SCC-47 and UM-SCC-104, 0.75 
µM for UM-SCC-103, 1 µM for HSC-4 and Detroit 562).  Cell viability was measured using 
trypan blue dye exclusion assays after 72 hour treatment. Data shown are average +/- SD from at 
least three independent determinations.  (C) FITC positivity was measured using annexin V 
apoptosis assays after 72 hour treatment with inhibitors at concentrations as above.  
Representative images for HSC-4 cells are shown along quantification (average +/- SD) from at 
least three independent determinations.  (D) Cleaved caspase 3 and cleaved PARP were detected 
via western blot after 24 hour treatment with concentrations as above.  GAPDH was used as a 
loading control.  Experiments were performed at least twice, and representative images are 
shown. (E) PIK3CA mutant HNSCC cells were treated with inhibitor concentrations as above for 
24 hours.  EdU vs PI assays were used to assess cell cycle progression.  Representative data for 
HSC-4 and quantification (average +/- SD) from at least three independent determinations are 
shown.  For panels (B) and (C), statistics were performed using two-way ANOVA with 
Bonferroni correction to compare vehicle and monotherapy treatments to combination treatment.  
All p-values are reported in Table 5-5 and Table 5-6, respectively. * indicates p < 0.05, and ** 






Figure 5-9. Pictilisib and brigatinib co-treatment induce cleavage of Caspase 6 and Caspase 
7 in UM-SCC-47 and HSC-4 cells.   
Cleaved caspase 6 and cleaved caspase 7 were detected via western blot after 24 hour treatment 
with vehicle (DMSO), PI3K alpha/delta-isoform inhibitor pictilisib (1 µM for UM-SCC-47, 2.5 
µM for HSC-4), PI3K beta-isoform inhibitor TGX-221 (5 µM), and/or ALK inhibitor brigatinib 
(0.5 µM for UM-SCC-47, 1 µM for HSC-4).  HSP90 was used as a loading control.  




































































Figure 5-10. PI3K inhibitor HS-173 and ALK/IGF-1R inhibitor AZD3463 recapitulate 
synergistic effects on cell death and apoptosis.   
(A) HNSCC cells were treated with vehicle (DMSO), PI3K alpha-isoform inhibitor HS-173 (0.5 
µM for Detroit 562 and UM-SCC104, 1 µM for UM-SCC-69, UM-SCC-103, and UM-SCC-47, 
2.5 µM for HSC-4), and/or ALK/IGF-1R inhibitor AZD3463 (0.5 µM for UM-SCC-69 and UM-
SCC-47, 1 µM for UM-SCC-103 and UM-SCC-104, 2.5 µM for HSC-4 and Detroit 562).  Cell 
viability was measured using trypan blue dye exclusion assays after 72 hour treatment. Data 
shown are average +/- SD from at least triplicate determinations as a result of no less than two 
independent experiments.  (B) FITC positivity was measured using annexin V apoptosis assays 
after 72 hour treatment with inhibitors at concentrations as above.  Representative images for 
HSC-4 cells are shown along quantification (average +/- SD) from at least three independent 
determinations.  (C) Cleaved caspase 3 and cleaved PARP were detected via western blot after 
24 hour treatment with concentrations as above.  GAPDH was used as a loading control.  
Experiments were performed at least twice, and representative images are shown. For panels (A) 
and (B), statistics were performed using two-way ANOVA to compare vehicle and monotherapy 
treatments to combination treatment.  * indicates p < 0.05, ** indicates p < 0.01, and *** 







Figure 5-11. HSC-4 ALK knockout cells are more responsive to AKT inhibitor GDC-0068 
than HSC-4 wildtype cells.   
(A) Schematic of sanger sequencing results from HSC-4 ALK knockout cells, showing copies of 
ALK with 29 bp deletion with or without additional point mutation and a third copy with a 83 bp 
insertion of an intronic region of the EZR gene.  (B) HSC-4 wildtype and ALK knockout cells 
were treated with increasing concentrations of GDC-0068 for 72 hours.  Cell viability was 
measured using a resazurin cell viability assay.  Experiments were repeated at least two times 
with similar results.  Mean +/- SD for quadruplicate determinations from a single representative 









HSC-4 Wildtype crRNACCATCCTCCTCGGAGC   TGAAGGCTGGCAGGCCCGAGGCCCGCGGCTCGCTAGCTCTGG
CCATCCTCCTCGGAGC                                                                                      TCGCTAGCTCTGG-----------------------------



































Figure 5-12. Sanger sequencing and western blot analysis confirm IGF-1R knockout in 
HSC-4 cells.  
(A) Schematic of sanger sequencing results from HSC-4 IGF-1R knockout cells, showing one 
copy of IGF-1R with mutation and two bp deletion as well as three additional copies with unique 
deletions of 1, 14, and 18 bp.  (B) Western blot analysis of HSC-4 wildtype and IGF-1R 










Figure 5-13. Gene expression in HSC-4 wildtype and ALK or IGF-1R knockout cells.   
Log2 fold change in gene expression of ALK, AKT1, IGF-1R, PDK1, and PIK3CA in HSC-4 
ALK or IGF-1R knockout cells as calculated using the DDCt method compared to HSC-4 









































Figure 5-14. HNSCC cell lines respond to PI3K inhibitor pictilisib in combination with 
inhibitors targeting ALK, IGF-1R, and other RTKs. 
HSC-4 cells were treated with increasing concentrations of PI3Ka/d inhibitor pictilisib and/or 
indicated RTK inhibitors for 72 hours.  Cell viability was measured using a resazurin cell 





























Figure 5-15. RTK + PI3K inhibitor combinations induce PARP cleavage.  
HNSCC cells were treated for 24 hours with DMSO or PI3K inhibitor pictilisib (2.5 µM for 
HSC-4 and UM-SCC-59, 1 µM for all other cell lines) +/- brigatinib (0.5 µM for UM-SCC-108, 
1 µM for all other cell lines), ADW742 (2.5 µM), TAE266 (1 µM for UM-SCC-108, 2.5 µM for 
all other cell lines), ponatinib (0.5 µM for UM-SCC-59, 1 µM for all other cell lines), or ENMD-
2076 (1 µM for UM-SCC-59, 2.5 µM for all other cell lines).  HSC-4 cells exhibit E545K 
PIK3CA mutation, while other cell lines (with the exception of UM-SCC-116 cells, which is 
PIK3CA wildtype and copy neutral) display at least one additional copy of wildtype PIK3CA.  
Experiments were performed at least twice for each cell line, and representative images are 
shown.  GAPDH was used as a loading control. 
 
 
Figure 5-16. PI3K inhibitor combination with ponatinib, but not other FGFR inhibitors, 
induces PARP Cleavage.  
HSC-4 cells were treated for 24 hours with DMSO or PI3K inhibitor pictilisib (2.5 µM) +/- 
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Figure 5-17. Combinatory inhibition of PI3K and downstream effectors does not result in 
synergistic responses.   
HSC-4 cells were treated with increasing concentrations of pan-PI3K inhibitor BKM120 and/or 
ALK inhibitor brigatinib (A), JAK inhibitor TG-101348 (B), AKT inhibitor MK-2206 (C), 
mTOR inhibitor rapamycin (D), or PDK1 inhibitor GSK-22334470 (E) for 72 hours.  Cell 
viability was measured using a resazurin cell viability assay. Each point is the mean and s.d. of 
quadruplicate determinations from a single experiment.  Each experiment was repeated 












Figure 5-18. PI3K inhibitor combinations targeting downstream effectors do not induce 
apoptosis.   
HSC-4 cells were treated for 24 hours with DMSO or PI3K inhibitor BKM120 (1 µM) +/- 
brigatinib (1 µM), MK-2206 (5 µM), rapamycin (5 µM), GSK-2233470 (5 µM), or TG-101348 
























Figure 5-19. PI3K inhibitor BKM120 and JAK inhibitor TG-101348 are synergistic in a 
subset of HNSCC cell lines.   
UM-SCC-47 (A), UM-SCC-103 (B), and UM-SCC-104 (C) cells were treated with increasing 
concentrations of pan-PI3K inhibitor BKM120 and/or JAK inhibitor TG-101348 for 72 hours.  
Cell viability was measured using a resazurin cell viability assay. Each point is the mean and s.d. 
of quadruplicate determinations from a single experiment.  Each experiment was repeated 








Figure 5-20. Pictilisib treatment reduces AKT phosphorylation in vivo.  
Athymic nude mice bearing UM-SCC-108 xenografts were treated with vehicle, pictilisib (100 
mg/kg), brigatinib (50 mg/kg), or combination for 1 hour, then euthanized.  Tumors were 
harvested and lysed, followed by western blot analysis of indicated proteins.  GAPDH was used 




Figure 5-21. Pictilisib induces apoptosis in vivo.  
Athymic nude mice bearing UM-SCC-108 xenografts were treated with vehicle, pictilisib (100 
mg/kg), brigatinib (50 mg/kg), or a combination of pictilisib and brigatinib for 6 hours, then 
euthanized.  Tumors were harvested and lysed, followed by western blot analysis of indicated 












Figure 5-22. UM-SCC-108 xenografts respond synergistically to combination treatment 
with pictilisib and brigatinib.  
UM-SCC-108 cells (2 million cells/tumor) were injected bilaterally into the flanks of athymic 
nude mice.  One week later, mice began treatment with vehicle, pictilisib (100 mg/kg), brigatinib 
(50 mg/kg), or combination via oral gavage 3 times per week.  Treatment continued for 3 weeks.  
The average and SEM for tumor volume (n=20-26 tumors per group) are shown.  Statistics were 
performed using the average tumor volume for each mouse and unpaired t-tests.  * indicates p < 






































Figure 5-23. Mice bearing UM-SCC-108 xenografts maintained weight during treatment.   
UM-SCC-108 cells (2 million cells/tumor) were injected bilaterally into the flanks of athymic 
nude mice.  One week later, mice began treatment with vehicle, pictilisib (100 mg/kg), brigatinib 
(50 mg/kg), or combination via oral gavage 3 times per week.  Treatment continued for 3 weeks.  
The average and SD of the weights for mice in each treatment group (n = 10-13) are shown. 
 



















Figure 5-24. Combination treatment with pictilisib and brigatinib extends time to tumor 
endpoint in UM-SCC-108 xenografts.    
UM-SCC-108 cells (2 million cells/tumor) were injected bilaterally into the flanks of athymic 
nude mice.  One week later, mice began treatment with pictilisib (100 mg/kg) or pitilisib and 
brigatinib (50 mg/kg) via oral gavage 3 times per week.  Treatment continued until mice reached 
their tumor endpoint (20% loss of body weight, tumor volume > 3000 mm3, or ulceration greater 
than half the surface area of the tumor), after which point mice were humanely euthanized. 
  

























Table 5-1. PI3K inhibitor concentrations for small molecule profiling. 
Cell Line HS-173 Concentration (µM) BKM120 Concentration (µM) 
UM-SCC-49 0.25 0.25 
UM-SCC-108 0.25 0.25 
UM-SCC-55 0.25 0.25 
UM-SCC-59 0.25 0.25 
UM-SCC-43 0.25 0.25 
HSC-4 0.25 0.25 
Detroit 562 1 1.5 
HSC-2 0.5 0.5 
UM-SCC-104 0.25 0.25 
UM-SCC-69 0.25 0.25 
 
 
Table 5-2. Primary antibodies for western blot analysis. 
Target Supplier Cat. No. Dilution 
IGF-1R Cell Signaling Technology 9750 1:1000 
pAKT (Ser473) Cell Signaling Technology 4060 1:1000 
Cleaved Caspase 3 Cell Signaling Technology 9664 1:500 
Cleaved Caspase 6 Cell Signaling Technology 9761 1:500 
Cleaved Caspase 7 Cell Signaling Technology 8438 1:500 
Cleaved PARP Cell Signaling Technology 5625 1:500 










AKT1 F: 5’-TCACGTTGGTCCACATCCTG-3’ 
R: 5’-GCACAAACGAGGGGAGTACA-3’ 




IGF-1R F: 5’-GCCGACGAGTGGAGAAATCTG-3’ 
R: 5’-TGGAGGTAGCCCTCGATCAC-3’ 
PDK1 F: 5’-CTGTGATACGGATCAGAAACCG-3’ 
R: 5’-TCCACCAAACAATAAAGAGTGCT-3’ 
β-actin  F: 5’-AAGTGTGACGTGGACATCCG-3’ 
R: 5’-GATGTGACAGCTCCCCACAC-3’ 
HPRT F: 5’-AGATGGTCAAGGTCGCAAGC-3’ 
R: 5’-ATGACACAAACATGATTCAAATCCC-3’ 







Table 5-4. Kinase library knockout screen identifies genes significantly depleted after PI3K 
inhibitor treatment. 
UM-SCC-108 cells transduced with the Human Kinase CRISPR Knockout Library were treated 
with 0.25 mM HS-173 or 0.5 mM BKM120 for 14 days.  DNA was harvested and sequencing 
was performed.  The MAGeCK algorithm (34) was used to identify genes that were significantly 
depleted compared to vehicle-treated controls (p-value < 0.05), which are highlighted in yellow.  
Note that guide RNAs targeting FAK and AURKA were not included in the library.  
 
Gene BKM120 p-value HS-173 p-value 
IGF-1R 0.0027 0.1872 
ALK 0.1834 0.0144 
EGFR 0.0911 0.2276 
ERBB2 0.6216 0.0158 
ERBB3 0.9272 0.0020 
ERBB4 0.5186 0.3459 
AXL 0.1210 0.0170 
AURKB 0.1267 0.4239 
AURKC 0.1629 0.2633 
AKT1 0.1264 0.0947 
AKT2 0.3303 0.0033 
AKT3 0.0255 0.3707 
PDK1 0.0895 0.2056 
MTOR 0.0338 0.0605 
JAK1 0.1435 0.3878 
JAK2 0.0243 0.9897 
JAK3 0.0565 0.4200 
FGFR1 0.9566 0.6241 
FGFR2 0.1226 0.0135 
FGFR3 0.9490 0.1247 
CDK4 0.0868 0.1082 






Table 5-5. Statistical analysis for trypan blue dye exclusion assays testing BKM120, 
pictilisib, and TGX-221 in combination with brigatinib. 
Two-way ANOVAs were performed in R to compare the natural logarithm of the percentage of 
living cells following vehicle, PI3K inhibitor monotherapy, brigatinib monotherapy, or 
combination treatment. Bonferroni correction was used to adjust p-values.  Significant results 









HSC-4 BKM + Brig 5.70E-06 1.71E-05 
HSC-4 Pic + Brig 5.60E-04 1.69E-03 
HSC-4 TGX + Brig 7.60E-01 1.00E+00 
Detroit 562 BKM + Brig 5.64E-03 1.69E-02 
Detroit 562 Pic + Brig 1.43E-03 4.28E-03 
Detroit 562 TGX + Brig 9.61E-02 2.88E-01 
UM-SCC-69 BKM + Brig 2.86E-01 8.57E-01 
UM-SCC-69 Pic + Brig 1.93E-02 5.81E-02 
UM-SCC-69 TGX + Brig 1.06E-01 3.19E-01 
UM-SCC-103 BKM + Brig 2.00E-04 6.00E-04 
UM-SCC-103 Pic + Brig 5.77E+00 1.73E-05 
UM-SCC-103 TGX + Brig 1.11E-01 3.32E-01 
UM-SCC-47 BKM + Brig 1.30E-02 3.92E-02 
UM-SCC-47 Pic + Brig 4.64E-02 1.39E-01 
UM-SCC-47 TGX + Brig 3.15E-01 9.44E-01 
UM-SCC-104 BKM + Brig 1.75E-02 8.26E-02 
UM-SCC-104 Pic + Brig 3.07E-03 9.21E-03 















Table 5-6. Statistical analysis for annexin V apoptosis assays testing BKM120, pictilisib, 
and TGX-221 in combination with brigatinib. 
Two-way ANOVAs were performed in R to compare the natural logarithm of the percentage of 
living cells following vehicle, PI3K inhibitor monotherapy, brigatinib monotherapy, or 
combination treatment. Bonferroni correction was used to adjust p-values.  Significant results 







adjusted p-value  
HSC-4 BKM + Brig 2.83E-02 8.49E-02 
HSC-4 Pic + Brig 1.59E-02 4.76E-02 
HSC-4 TGX + Brig 6.83E-01 1.00E+00 
Detroit 562 BKM + Brig 3.49E-01 1.00E+00 
Detroit 562 Pic + Brig 8.34E-04 2.50E-03 
Detroit 562 TGX + Brig 2.90E-01 8.70E-01 
UM-SCC-103 BKM + Brig 2.30E-01 6.89E-01 
UM-SCC-103 Pic + Brig 3.07E-03 9.21E-03 
UM-SCC-103 TGX + Brig 1.80E-01 5.40E-01 
UM-SCC-47 BKM + Brig 9.74E-02 2.92E-01 
UM-SCC-47 Pic + Brig 3.70E-05 1.11E-04 





Table 5-7. Statistical analysis for annexin V apoptosis and trypan blue dye exclusion assays 
testing HS-173 in combination with AZD3463. 
Two-way ANOVAs were performed in R to compare the natural logarithm of the percentage of 
living cells following vehicle, HS-173 monotherapy, AZD3463 monotherapy, or combination 
treatment. Bonferroni correction was used to adjust p-values.  Significant results (ANOVA 
adjusted p-value < 0.05) are highlighted in red. 
Cell Line Annexin V p-value Trypan Blue p-value 
HSC-4 8.91E-02 6.86E-04 
Detroit 562 1.29E-01 9.03E-02 
UM-SCC-69 N/A 5.17E-02 
UM-SCC-103 5.37E-01 1.52E-03 
UM-SCC-47 6.32E-02 2.74E-03 
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Chapter 6 : Summary and Perspectives 
Summary 
 In my thesis, I studied the role of the phosphatidylinositol 3-kinase (PI3K) pathway in 
head and neck squamous cell carcinoma (HNSCC); specifically, I evaluated the hypothesis that 
resistance to PI3K inhibitors is due to compensatory signaling and can be overcome using 
inhibitors of co-dependent pathways in combination with PI3K targeting agents.  My work first 
evaluated the possibility that the inhibition of EGFR, which is overexpressed in the majority of 
HNSCC tumors, sensitizes HNSCC cells to PI3K inhibition.  These studies were performed via 
various pharmacologic treatments in a diverse set of in vitro HNSCC models.  Second, I 
examined the interplay between PI3K and Notch signaling, as inactivation of NOTCH1 is a 
common event in HNSCC.  My work demonstrated that loss of NOTCH and activation of PI3K 
signaling cooperate to decrease time to endpoint in a transgenic mouse model.  Finally, I took an 
unbiased approach to nominate other signaling pathways that could compensate in the presence 
of PI3K inhibitors and thereby drive treatment resistance.  Using a small molecule profiling 
screen, I nominated several synergistic drug pairs and validated these dual-therapies using 
additional experiments.  I chose to focus on the combination of PI3K inhibitor pictilisib and 
ALK inhibitor brigatinib for mechanistic studies, and I performed a xenograft experiment 
displaying the efficacy of these two inhibitors when used together.  Here, I consider these 
findings in the context of previously published work and propose future directions to further 





Section 1: Barriers and opportunities in genetic determinants of HNSCC 
 Despite recent advances in cancer therapy, prognoses for HNSCC patients have not 
improved substantially (1, 2). Progress has been hampered at least in part by the complex array 
of mutations and by HPV status as well as other factors in HNSCC, which make it difficult to 
determine the optimal course of treatment for each patient.  Interestingly, we are still uncovering 
the genetic landscape of HNSCC, understanding the differences between epidemiologic HNSCC 
cohorts, heterogeneity within individual patient tumors, interplay with the tumor environment 
(both immune and otherwise), and various other factors. Diversity both between and among 
HNSCCs has presented challenges throughout the course of my thesis and remains a significant 
consideration in the biology and treatment of head and neck cancer. 
 In the first chapter of my thesis, I review the genetic determinants of HNSCC in diverse 
epidemiologic cohorts.  It is apparent that a variety of etiological factors play an important role 
in the prevention, development, and treatment of HNSCCs, and additional studies should 
continue to seek out these differences in order to inform patient-specific treatment protocols and 
improve outcomes.  The incidence of HNSCC is highest in low resource settings, particularly in 
southeast Asia; many of these regions also are impacted by additional risk factors (such as the 
use of betel quid).  Furthermore, mortality is correlated with incidence, such that regions with 
high rates of HNSCC also are characterized by poor outcomes (3).  There are a host of social 
factors that may contribute to this association—for example, limited awareness of HNSCC and 
its risk factors, lack of access to health care, and delays in the initiation of treatment.  
Importantly, genetic factors also have potential significance.  With the ever-increasing ease and 




genetic changes that may predispose patient subsets to develop HNSCC tumors of a specific 
subsite or severity.  As an example of this, an emerging trend in HNSCC incidence is an increase 
in the rate of tongue tumors in young, low-risk, female patients.  The factors underlying this 
group of oral cavity cancers remain incompletely understood, but they may be associated with 
changes in DNA damage response, apoptosis, cell cycle, and Fanconi anemia-related genes (4).  
To date, the majority of molecular studies in HNSCC have been performed in tumors from 
Caucasian males in developed countries (a minority group for this cancer type), but new analyses 
will inform better tumor characterization and clinical decision-making for individuals with a 
wide array of ethnic backgrounds.   
 In the latter chapters of my thesis, I focus on the how activation or blockade of PI3K 
signaling may impact response to treatment.  The majority of TCGA patients display aberration 
in one or more PI3K pathway genes (5), but the status of any single gene or any group of genes 
has not, to my knowledge, been validated as a critical biomarker of response in this cancer type.  
Clinical trial data has not demonstrated that mutation, amplification, or loss of PI3K pathway 
genes is linked to sensitivity or resistance, although recent clinical trials for EGFR targeting 
agents have noted poorer outcomes following EGFR inhibition in patients with PI3K activation.  
In the phase III E2303 trial, which compared cisplatin and cisplatin plus cetuximab in recurrent 
and metastatic (R/M) HNSCC patients (6), PIK3CA mutation or PTEN loss was associated with 
poor response to EGFR targeting therapy (7).  This finding was also noted in the LUX-H&N1 
trial, which compared second-line treatments with afatinib and methotrexate in R/M HNSCCs 
(8); here, PTEN high tumors received greater benefit from afatinib (9).  Preclinical studies have 




cetuximab (10, 11).  Further studies are warranted to validate these results in larger, prospective 
trials. 
Similarly, there is no proven biomarker for response to PI3K inhibitor treatment in 
HNSCC, although various factors have been proposed in cell lines, xenografts, or underpowered 
clinical trials.  In contrast to results in other cancer types (most notably breast cancer) (12), 
PIK3CA mutation has not been associated with sensitivity to PI3K inhibition in HNSCC trials to 
date (13, 14).  While precision medicine trials have shown a trend supporting PIK3CA alterations 
as a marker for response to PI3K inhibitors (15), these often do not reach statistical significance 
or have a very limited number of HNSCC patients enrolling.  For example, Janku et al. 
conducted an analysis of responses to PI3K/AKT/mTOR inhibitors in tumors with H1047R 
PIK3CA mutations including 4 HNSCC patients; after inhibitor treatment, two of these patients 
experienced progressive disease, one had little change in tumor burden, and another had an 
incomplete response to therapy (16). It is possible that the difference in outcomes between 
tumors with and without PIK3CA mutations has not been noted due to an insufficient number of 
PIK3CA mutant tumors in any single clinical trial; ongoing studies of PI3K inhibitor copanlisib 
in HNSCC patients with PIK3CA mutation or amplification or PTEN loss will better elucidate 
any potential differences in response attributable to PI3K activation (NCT02822482).  It is also 
feasible that other features predict responses to PI3K inhibitor: in the recent BERIL-1 study, a 
phase II trial comparing outcomes in R/M HNSCC patients treated with paclitaxel with or 
without pan-PI3K inhibitor buparlisib (n = 79 per group), follow-up analysis revealed that TP53 
alteration, low tumor mutation burden, HPV negativity, and high infiltration of TILs or CD8+ T-
cells was associated with improved response to bupalisib.   Recent preclinical work has proposed 




discussed further below.  Together these data suggest that a more nuanced understanding of 
tissue type specific and PI3K inhibitor response mechanisms may be required to develop 
clinically effective companion diagnostics for this class of inhibitors in HNSCC.   
My work, consistent with previous studies, indicates that responses to PI3K inhibition 
(either as monotherapy or in combination with other targeted inhibitors) are complex and cannot 
be predicted solely based on genetic mutation, copy number alteration, or RNA expression of a 
single gene.  Over the course of my thesis, I treated a diverse set of HNSCC cell lines with PI3K 
inhibitors displaying varying isoform selectivity as monotherapies.  Alpha isoform targeting 
agents were clearly more effective than other PI3K inhibitors, but the sensitivity profiles for any 
individual pan- or alpha-isoform PI3K inhibitor were more difficult to stratify.  This was 
increasingly true for drug combinations: PIK3CA mutation, copy number, RNA expression, and 
HPV status did not prove to be meaningful biomarkers for either PI3K and EGFR inhibitor dual-
therapies or for other synergistic drug pairs.  In the case of HS-173 and FAK inhibitor TAE226, 
we observed greater synergy in PIK3CA mutant cell lines as compared to PIK3CA wild type cell 
lines in our initial validation experiments.  However, when this association was tested more 
rigorously with other PI3K and FAK inhibitors, dual-therapy was beneficial also in many 
PIK3CA wildtype models; this could be due to differences in selectivity or mechanism of action 
for individual agents (18).  Thus, PI3K pathway activation (measured at the DNA level via 
mutation or copy number status or at the protein level via relative downstream phosphorylation) 
appears to be an insufficient biomarker for sensitivity in HNSCC cell lines; other cellular 
features, including additional alteration in PI3K pathway members (such as downstream 
mutations in AKT1) or activation of receptor tyrosine kinases (perhaps via upstream 




affect inhibitor responses.  Indeed, multifaceted analyses, such as those considering gene sets 
rather than individual genetic changes, may be needed to predict sensitivity.  For example, 
responses to EGFR or FAK inhibitor may be better stratified using gene sets assessing activation 
of PI3K, mTOR or other related signaling nodes instead of PIK3CA mutation status alone.  
Alternatively, an additional pathway that is changed as a result of PI3K activation (eg: epithelial 
to mesenchymal transition or apoptosis) may be even more effective in predicting response. 
  
Section 2: Improving strategies to overcome compensatory resistance through PI3K 
and EGFR 
One of the most widely studied mechanisms of resistance to PI3K inhibition is signaling 
through the epidermal growth factor receptor and the downstream Ras-MEK-ERK pathway.  In 
my thesis, I considered this resistance mechanism using a wide variety of cell lines (displaying a 
diverse array of genetic alterations) and a large set of ERBB family-targeting drugs.  Initially, 
our work focused on PIK3CA amplified HNSCCs, demonstrating that 4/6 (67%) of cell lines 
with additional copies of wild-type PIK3CA maintained Ras-MEK-ERK pathway activity 
following PI3K inhibitor treatment and that two of these models also were sensitive to dual 
inhibition of PI3K and EGFR or MEK.  Later work extended this observation to a larger panel of 
ERBB inhibitors and cell lines (including several with PIK3CA mutations).  Overall, our findings 
mirrored those of previous studies in showing that dual-therapy with PI3K and EGFR inhibitors 
was often more effective than either monotherapy (19-22), but it also extended this observation 
to consider individual classes of ERBB-targeting agents that might result in heightened responses 
when used as part of combination treatments.  Our work demonstrated that irreversible inhibitors 




targeting agents in HNSCC cell lines.  This represented an advance in the field as previous work 
had primarily considered dual-therapies that included either reversible EGFR inhibitors or 
EGFR-targeting antibodies such as cetuximab; a direct comparison of PI3K combination with 
several pharmacologies against EGFR had, to my knowledge, never been performed. 
Beyond direct inhibition of the receptor tyrosine kinases PI3K and EGFR themselves, 
previous work has also examined drug combinations targeting PI3K and EGFR via inhibition of 
downstream effectors including mTOR and MEK, respectively.  Several papers have noted 
synergy with mTOR inhibitors and EGFR agents (23-25).  In one of these studies, Jimeno et al. 
used H1047R PIK3CA mutant Detroit 562 cells in a xenograft model and noted improved 
response to mTOR inhibitor temsirolimus and erlotinib.  This response co-occurred with changes 
in MAPK and p70 S6 kinase phosphorylation (downstream of EGFR and mTOR, respectively) 
and in Ki67, effects that were not evidenced in less responsive xenograft models or after single-
agent treatment.  Our work with Detroit 562 in vitro showed minimal responses to PI3K inhibitor 
HS-173 and reversible EGFR inhibitors (including erlotinib) that could be enhanced to 
synergistic levels with multiple irreversible EGFR inhibitors (26).  We did not specifically 
consider erlotinib with mTOR inhibitors (temsirolimus or otherwise); however, I would expect, 
based on our work in other models, that such dual-therapies might inhibit MAPK and p70 S6 
kinase phosphorylation.  As our ineffective reversible EGFR inhibitor combinations blocked 
MAPK phosphorylation (p70 S6 kinase phosphorylation was not tested), I expect that erlotinib 
and temsirolimus may also fail to induce significant cell death in our system. Thus, it is possible 
that one or more additional effectors, perhaps further downstream of MAPK/p70 S6 kinase or 
part of a second escape pathway, may be responsible for synergistic effects.  Alternatively, in 




potentially other HNSCCs.  We have not yet tested our PI3K and irreversible EGFR inhibitor 
combinations in xenografts, but these experiments would allow us to better compare our 
responses to those in other publications and could reveal the potential of our results to translate 
clinically. 
In light of the synergy observed following treatment with agents targeting the PI3K and 
EGFR pathways in preclinical models, phase I and II trials have been performed to examine 
these dual-therapies in HNSCC patients.  Of these trials, three have been completed, all in 
patients receiving second-line treatment due to chemotherapy resistance, recurrence, and/or 
metastasis.  The first of these trials examined temsirolimus with cetuximab and resulted in dose-
limited toxicities in 1/3 of patients (27).  The second considered another mTOR inhibitor, 
everolimus, with erlotinib.  This combination had a reasonable toxicity profile and stopped or 
decreased tumor growth in several patients, but it did not result in clinical benefit as compared to 
previous trials considering erlotinib as a monotherapy (28).  The third trial, which considered 
cetuximab with or without PI3K inhibitor PX-866, also did not provide evidence of improvement 
with the addition of PI3K inhibitor (14).  Several other trials using PI3K and EGFR targeting 
agents, sometimes alongside of cytotoxic chemotherapy or radiotherapy, have been initiated and 
are in various stages of completion.  Toxicity seems to be a major concern in many of these trials 
and may limit the use of such combinations in patients.  As a result, the development of more 
specific combinations and/or more effective PI3K and EGFR inhibitors is warranted. 
Nevertheless, previous work also suggests that the use of currently available PI3K and 
EGFR therapies may be optimized in other ways.  For example, the sequence of combination 
treatments may be an important consideration.  Lattanzio and colleagues showed that Cal-33 




data showed minimal responses in this model when EGFR and PI3K targeting drugs were 
administered together.  The type of EGFR targeting agent that was used may also explain this 
conflicting data: while we did not consider cetuximab or other EGFR targeting antibodies in our 
experiments, small molecules and biologics could have very different response profiles in 
combination with PI3K inhibitors.  
An additional strategy to improve PI3K and EGFR inhibitor combination treatments is to 
combine them with radiation therapy (RT), one of the most widely used treatment modalities for 
HNSCC.  As reviewed elsewhere (30), activation of the EGFR and PI3K pathways may lead to 
radiosensitivity in at least three ways: 1) increase intrinsic cell survival via activation of Ras 
and/or overexpression of EGFR, 2) promote cell proliferation by altering cell cycle regulation, 
and 3) increase hypoxia, leading to genomic instability, invasion, and metastasis.  In accordance 
with this, blocking PI3K and EGFR signaling using BKM120 and cetuximab improved 
responses to radiation in Cal-27 cells (29).  Bozec et al. also considered cetuximab, BKM120, 
and/or radiation in orthotopic xenograft models of Cal-33; their study showed that cetuximab 
followed by BKM120 was effective and that this effect was enhanced with the addition of 
radiotherapy (31).  In contrast, Blas et al. recently demonstrated that BKM120 or MEK inhibitor 
binimetinib was more effective when administered with RT, but that the triple combination did 
not improve responses (32).  These conflicting data clearly demonstrate that although the effects 
of PI3K and EGFR pathway inhibition with RT are promising, the best combination of agents in 
any particular model remains incompletely understood.  Differential responses to treatment with 
targeted therapies and/or RT are expected: as such, a better understanding of the patient 
population of interest, the timing of RT treatment (before, after, or during targeted therapy), and 




effective triple therapy protocols.  Overall, our findings using PI3K and EGFR inhibitor 
combinations highlight the diversity of responses to dual-therapies that target only two signaling 
pathways.  In the context of other work examining these agents, additional factors, including but 
not limited to timing and other co-treatments, require further consideration before compensation 
through the PI3K and EGFR pathways might be effectively exploited in a population of HNSCC 
patients. 
 
Section 3: Examining Cross-Talk Between PI3K and Notch Signaling 
 Recent sequencing studies have identified frequent aberrations in the PI3K and NOTCH 
signaling pathways as well as the importance of these pathways in HNSCC and other cancer 
types (5, 33-35).  Molecular changes in each of these pathways have been studied separately in 
various preclinical models, including patient-derived cell lines and transgenic mice.  For 
example, recent work from our laboratory has characterized a panel of UM-SCC cell lines and 
demonstrated hotspot PIK3CA mutation in one oral cavity model (UM-SCC-43) and copy 
number amplification of wild-type PIK3CA in several others (36, 37).  Additionally, NOTCH1 
mutations and deletions are found in 14 and 43%, respectively, of the cell lines in the oral cavity 
subset (36).  Transgenic mouse models have also been developed to study the role of these genes 
in HNSCC.  Du et al. described a model of PIK3CA amplification, in which mice exhibit 
increased expression of wild-type PI3K driven by the K5 promoter.  This resulted in increased 
signaling through PDK1 and accelerated tumor formation after chronic 16-week exposure to 
tobacco analogue 4-nitroquinoline N-oxide (4-NQO) (38).  Similarly, loss of tumor suppressor 
Pten resulted in the rapid development of multiple oral tumors following 4-NQO exposure (39).  




in epithelial cells, including one recent publication showing that this led to head and neck 
carcinogenesis (40).  Beyond these in vitro and in vivo analyses, HNSCC patient samples in 
TCGA demonstrated NOTCH1 alterations in 21% and PIK3CA mutations and/or copy number 
changes in 35% of cases (5, 41, 42).   As a whole, these research models—cell lines, transgenic 
mice, and tumor samples—indicate that the PI3K and NOTCH signaling pathways play an 
important role in HNSCC; however, the way that these pathways interact has not been fully 
characterized. 
Taken together, at least 34/505 (6.7%) HNSCC TCGA patients exhibit both inactivation 
of NOTCH1 and activation of PIK3CA.  Interestingly, these changes may be even more frequent 
in the HPV positive patient subset (43) and may be associated with tobacco-associated tumors 
(44).  Emerging data suggests cross-talk between the PI3K and NOTCH pathways.  Our UM-
SCC-47 PIK3CA knockout cell line displays differential expression of Notch pathways genes, 
most notably HES2 and DLL1.  What is more, this knockout cell line exhibits loss of DNp63 at 
the mRNA and protein levels.  p63 and its transcriptional targets can be regulated by NOTCH 
signaling (45, 46) and also display altered expression in an in vitro model of NOTCH1 knockout.    
Additional data from Zheng et al. shows that treatment with gamma secretase inhibitor PF-
03084014 activated PI3K signaling in HNSCC models (47).  Together, these data motivate 
investigation of the interaction between PI3K and NOTCH alterations in HNSCCs. 
Importantly, Sambandam et al. recently demonstrated that cell lines with loss-of-function 
mutations in NOTCH1 displayed increased sensitivity to PI3K/mTOR inhibitors (17).  This is in 
agreement with results for a patient tumor xenograft system in which two cases with inactivating 
NOTCH1 mutations responded to PI3K inhibition (11) and with a phase I study where 




HNSCC (48).  Furthermore, these data are consistent with our findings using a genetically 
engineered mouse model where Notch1 and/or overexpression of H1047R mutant Pik3ca are 
driven by Cre recombinase in K14 positive epithelial cells.  Following exposure to 4-NQO, we 
observed that double alteration (Notch1 loss + Pik3ca mutation) accelerates time to endpoint as 
compared to single gene manipulation or K14-Cre alone.  Showing that oncogenic perturbation 
of these pathways synergistically accelerates tumor formation suggests that mutation status for 
PIK3CA, NOTCH1, or related genes may affect response to targeted inhibitors of these pathways 
or that PI3K and NOTCH altering treatments might be synergistic.  While this finding is 
consistent with the results of other groups, previous models of in vitro and in vivo HNSCC have 
suggested that PDK1 may play an important role downstream of PI3K and be responsible for 
synergy between PI3K inhibition and loss of NOTCH (17, 38).  In contrast, we did not detect any 
change in PDK1 in our Notch1c/c/Pik3ca H1047R SCC tumors.  It is possible that PDK1-dependent 
mechanisms are specific to cases without aberration in NOTCH or PI3K signaling and/or that 
another pathway—likely outside of the canonical role of AKT in PI3K activation and potentially 
involving immune interactions—is an underlying factor in our observations. 
Responses to EGFR targeting agents have also been linked to altered NOTCH signaling.  
Cetuximab interacted with NOTCH1 and HIF1a to reduce angiogenesis in a transgenic model of 
double Pten and Tgfrb knockout (49), while erlotinib showed synergy with PF-03084014 in cell 
line and xenograft HNSCC models (50).  These effects have also been seen in clinical samples 
where NOTCH and Wnt signaling were differentially expressed in patient tumors following the 
cessation of cetuximab therapy.  It remains to be determined if these effects are mediated by 
PI3K downstream of EGFR or via other signaling events (51).  Recent work demonstrated that 




of breast and other epithelial tumor types by decreasing the proportion of cancer stem cells (52).  
While interesting, this study only considered targeting NOTCH2 and NOTCH3 and findings 
have yet to be validated in HNSCC. Additionally, the interplay between EGFR, PI3K and/or 
NOTCH may not be significant in all HNSCCs; in contrast to the findings of Zheng et al (50), 
data from our laboratory examining responses of several UM-SCC cell lines to the combination 
of EGFR inhibitor gefitinib and PF-03084014 did not result in drug synergy.   
Loss of NOTCH signaling may also result in enhanced responses to other pharmacologic 
treatments—not just inhibitors of receptor tyrosine kinases like PI3K and EGFR.  Marked 
responses to Wnt inhibitor LGK974 were observed in HNSCC models with loss of function 
NOTCH mutations (53), and sensitivity to DNA damage agents, including cisplatin, is 
heightened in cases of decreased NOTCH signaling (54-58).  Increased sensitivity in the case of 
NOTCH inactivation may also extend to other therapies, but has not yet been shown.  The shared 
and unique mechanisms underlying these differential treatment responses also have yet to be 
fully elucidated. 
Ultimately, it will be important to explore how specific alterations in NOTCH and/or 
PI3K pathway members impact carcinogenesis and response to therapy.  As mentioned above, 
Demehri et al. showed with several transgenic mouse models that severity of Notch alteration 
correlates with mouse lifespan and age of spontaneous tumor onset: lack of gamma secretase 
activity was embryonically lethal, but mice lived almost as long as wildtype littermates with 
other less profound alterations in Notch signaling, although skin tumors often formed in many of 
the Notch-deficient models (59). This study also demonstrated that NOTCH pathway members 
could affect survival and tumor phenotypes in disparate ways; mice lacking Notch effector Rpbj 




similar timespans but displayed skin tumors at 3 months old (59).  Other Notch altered GEMMs 
include those expressing the dominant-negative form of dnMaml1.  With global expression of 
this transgene, mice displayed alopecia and skin cancer formation, but expression of dnMaml1 
specifically in K14 positive epithelial cells limited this phenotype and resulted in dysplasia and 
low-grade SCCs only after 4-NQO treatment (40). Thus, it will be informative to assess the role 
a diverse array of alterations in further mouse models with co-alteration of PI3K and Notch 
genes.  Similar to the effects of various genetic changes in the NOTCH pathway, these changes 
could also have varying effects in combination with activating PIK3CA mutation.  An additional 
layer of complexity lies in the diversity of means by which PI3K signaling might be increased: 
mutant Pik3ca, amplified Pik3ca, loss of Pten, and other PI3K pathway changes could all be 
considered with alterations in Notch1 and other family members.  Studying the similarities and 
differences in a varied selection of models with Notch loss and PI3K activation would provide 
further insight into the function of these pathways individually and collectively as well as inform 
the subset of patients that may benefit from biomarker-driven treatment paradigms in HNSCC. 
 
Section 4: Combination strategies to overcome PI3K inhibitor resistance 
 The early chapters of my thesis examined compensatory signals that may allow cell 
survival in the presence of PI3K inhibition by specifically evaluating pathways that were known, 
based on previous data, to mediate PI3K inhibitor resistance.  In the fifth chapter of my 
dissertation, however, I profiled PI3K inhibitor resistance mechanisms in an unbiased manner 
using a small molecule screening approach.  In doing so, I validated synergistic drug pairs 
including PI3K and EGFR inhibitors and identified new co-dependencies that had not been 




 We modeled our small molecule studies after the work of Garnett et al, who used a 
resazurin cell viability assay in 384-well plate format to test nearly 50,000 drug-cell line 
combinations (60).  Our assay extended this approach to evaluate not only monotherapies, but 
also PI3K inhibitor combination treatments.  We examined approximately 14,000 drug-cell line 
pairs with monotherapies, another set of 14,000 in combination with HS-173, and a third set of 
14,000 in combination with BKM120.  Using these experiments, some of the more novel PI3K 
inhibitor combinations that we identified included those targeting upstream RTKs, including 
ALK, IGF-1R, FAK, AURKA, and others. 
 Much of the previous work on compensatory resistance to PI3K inhibition has noted 
contributions from pathways downstream of PI3K or other co-dependent RTKs, including PDK1 
(17), AKT (61), mTOR (62-64), and MEK (65, 66).  In our studies, consistent with previous 
publications (65, 66), we observed that inhibiting PI3K and MEK was functionally similar to 
inhibiting PI3K and EGFR.  Prior studies have also highlighted the importance of AKT in 
combination responses; these publications describe similar evidence of synergy when replacing 
PI3K inhibitors with AKT inhibition or siRNA (21) or displaying reduced AKT phosphorylation 
following combination treatment (19, 21, 22, 67, 68).   Similarly, the work of Sambandam et al. 
demonstrated the importance of PDK1 inhibition in PI3K inhibitor responses by showing that: 1) 
reductions in the level of phosphorylated and total PDK1 were present in cell lines that were 
more sensitive to PI3K inhibition, and 2) AKT inhibitor MK-2206 and PDK1 inhibitor 
GSK2334470 were synergistic when used together, recapitulating or exceeding the effects of 
PI3K inhibitor monotherapy (17).  In contrast, we observed that AKT phosphorylation was 
similarly reduced following treatment with PI3K monotherapy and ineffective combinations as 




necessary but not sufficient for response to PI3K inhibitor therapy.  PDK1 phosphorylation was 
also largely unchanged with PI3K mono- and dual-therapy in our models.  Furthermore, we 
observed little benefit when adding PDK1, AKT, or mTOR inhibitors to PI3K inhibitors. Based 
on these findings, we can conclude that although PDK1, AKT, and mTOR are downstream 
effectors common to PI3K and the other RTKs involved in our synergistic drug pairs, additional 
mechanisms are responsible for combination effects.  
 The results of our small molecule screen suggest that PI3K inhibitor combinations 
targeting upstream rather than downstream signals may be a more effective means of blocking 
HNSCC proliferation.  Of the top ranked combination inhibitors from our profiling experiments, 
11 target RTKs, one inhibits HDACs, and three block downstream signaling molecules (AKT 
and Bcl-2).  While individual cases may be driven by resistance through AKT, mTOR, or other 
similar pathways, this data may indicate that broader effects are achieved by inhibiting upstream 
signals.  This result is not necessarily unexpected—cancer cells can compensate and bypass the 
inhibition of specific downstream signals more easily than they can overcome the more global 
changes induced by inhibition of RTKs like EGFR.  Accordingly, the mechanism underlying the 
effects of any RTK and PI3K combination may involve a complex array of network-level 
changes, a decrease in several important signaling nodes simultaneously rather than a profound 
reduction in any one effector.  If this is the case, multiple separate RTK-targeting agents may be 
sufficient to shift cancer cells toward response to PI3K inhibition. 
 Recent work has successfully implicated upstream inhibition in combination with PI3K 
targeting drugs to improve responses in HNSCC.  For instance, based on earlier work showing 
that the dimerization of AXL and EGFR promotes signaling through PI3K and mTOR (but 




and target the transcription factors that were responsible for the increased expression of AXL in 
HNSCCs. They found that a c-JUN, a member of the AP-1 transcription factor (TF) complex, 
was likely responsible for the upregulation of AXL and that blocking the activity of this TF 
improved the response to PI3K inhibitor BYL719 (69).  As a second example, Brand and co-
authors blocked HER3 signaling as a means of reversing PI3K inhibitors resistance mediated by 
HPV oncoproteins E6 and E7 in HPV positive HNSCCs (70).  These studies support the role of 
RTKs in HNSCC resistance mechanisms and validate that combination PI3K and RTK blockade 
may result in improved PI3K inhibitor responses. 
 In further support of this idea is the ability of many HNSCC cell lines to respond to 
multiple pairs of inhibitors rather than to just one dual-therapy.  For example, UM-SCC-108 cells 
respond to the combination of PI3K inhibitor and EGFR inhibitor, MEK inhibitor, ALK 
inhibitor, IGF-1R inhibitor, FAK inhibitor, or AURKA inhibitor.  Similar responses in UM-
SCC-108 are also achieved with the combination of EGFR and FGFR or EGFR and IGF-1R 
inhibitors.  This data could suggest the existence of one or two critical downstream signaling 
molecules that are sufficiently blocked only via multiple levels of inhibition.  Alternatively, it 
could indicate that UM-SCC-108 cells have several RTK dependencies and that the loss of a 
subset of these dependencies results in cell death.  The complexity of responses in this model and 
others lead me to favor the latter hypothesis.  Under this premise, the cell would have to activate 
a single additional pathway (one of many possible such pathways, but likely one that has a broad 
effect on cell function) in order to regain the potential to grow and divide.  The specific pathway 
responsible for recurrence is dependent on the selective pressure being applied and certainly 
could vary between and even within tumors from individual patients.  While the effect of 




regression, the ability of other pathways to bypass even this dual-blockade should be noted.  The 
emergence of secondary resistance mechanisms is likely and this phenomenon may be 
responsible for the recurrence of HNSCC and other cancer types following targeted therapy 
treatment. 
 In our HNSCC cell lines, treatment with RTK inhibitor brigatinib was one of the most 
effective means of sensitization to PI3K inhibition.  Brigatinib is conventionally regarded an 
inhibitor of ALK and used clinically to treat ALK-fusion positive lung cancer patients.  ALK 
signaling is not commonly considered as a resistance mechanism in HNSCC since fusion events 
are rare and ALK expression is often quite low in this cancer type.  Nevertheless, previous 
studies have shown that EGFR inhibitors may increase the expression of ALK and display 
greater efficacy with ALK inhibitors (71, 72); this work demonstrates that ALK signaling is 
indeed important in some head and neck cancers.  PI3K and ALK dual-therapy, however, has not 
been considered in HNSCC.  The only previous studies of PI3K and ALK inhibitors examine 
such combinations in the context of other tumor types driven by ALK signaling due to fusion 
with EML4 or other genes (68, 73-75).  Our work, then, may represent the first evidence of 
interaction between PI3K and ALK signaling in the absence of ALK gene fusion.   
However, brigatinib is not a perfectly selective inhibitor of ALK—it also displays 
activity at IGF-1R, EGFR, and other RTKs, especially at higher concentrations (76, 77).  While 
ALK inhibition may be an important component of the response to combinations of brigatinib 
and PI3K inhibitor, we cannot exclude the possibility that the blockade of IGF-1R and/or EGFR 
contribute at least partially to this response.  Our screening data and validation show that IGF-1R 
inhibition can improve responses to PI3K targeting therapy, a phenomenon that has been 




EGFR combination therapy is also well-validated in HNSCC.  The genetic knockouts of ALK 
and IGF-1R that we generated in combination-responsive HSC-4 cells offer insight into the 
effect of blocking an individual RTK, mimicking a perfectly selective pharmacologic treatment.  
ALK knockout HSC-4 cells are more sensitive to monotherapy with AKT inhibitor GDC-0068 
than wildtype HSC-4 cells.  Responses to PI3K inhibition are not markedly different in the 
knockout model, suggests that ALK alone is not responsible for the synergy of ALK and PI3K 
targeting agents in HNSCC.  In spite of this, we cannot conclude that ALK does not play a role 
in the combination response as the process of developing such a cell line may have introduced 
other compensatory changes (such as the upregulation of another RTK) to prevent response to 
single-agent PI3K inhibitor. 
While the mechanistic basis for responses to pictilisib and brigatinib has not been fully 
elucidated, co-treatment with these agents three times per week inhibited tumor growth in a cell-
line derived xenograft mouse model.  However, despite the significant result observed after a 
three-week course with these inhibitors, tumors did progress as treatment continued for extended 
lengths of time.  This observation is in support of the development of additional compensatory 
mechanisms mediating treatment resistance, as described above.  Although the combination of 
PI3K and ALK inhibitor extended survival for weeks past what would have been observed in 
mice with vehicle- and brigatinib-treated tumors, our study motivates further exploration of 
compensatory signaling in HNSCC and the development of improved treatment paradigms 
including those leveraging radiation, targeted therapies (against both RTKs and other important 
signaling molecules), and immunotherapies.  
My thesis has focused primarily on the use of targeted therapies with PI3K inhibitors, but 




improve the efficacy of immune checkpoint receptor (ICR) blockade.  One indication of the 
involvement of the PI3K pathway in responses to immunotherapies is based on data using 
models with loss of tumor suppressor PTEN, which acts in opposition to PI3K signaling.  In 
multiple cancer types, increased expression of PD-L1 has been observed in models with loss of 
PTEN (80-83), and there is some evidence that this may also be the case in HNSCC (84). 
The role of PI3K signaling in cellular metabolism represents one key means by which it 
may contribute to not only cell proliferation but also immune responses.  Specifically, PI3K 
promotes glucose uptake and enhances glycolysis via the mTOR-AKT pathway (85). This 
contributes to the prioritization of the aerobic glycolysis pathway over oxidative 
phosphorylation, a phenomenon considered a hallmark of cancer and coined as the Warburg 
effect (86). As a result, cancer cells with activating mutations or amplifications of PIK3CA may 
directly compete with cytotoxic T-lymphocytes (CTLs) for the limited glucose supply in the 
tumor microenvironment (TME). Indeed, extracellular glucose is a key nutrient source to 
maintain CTL effector function. Innate immune priming expands CTLs and is ideally achieved 
with ICR blockade. Maintaining CTL activation entails rapid genome replication, active 
migration to come in proximity to target tumor cells, production of a large amount of cytokines 
de novo, and establishment of immunologic synapses—all of these processes are metabolically 
demanding and require bioenergetics support.  Furthermore, deprivation of extracellular glucose 
leads to rapid CTL exhaustion (87-91). Thus, inhibiting the PI3K pathway eliminates one 
competing factor for extracellular glucose and reprograms cancer metabolism to favor sustained 
immune effector activation. 
 Beyond its actions to promote the Warburg effect in tumor cells, the PI3K pathway also 




mechanism to ICR blockade is the compensatory upregulation of other ICR members, including 
T-cell Ig and mucin domain-3 protein (TIM-3). Utilizing clinical HNSCC specimens, a recent 
study demonstrated that the ICRs PD-1 and TIM-3 are co-expressed by the most exhausted and 
dysfunctional CTLs. Interestingly, PD-1 blockade-treated HNSCC TILs exhibit further 
upregulation of TIM-3 expression, and this response is dependent on the activation of the 
PI3K/AKT pathway (92). Thus, targeting the PI3K pathway can also directly prevent 
compensatory induction of additional ICR signaling to maintain CTL activation and might 
mediate improved responses to ICR blockade.  Additional studies are needed to further explore 
these interactions and determine the optimal means of combining PI3K inhibitors with 
immunotherapy in HNSCC. 
 
Section 5: Future Directions 
 For each project discussed in my thesis, multiple additional studies could be performed to 
further our understanding of the role of specific signaling pathways in PI3K inhibitor resistance.  
In relation to the contribution of EGFR signaling, the further work I think would be most 
informative would extend my findings on the efficacy of irreversible EGFR inhibitor 
combinations to in vivo models.  I would like to use xenografts to evaluate PI3K and reversible 
or irreversible EGFR inhibitor monotherapies compared to PI3K and reversible or irreversible 
EGFR inhibitor combinations; I hypothesize based on my in vitro work that the combination of 
PI3K and irreversible EGFR inhibitor would be more effective in reducing tumor burden than 
PI3K and reversible EGFR inhibitor combination or any monotherapy treatment.  Additionally, 
given that cetuximab has been used most widely to target EGFR in the clinic and works via 




combination to PI3K and cetuximab or appropriate monotherapy treatments in mouse models.  If 
this experiment showed that PI3K and irreversible EGFR combinations are most effective, it 
would support the advance of such drug pairs into further preclinical and clinical studies. 
 To extend my studies using our transgenic mouse model of the hotspot H1047R Pik3ca 
mutation in HNSCC, I think it would be useful to consider the effects of combining this 
alteration with additional transgenes.  For example, we could replace the mice with Notch1 loss 
that we studied with animals displaying other Notch pathway alterations (dnMaml, Rpbj KO, etc) 
or mutant p53.  Evaluating the time to endpoint for mice of each of these PI3K aberrant and 
Notch deficient strains is warranted based on the disparate effects observed with various 
mechanisms of Notch inactivation in the literature (40, 59).  The specific co-altered strains that 
display the greatest acceleration in time to tumor formation could provide insight on the subset 
of HNSCC patients with loss-of-function alterations in NOTCH1 and other genes that might be 
most likely to respond to PI3K inhibition.  Conversely, strains without accelerated tumor 
formation might represent genetic subsets that would not be responsive to these therapies.  
Furthermore, it will be informative to compare these results in Notch GEMMs to those 
displaying alteration in p53, the most commonly mutated gene in HNSCC.  Previous preclinical 
work has demonstrated that PI3K inhibition may be more effective in p53 wild-type models (93); 
thus, I hypothesize that K14; p53 mutant; Pik3caH1047R mice might display significantly shorter 
time to endpoint following 4-NQO exposure as compared to K14; p53 mutant, K14; Pik3caH1047R 
strains.  However, if I were to observe result—delayed time to tumor formation in K14; p53 
mutant; Pik3caH1047R mice—it would provide further validation for the the results of the BERIL-




 Finally, to continue my studies of PI3K and upstream RTK inhibition (including ALK, 
IGF-1R, etc), I would 1) perform experiments to further delineate the critical target of brigatinib 
and other ALK/IGF-1R inhibitors and 2) consider the mechanisms of resistance that may 
develop following combination treatments that initially result in synergy.  The generation of 
HSC-4 or other combination-responsive cell lines with CRISPR/Cas9 knockout of ALK alone, 
IGF-1R alone, or both ALK and IGF-1R would could reveal the relative contributions of each of 
these pathways in PI3K inhibitor resistance.  Furthermore, unbiased evaluation of gene 
expression and protein level changes (using RNA sequencing or proteomic approaches, for 
example) in these cell lines would suggest other compensatory signals that may drive resistance 
to PI3K inhibitor monotherapy.  As an additional means of considering how HNSCCs might 
escape PI3K and ALK/IGF-1R inhibitor blockade, I could develop a model of acquired 
resistance to these combination treatments by culturing cells in pictilisib and brigatinib for long 
periods of time and isolating clones that survived this paradigm.  Comparing the genetic and 
drug sensitivity profiles of such clones would provide further insights on secondary resistance 
mechanisms.  Evaluation of DNA, RNA, and protein extracted from xenografts following 
extended treatment with the same drug combinations could also be used to evaluate these 
questions in the in vivo setting. 
 Strides continue to be made regarding the most effective use of PI3K inhibitors in 
HNSCC and other cancer types.  Nevertheless, challenges remain in areas including toxicity, 
patient selection, and primary and secondary resistance to these agents.  More work is needed to 
develop safer, more effective drugs, establish biomarkers for response, and elucidate and target 




combined efforts of the cancer research community, I hope that in time PI3K inhibitors will have 
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Table A.1. Inhibitor Library Used in Small Molecule Profiling 
1406 inhibitors were purchased (most as part of the Selleckchem inhibitor library) and were used 
in small molecule profiling studies as described in Chapter 5.  The catalog number, product 
name, pathway, and molecular target for each inhibitor are listed below. 
 
Cat No Product Name Pathway Targets 
S1001 ABT-263 (Navitoclax) Apoptosis Bcl-2 
S1002 ABT-737 Apoptosis Bcl-2,Autophagy 
S1003 Linifanib (ABT-869) Protein Tyrosine Kinase VEGFR,PDGFR,CSF-1R 
S1004 Veliparib (ABT-888) DNA Damage PARP 
S1005 Axitinib Protein Tyrosine Kinase c-Kit,PDGFR,VEGFR 
S1006 Saracatinib (AZD0530) Angiogenesis Bcr-Abl,Src 
S1007 FG-4592 Angiogenesis HIF 
S1008 Selumetinib (AZD6244) MAPK MEK 
S1010 Nintedanib (BIBF 1120) Protein Tyrosine Kinase VEGFR,PDGFR,FGFR 
S1011 Afatinib (BIBW2992) Protein Tyrosine Kinase EGFR,HER2 
S1012 BMS-536924 Protein Tyrosine Kinase IGF-1R 
S1013 Bortezomib (PS-341) Proteases Proteasome 
S1014 Bosutinib (SKI-606) Angiogenesis Src 
S1017 Cediranib (AZD2171) Protein Tyrosine Kinase VEGFR 
S1018 Dovitinib (TKI-258, CHIR-258) Angiogenesis FLT3,VEGFR,FGFR,c-Kit,PDGFR 
S1020 PD184352 (CI-1040) MAPK MEK 
S1021 Dasatinib Angiogenesis Bcr-Abl,Src,c-Kit 
S1023 Erlotinib HCl (OSI-744) Protein Tyrosine Kinase EGFR,Autophagy 
S1025 Gefitinib (ZD1839) Protein Tyrosine Kinase EGFR 
S1026 Imatinib Mesylate (STI571) Protein Tyrosine Kinase c-Kit,Bcr-Abl,PDGFR 
S1028 Lapatinib (GW-572016) Ditosylate Protein Tyrosine Kinase EGFR,HER2 
S1029 Lenalidomide (CC-5013) Apoptosis TNF-alpha 
S1030 Panobinostat (LBH589) Epigenetics HDAC 
S1032 Motesanib Diphosphate (AMG-706) Protein Tyrosine Kinase PDGFR,VEGFR,c-Kit 
S1033 Nilotinib (AMN-107) Angiogenesis Bcr-Abl 
S1034 NVP-AEW541 Protein Tyrosine Kinase IGF-1R 
S1035 Pazopanib HCl (GW786034 HCl) Protein Tyrosine Kinase PDGFR,VEGFR,c-Kit 
S1036 PD0325901 MAPK MEK 
S1038 PI-103 PI3K/Akt/mTOR PI3K,DNA-PK,Autophagy,mTOR 
S1039 Rapamycin (Sirolimus) PI3K/Akt/mTOR mTOR,Autophagy 
S1040 Sorafenib Tosylate MAPK VEGFR,Raf,PDGFR 
S1044 Temsirolimus (CCI-779, NSC 683864) PI3K/Akt/mTOR mTOR 
S1045 Trichostatin A (TSA) Epigenetics HDAC 
S1046 Vandetanib (ZD6474) Protein Tyrosine Kinase VEGFR 
S1047 Vorinostat (SAHA, MK0683) Epigenetics HDAC,Autophagy 
S1048 VX-680 (Tozasertib, MK-0457) Cell Cycle Aurora Kinase 
S1049 Y-27632 2HCl Cell Cycle ROCK,Autophagy 
S1052 Elesclomol (STA-4783) Cytoskeletal Signaling HSP (e.g. HSP90) 
S1053 Entinostat (MS-275) Epigenetics HDAC 
S1055 Enzastaurin (LY317615) TGF-beta/Smad PKC 
S1056 AC480 (BMS-599626) Protein Tyrosine Kinase HER2,EGFR 
S1057 Obatoclax Mesylate (GX15-070) Apoptosis Autophagy,Bcl-2 
S1060 Olaparib (AZD2281, Ku-0059436) DNA Damage PARP 
S1061 Nutlin-3 Apoptosis E3 Ligase ,Mdm2 
S1064 Masitinib (AB1010) Protein Tyrosine Kinase PDGFR,c-Kit 
S1065 GDC-0941 PI3K/Akt/mTOR PI3K 
S1066 SL-327 MAPK MEK 
S1067 SB431542 TGF-beta/Smad TGF-beta/Smad 
S1068 Crizotinib (PF-02341066) Protein Tyrosine Kinase ALK,c-Met 
S1069 AUY922 (NVP-AUY922) Cytoskeletal Signaling HSP (e.g. HSP90) 




S1071 HA14-1 Apoptosis Bcl-2 
S1072 ZSTK474 PI3K/Akt/mTOR PI3K 
S1075 SB216763 PI3K/Akt/mTOR GSK-3 
S1076 SB203580 MAPK p38 MAPK 
S1077 SB202190 (FHPI) MAPK p38 MAPK 
S1078 MK-2206 2HCl PI3K/Akt/mTOR Akt 
S1080 SU11274 Protein Tyrosine Kinase c-Met 
S1082 Vismodegib (GDC-0449) Stem Cells &  Wnt Hedgehog/Smoothened 
S1084 Brivanib (BMS-540215) Protein Tyrosine Kinase VEGFR,FGFR 
S1085 Belinostat (PXD101) Epigenetics HDAC 
S1087 Iniparib (BSI-201) DNA Damage PARP 
S1088 NVP-ADW742 Protein Tyrosine Kinase IGF-1R 
S1089 Refametinib (RDEA119, Bay 86-9766) MAPK MEK 
S1090 PCI-24781 (Abexinostat) Cytoskeletal Signaling HDAC 
S1091 OSI-906 (Linsitinib) Protein Tyrosine Kinase IGF-1R 
S1092 KU-55933 (ATM Kinase Inhibitor) DNA Damage ATM/ATR 
S1093 GSK1904529A Protein Tyrosine Kinase IGF-1R 
S1094 PF-04217903 Protein Tyrosine Kinase c-Met 
S1095 LAQ824 (Dacinostat) Epigenetics HDAC 
S1096 Quisinostat (JNJ-26481585) Epigenetics HDAC 
S1098 Rucaparib (AG-014699,PF-01367338) DNA Damage PARP 
S1100 MLN8054 Cell Cycle Aurora Kinase 
S1101 Vatalanib (PTK787) 2HCl Protein Tyrosine Kinase c-Kit,VEGFR 
S1102 U0126-EtOH MAPK MEK 
S1103 ZM 447439 Cell Cycle Aurora Kinase 
S1104 GDC-0879 MAPK Raf 
S1105 LY294002 PI3K/Akt/mTOR Autophagy,PI3K 
S1106 OSU-03012 (AR-12) PI3K/Akt/mTOR PDK-1 
S1107 Danusertib (PHA-739358) Cell Cycle FGFR,Aurora Kinase,c-RET,Bcr-Abl 
S1109 BI 2536 Cell Cycle PLK 
S1110 Varespladib (LY315920) Metabolism Phospholipase (e.g. PLA) 
S1111 Foretinib (GSK1363089) Protein Tyrosine Kinase VEGFR,c-Met 
S1112 SGX-523 Protein Tyrosine Kinase c-Met 
S1113 GSK690693 PI3K/Akt/mTOR Akt 
S1114 JNJ-38877605 Protein Tyrosine Kinase c-Met 
S1115 Odanacatib (MK-0822) Others Cysteine Protease 
S1116 Palbociclib (PD-0332991) HCl Cell Cycle CDK 
S1117 Triciribine PI3K/Akt/mTOR Akt 
S1118 XL147 PI3K/Akt/mTOR PI3K 
S1119 Cabozantinib (XL184, BMS-907351) Protein Tyrosine Kinase Tie-2,TAM Receptor,FLT3,VEGFR,c-Met,c-Kit 
S1120 Everolimus (RAD001) PI3K/Akt/mTOR mTOR 
S1121 TW-37 Apoptosis Bcl-2 
S1122 Mocetinostat (MGCD0103) Epigenetics HDAC 
S1124 BMS-754807 Protein Tyrosine Kinase IGF-1R,Trk receptor,c-Met 
S1129 SRT1720 Epigenetics Sirtuin 
S1130 YM155 (Sepantronium Bromide) Apoptosis Survivin 
S1132 INO-1001 DNA Damage PARP 
S1133 Alisertib (MLN8237) Cell Cycle Aurora Kinase 
S1134 AT9283 JAK/STAT Aurora Kinase,JAK,Bcr-Abl 
S1138 Brivanib Alaninate (BMS-582664) Protein Tyrosine Kinase VEGFR,FGFR 
S1139 ADL5859 HCl Neuronal Signaling Opioid Receptor 
S1140 Andarine Endocrinology & Hormones Androgen Receptor 
S1141 17-AAG (Tanespimycin) Cytoskeletal Signaling HSP (e.g. HSP90) 
S1142 17-DMAG (Alvespimycin) HCl Cytoskeletal Signaling HSP (e.g. HSP90) 
S1143 AG-490 (Tyrphostin B42) Protein Tyrosine Kinase JAK,EGFR 
S1144 Ivacaftor (VX-770) Transmembrane Transporters CFTR 
S1145 SNS-032 (BMS-387032) Cell Cycle CDK 
S1147 Barasertib (AZD1152-HQPA) Cell Cycle Aurora Kinase 
S1148 Docetaxel Others   
S1150 Paclitaxel Others   
S1152 PLX-4720 MAPK Raf 
S1153 Roscovitine (Seliciclib,CYC202) Cell Cycle CDK 
S1154 SNS-314 Mesylate Cell Cycle Aurora Kinase 
S1155 S3I-201 JAK/STAT STAT 
S1157 CEP-18770 (Delanzomib) Proteases Proteasome 
S1159 Ganetespib (STA-9090) Cytoskeletal Signaling HSP (e.g. HSP90) 
S1163 AT13387 Cytoskeletal Signaling HSP (e.g. HSP90) 
S1164 Lenvatinib (E7080) Protein Tyrosine Kinase VEGFR 
S1166 Cisplatin Others   
S1167 CP-724714 Protein Tyrosine Kinase EGFR,HER2 
S1168 Valproic acid sodium salt (Sodium valproate) Neuronal Signaling GABA Receptor,HDAC,Autophagy 
S1169 TGX-221 PI3K/Akt/mTOR PI3K 
S1170 WZ3146 Protein Tyrosine Kinase EGFR 
S1171 CYC116 Cell Cycle VEGFR,Aurora Kinase 
S1172 JNJ-26854165 (Serdemetan) Apoptosis E3 Ligase ,p53 




S1174 MK-2866 (GTx-024) Endocrinology & Hormones Androgen Receptor 
S1175 BIIB021 Cytoskeletal Signaling HSP (e.g. HSP90) 
S1176 Plinabulin (NPI-2358) Angiogenesis VDA 
S1177 PD98059 MAPK MEK 
S1178 Regorafenib (BAY 73-4506) Protein Tyrosine Kinase c-RET,VEGFR 
S1179 WZ8040 Protein Tyrosine Kinase EGFR 
S1180 XAV-939 Stem Cells &  Wnt Wnt/beta-catenin 
S1181 ENMD-2076 Angiogenesis Aurora Kinase,FLT3,VEGFR 
S1183 Danoprevir (ITMN-191) Proteases HCV Protease 
S1185 Ritonavir Proteases HIV Protease 
S1186 BIBR 1532 DNA Damage Telomerase 
S1188 Anastrozole Endocrinology & Hormones Aromatase 
S1189 Aprepitant Others Substance P 
S1190 Bicalutamide Endocrinology & Hormones Androgen Receptor 
S1191 Fulvestrant Endocrinology & Hormones Estrogen/progestogen Receptor 
S1193 Thalidomide Apoptosis E3 Ligase ,TNF-alpha 
S1194 CUDC-101 Epigenetics EGFR,HER2,HDAC 
S1195 TAK-700 (Orteronel) Metabolism P450 (e.g. CYP17) 
S1196 Exemestane Endocrinology & Hormones Aromatase 
S1197 Finasteride Endocrinology & Hormones 5-alpha Reductase 
S1198 Irinotecan DNA Damage Topoisomerase 
S1200 Decitabine Epigenetics DNA Methyltransferase 
S1202 Dutasteride Endocrinology & Hormones 5-alpha Reductase 
S1205 PIK-75 PI3K/Akt/mTOR DNA-PK,PI3K 
S1207 Tivozanib (AV-951) Protein Tyrosine Kinase PDGFR,c-Kit,VEGFR 
S1208 Doxorubicin (Adriamycin) DNA Damage Autophagy,Topoisomerase 
S1210 Methotrexate Metabolism DHFR 
S1216 PFI-1 (PF-6405761) Epigenetics Epigenetic Reader Domain 
S1219 YM201636 PI3K/Akt/mTOR PI3K 
S1220 OSI-930 Protein Tyrosine Kinase CSF-1R,VEGFR,c-Kit 
S1225 Etoposide DNA Damage Topoisomerase 
S1226 KU-0063794 PI3K/Akt/mTOR mTOR 
S1227 Raloxifene HCl Endocrinology & Hormones Estrogen/progestogen Receptor 
S1228 Idarubicin HCl DNA Damage Topoisomerase 
S1230 Flavopiridol (Alvocidib) Cell Cycle CDK 
S1231 Topotecan HCl DNA Damage Topoisomerase 
S1233 2-Methoxyestradiol (2-MeOE2) Angiogenesis HIF 
S1234 AG-1024 Protein Tyrosine Kinase IGF-1R 
S1235 Letrozole Endocrinology & Hormones Aromatase 
S1237 Temozolomide Ubiquitin Autophagy 
S1244 Amuvatinib (MP-470) Protein Tyrosine Kinase FLT3,PDGFR,c-Kit 
S1249 JNJ-7706621 Cell Cycle Aurora Kinase,CDK 
S1250 Enzalutamide (MDV3100) Endocrinology & Hormones Androgen Receptor 
S1251 Dienogest Endocrinology & Hormones Estrogen/progestogen Receptor 
S1256 Rufinamide Transmembrane Transporters Sodium Channel 
S1258 Prasugrel Neuronal Signaling P2 Receptor 
S1259 Ramelteon GPCR & G Protein MT Receptor 
S1260 Cinacalcet HCl GPCR & G Protein CaSR 
S1261 Celecoxib Neuronal Signaling COX 
S1262 Avagacestat (BMS-708163) Proteases Beta Amyloid,Gamma-secretase 
S1263 CHIR-99021 (CT99021) PI3K/Akt/mTOR GSK-3 
S1264 PD173074 Angiogenesis VEGFR,FGFR 
S1266 WYE-354 PI3K/Akt/mTOR mTOR 
S1267 Vemurafenib (PLX4032, RG7204) MAPK Raf 
S1274 BX-795 PI3K/Akt/mTOR IκB/IKK,PDK-1 
S1275 BX-912 PI3K/Akt/mTOR PDK-1 
S1280 Amisulpride Neuronal Signaling Dopamine Receptor 
S1281 Aniracetam Neuronal Signaling AMPA Receptor-kainate Receptor-NMDA Receptor 
S1283 Asenapine Neuronal Signaling Adrenergic Receptor,5-HT Receptor 
S1284 Benazepril HCl Endocrinology & Hormones RAAS 
S1288 Camptothecin DNA Damage Topoisomerase 
S1290 Celastrol Proteases Proteasome 
S1291 Cetirizine DiHCl Neuronal Signaling Histamine Receptor 
S1293 Cilnidipine Transmembrane Transporters Calcium Channel 
S1294 Cilostazol Metabolism PDE 
S1304 Megestrol Acetate Endocrinology & Hormones Androgen Receptor,Estrogen/progestogen Receptor 
S1315 Ki16425 GPCR & G Protein LPA Receptor 
S1319 Costunolide DNA Damage Telomerase 
S1322 Dexamethasone (DHAP) Others IL Receptor,Autophagy 
S1324 Doxazosin Mesylate Neuronal Signaling Adrenergic Receptor 
S1328 Etodolac Neuronal Signaling COX 
S1329 Etomidate Neuronal Signaling GABA Receptor 
S1332 Flumazenil Neuronal Signaling GABA Receptor 
S1333 Fluoxetine HCl Neuronal Signaling 5-HT Receptor 
S1336 Fluvoxamine maleate Neuronal Signaling 5-HT Receptor 




S1343 Ginkgolide B Others PAFR 
S1344 Glimepiride Proteases Potassium Channel 
S1352 TG100-115 PI3K/Akt/mTOR PI3K 
S1353 Ketoconazole Metabolism P450 (e.g. CYP17) 
S1354 Lansoprazole Transmembrane Transporters Proton Pump 
S1357 Lidocaine Neuronal Signaling Histamine Receptor 
S1358 Loratadine Neuronal Signaling Histamine Receptor 
S1359 Losartan Potassium (DuP 753) Endocrinology & Hormones RAAS 
S1360 GSK1059615 PI3K/Akt/mTOR mTOR,PI3K 
S1361 MGCD-265 Protein Tyrosine Kinase c-Met,Tie-2,VEGFR 
S1362 Rigosertib (ON-01910) Cell Cycle PLK 
S1363 Ki8751 Protein Tyrosine Kinase c-Kit,VEGFR,PDGFR 
S1366 BMS-707035 Microbiology Integrase 
S1367 Amonafide DNA Damage Topoisomerase 
S1376 Gestodene Endocrinology & Hormones Estrogen/progestogen Receptor 
S1377 Drospirenone Endocrinology & Hormones Estrogen/progestogen Receptor 
S1378 Ruxolitinib (INCB018424) JAK/STAT JAK 
S1379 Isotretinoin Metabolism Hydroxylase 
S1380 Lopinavir Proteases HIV Protease 
S1382 Mianserin HCl Neuronal Signaling Histamine Receptor 
S1385 Mosapride Citrate Neuronal Signaling 5-HT Receptor 
S1386 Nafamostat Mesylate Proteases Serine Protease 
S1387 Naftopidil DiHCl Neuronal Signaling Adrenergic Receptor 
S1389 Omeprazole Transmembrane Transporters Autophagy,Proton Pump 
S1390 Ondansetron HCl Neuronal Signaling 5-HT Receptor 
S1391 Oxcarbazepine Transmembrane Transporters Sodium Channel 
S1392 Pelitinib (EKB-569) Protein Tyrosine Kinase EGFR 
S1396 Resveratrol Epigenetics Sirtuin,Autophagy 
S1397 Rocuronium Bromide Neuronal Signaling AChR 
S1398 Stavudine (d4T) Microbiology Reverse Transcriptase 
S1401 Tenofovir Microbiology Reverse Transcriptase 
S1404 Trilostane Metabolism Dehydrogenase 
S1409 Alfuzosin HCl Neuronal Signaling Adrenergic Receptor 
S1415 Clopidogrel Neuronal Signaling P2 Receptor 
S1421 Staurosporine TGF-beta/Smad PKC 
S1422 Droxinostat Cytoskeletal Signaling HDAC 
S1425 Ranolazine 2HCl Transmembrane Transporters Calcium Channel 
S1426 Repaglinide Transmembrane Transporters Potassium Channel 
S1430 Rolipram Metabolism PDE 
S1431 Sildenafil Citrate Metabolism PDE 
S1432 Sumatriptan Succinate Neuronal Signaling 5-HT Receptor 
S1436 Tianeptine sodium Neuronal Signaling 5-HT Receptor 
S1437 Tizanidine HCl Neuronal Signaling Adrenergic Receptor 
S1438 Topiramate Metabolism Carbonic Anhydrase 
S1441 Venlafaxine Neuronal Signaling 5-HT Receptor 
S1442 Voriconazole Metabolism P450 (e.g. CYP17) 
S1451 Aurora A Inhibitor I Cell Cycle Aurora Kinase 
S1452 Ispinesib (SB-715992) Cytoskeletal Signaling Kinesin 
S1453 Tipifarnib Metabolism Transferase 
S1454 PHA-680632 Cell Cycle Aurora Kinase 
S1455 Cilomilast Metabolism PDE 
S1456 Zibotentan (ZD4054) GPCR & G Protein Endothelin Receptor 
S1457 Atazanavir Sulfate Proteases HIV Protease 
S1458 VX-745 MAPK p38 MAPK 
S1459 Thiazovivin Cell Cycle ROCK 
S1460 SP600125 MAPK JNK 
S1462 AZD6482 PI3K/Akt/mTOR PI3K 
S1465 Moxifloxacin HCl DNA Damage Topoisomerase 
S1470 TSU-68 (SU6668, Orantinib) Protein Tyrosine Kinase PDGFR,FGFR,VEGFR 
S1472 Safinamide Mesylate Metabolism MAO 
S1474 GSK429286A Cell Cycle ROCK 
S1475 Pimasertib (AS-703026) MAPK MEK 
S1476 SB525334 TGF-beta/Smad TGF-beta/Smad 
S1478 Oligomycin A Transmembrane Transporters ATPase 
S1480 VX-222 (VCH-222, Lomibuvir) Proteases HCV Protease 
S1481 Zosuquidar (LY335979) 3HCl Transmembrane Transporters P-gp 
S1482 Daclatasvir (BMS-790052) Proteases HCV Protease 
S1484 MC1568 Cytoskeletal Signaling HDAC 
S1485 HMN-214 Cell Cycle PLK 
S1486 AEE788 (NVP-AEE788) Protein Tyrosine Kinase VEGFR,EGFR,HER2 
S1487 PHA-793887 Cell Cycle CDK 
S1488 Naratriptan Neuronal Signaling 5-HT Receptor 
S1489 PIK-93 PI3K/Akt/mTOR PI3K 
S1490 Ponatinib (AP24534) Angiogenesis Bcr-Abl,PDGFR,VEGFR,FGFR 
S1491 Fludarabine JAK/STAT STAT,DNA/RNA Synthesis 




S1497 Pralatrexate Metabolism DHFR 
S1501 Mycophenolate Mofetil Metabolism Dehydrogenase 
S1504 Dyphylline Metabolism PDE 
S1512 Tadalafil Metabolism PDE 
S1515 Pracinostat (SB939) Cytoskeletal Signaling HDAC 
S1519 CCT129202 Cell Cycle Aurora Kinase 
S1523 SAR245409 (XL765) PI3K/Akt/mTOR PI3K,mTOR 
S1524 AT7519 Cell Cycle CDK 
S1525 MK-1775 Cell Cycle Wee1 
S1526 Quizartinib (AC220) Angiogenesis FLT3 
S1528 LY2811376 Proteases Beta Amyloid,BACE 
S1529 Hesperadin Cell Cycle Aurora Kinase 
S1530 BIX 02188 MAPK MEK 
S1531 BIX 02189 MAPK MEK 
S1532 AZD7762 Cell Cycle Chk 
S1533 R406 (free base) Angiogenesis Syk 
S1534 Org 27569 GPCR & G Protein Cannabinoid Receptor 
S1536 CP-673451 Protein Tyrosine Kinase PDGFR 
S1537 DMXAA (Vadimezan) Angiogenesis VDA 
S1538 Telaprevir (VX-950) Proteases HCV Protease 
S1540 Saxagliptin Proteases DPP-4 
S1541 EX 527 (Selisistat) Epigenetics Sirtuin 
S1544 AM1241 GPCR & G Protein Cannabinoid Receptor 
S1545 SB408124 GPCR & G Protein OX Receptor 
S1548 Dapagliflozin GPCR & G Protein SGLT 
S1549 Nebivolol Neuronal Signaling Adrenergic Receptor 
S1550 Pimobendan Metabolism PDE 
S1555 AZD8055 PI3K/Akt/mTOR mTOR 
S1556 PHT-427 PI3K/Akt/mTOR Akt,PDK-1 
S1557 KRN 633 Protein Tyrosine Kinase VEGFR,PDGFR 
S1558 AT7867 PI3K/Akt/mTOR S6 Kinase,Akt 
S1561 BMS-777607 Protein Tyrosine Kinase c-Met,TAM Receptor 
S1565 VX-809 (Lumacaftor) Transmembrane Transporters CFTR 
S1567 Pomalidomide Apoptosis TNF-alpha 
S1568 PD318088 MAPK MEK 
S1570 KU-60019 DNA Damage ATM/ATR 
S1572 BS-181 HCl Cell Cycle CDK 
S1573 Fasudil (HA-1077) HCl Cell Cycle ROCK,Autophagy 
S1574 BIRB 796 (Doramapimod) MAPK p38 MAPK 
S1575 RO4929097 Proteases Gamma-secretase,Beta Amyloid 
S1577 Tie2 kinase inhibitor Protein Tyrosine Kinase Tie-2 
S1578 Candesartan Endocrinology & Hormones RAAS 
S1582 H 89 2HCl PI3K/Akt/mTOR PKA,S6 Kinase 
S1590 TWS119 PI3K/Akt/mTOR GSK-3 
S1593 Apixaban Metabolism Factor Xa 
S1594 Semagacestat (LY450139) Proteases Gamma-secretase 
S1604 Olmesartan Medoxomil Endocrinology & Hormones RAAS 
S1608 Pyridostigmine Bromide Neuronal Signaling AChR 
S1613 Silodosin Neuronal Signaling Adrenergic Receptor 
S1614 Riluzole Transmembrane Transporters Sodium Channel,GluR 
S1615 Risperidone Neuronal Signaling 5-HT Receptor 
S1620 Darunavir Ethanolate Proteases HIV Protease 
S1623 Acetylcysteine Others Others 
S1626 Naproxen Neuronal Signaling COX 
S1630 Allopurinol GPCR & G Protein Others 
S1638 Ibuprofen Neuronal Signaling COX 
S1639 Amprenavir Proteases HIV Protease 
S1645 Ketoprofen Neuronal Signaling COX 
S1646 Ketorolac Neuronal Signaling COX 
S1649 Zolmitriptan Neuronal Signaling 5-HT Receptor 
S1657 Enalaprilat Dihydrate Endocrinology & Hormones RAAS 
S1662 Isradipine Transmembrane Transporters Calcium Channel 
S1665 Estrone Endocrinology & Hormones Estrogen/progestogen Receptor 
S1672 Aminoglutethimide Endocrinology & Hormones Aromatase 
S1673 Aminophylline Metabolism PDE 
S1693 Carbamazepine Transmembrane Transporters Sodium Channel,Autophagy 
S1702 Didanosine Microbiology Reverse Transcriptase 
S1703 Divalproex Sodium Ubiquitin Autophagy 
S1704 Emtricitabine Microbiology Reverse Transcriptase 
S1706 Lamivudine Microbiology Reverse Transcriptase 
S1713 Piroxicam Neuronal Signaling COX 
S1714 Gemcitabine DNA Damage DNA/RNA Synthesis,Autophagy 
S1718 Adefovir Dipivoxil Microbiology Reverse Transcriptase 
S1719 Zalcitabine Microbiology Reverse Transcriptase 
S1738 Telmisartan Endocrinology & Hormones RAAS 




S1747 Nimodipine Transmembrane Transporters Autophagy,Calcium Channel 
S1763 Quetiapine Fumarate Neuronal Signaling Dopamine Receptor 
S1771 Chlorprothixene Neuronal Signaling Dopamine Receptor 
S1776 Toremifene Citrate Endocrinology & Hormones Estrogen/progestogen Receptor 
S1782 Azacitidine DNA Damage DNA Methyltransferase 
S1793 Ramipril Endocrinology & Hormones RAAS 
S1801 Ranitidine Neuronal Signaling Histamine Receptor 
S1802 Acadesine PI3K/Akt/mTOR AMPK 
S1805 Acetylcholine Chloride Neuronal Signaling AChR 
S1813 Amlodipine Besylate Transmembrane Transporters Calcium Channel 
S1816 Chlorpheniramine Maleate Neuronal Signaling Histamine Receptor 
S1828 Proparacaine HCl Transmembrane Transporters Sodium Channel 
S1831 Carvedilol Neuronal Signaling Adrenergic Receptor 
S1835 Azithromycin Ubiquitin Autophagy 
S1845 Cimetidine Neuronal Signaling Histamine Receptor 
S1847 Clemastine Fumarate Neuronal Signaling Histamine Receptor 
S1856 Metoprolol Tartrate Neuronal Signaling Adrenergic Receptor 
S1869 Dapoxetine HCl Neuronal Signaling 5-HT Receptor 
S1880 Roxatidine Acetate HCl Neuronal Signaling Histamine Receptor 
S1885 Felodipine Transmembrane Transporters Calcium Channel 
S1890 Nizatidine Neuronal Signaling Histamine Receptor 
S1894 Valsartan Endocrinology & Hormones RAAS 
S1898 Tropisetron Neuronal Signaling 5-HT Receptor 
S1903 Diclofenac Sodium Neuronal Signaling COX 
S1905 Amlodipine Transmembrane Transporters Calcium Channel 
S1908 Flutamide Endocrinology & Hormones Androgen Receptor 
S1909 Fluvastatin Sodium Metabolism HMG-CoA Reductase 
S1913 Tropicamide Neuronal Signaling AChR 
S1914 Pregnenolone Endocrinology & Hormones Estrogen/progestogen Receptor 
S1929 Irsogladine Metabolism AChR,PDE 
S1941 Enalapril Maleate Endocrinology & Hormones RAAS 
S1959 Tolfenamic Acid Neuronal Signaling COX 
S1969 Nefiracetam Neuronal Signaling GABA Receptor 
S1971 Nicorandil Transmembrane Transporters Potassium Channel 
S1972 Tamoxifen Citrate Endocrinology & Hormones Autophagy,Estrogen/progestogen Receptor 
S1975 Aripiprazole Neuronal Signaling 5-HT Receptor 
S1978 Methscopolamine Neuronal Signaling AChR 
S1979 Amiodarone HCl Transmembrane Transporters Potassium Channel,Autophagy 
S1994 Lacidipine Transmembrane Transporters Calcium Channel 
S2001 Elvitegravir (GS-9137, JTK-303) Microbiology Integrase 
S2003 Maraviroc Microbiology CCR 
S2005 Raltegravir (MK-0518) Microbiology Integrase 
S2006 Pyrimethamine Metabolism DHFR 
S2012 PCI-34051 Epigenetics HDAC 
S2013 PF-573228 Angiogenesis FAK 
S2014 BMS-265246 Cell Cycle CDK 
S2017 Benidipine HCl Transmembrane Transporters Calcium Channel 
S2020 Formoterol Hemifumarate Neuronal Signaling Adrenergic Receptor 
S2024 Ketotifen Fumarate Neuronal Signaling Histamine Receptor 
S2025 Urapidil HCl Neuronal Signaling 5-HT Receptor 
S2026 Ginkgolide A Neuronal Signaling GABA Receptor 
S2030 Flunarizine 2HCl Transmembrane Transporters Calcium Channel 
S2037 Candesartan Cilexetil Endocrinology & Hormones RAAS 
S2038 Phentolamine Mesylate Neuronal Signaling Adrenergic Receptor 
S2040 Nimesulide Neuronal Signaling COX 
S2042 Cyproterone Acetate Endocrinology & Hormones Androgen Receptor 
S2043 Memantine HCl Neuronal Signaling AMPA Receptor-kainate Receptor-NMDA Receptor 
S2044 Cyproheptadine HCl Neuronal Signaling Histamine Receptor 
S2046 Pioglitazone HCl Metabolism P450 (e.g. CYP17) 
S2047 Lornoxicam Neuronal Signaling COX 
S2051 Captopril Endocrinology & Hormones RAAS 
S2054 Orphenadrine Citrate Neuronal Signaling AChR 
S2055 Gimeracil Metabolism Dehydrogenase 
S2059 Terazosin HCl Neuronal Signaling Adrenergic Receptor 
S2061 Lovastatin Metabolism HMG-CoA Reductase 
S2065 Lafutidine Neuronal Signaling Histamine Receptor 
S2077 Atorvastatin Calcium Metabolism HMG-CoA Reductase 
S2078 Famotidine Neuronal Signaling Histamine Receptor 
S2079 Moexipril HCl Endocrinology & Hormones RAAS 
S2080 Clevidipine Butyrate Transmembrane Transporters Calcium Channel 
S2084 Duloxetine HCl Neuronal Signaling 5-HT Receptor 
S2085 Trimebutine Neuronal Signaling Opioid Receptor 
S2086 Ivabradine HCl Neuronal Signaling Adrenergic Receptor 
S2087 Rivastigmine Tartrate Neuronal Signaling AChR 
S2091 Betaxolol Neuronal Signaling Adrenergic Receptor 




S2096 Almotriptan Malate Neuronal Signaling 5-HT Receptor 
S2099 Temocapril HCl Endocrinology & Hormones RAAS 
S2101 Gabexate Mesylate Proteases Serine Protease 
S2102 Rasagiline Mesylate Metabolism MAO 
S2103 Naltrexone HCl Neuronal Signaling Opioid Receptor 
S2104 Levosulpiride Neuronal Signaling Dopamine Receptor 
S2108 Flunixin Meglumin Neuronal Signaling COX 
S2109 Imidapril HCl Endocrinology & Hormones RAAS 
S2113 Cisatracurium Besylate Neuronal Signaling Adrenergic Receptor 
S2118 Ibutilide Fumarate Transmembrane Transporters Sodium Channel 
S2126 Naftopidil Neuronal Signaling Adrenergic Receptor 
S2127 S- (+)-Rolipram Metabolism PDE 
S2128 Bazedoxifene HCl Endocrinology & Hormones Estrogen/progestogen Receptor 
S2130 Atropine Neuronal Signaling AChR 
S2131 Roflumilast Metabolism PDE 
S2134 AZD8330 MAPK MEK 
S2149 GSK1292263 Endocrinology & Hormones GPR 
S2151 LDE225 (NVP-LDE225,Erismodegib) Stem Cells &  Wnt Hedgehog/Smoothened 
S2153 CGS 21680 HCl Angiogenesis Adenosine Receptor 
S2158 KW-2449 Angiogenesis Bcr-Abl,Aurora Kinase,FLT3 
S2160 Almorexant HCl GPCR & G Protein OX Receptor 
S2161 RAF265 (CHIR-265) MAPK VEGFR,Raf 
S2162 AZD1480 JAK/STAT JAK 
S2163 PF-4708671 PI3K/Akt/mTOR S6 Kinase 
S2168 PD128907 HCl Neuronal Signaling Dopamine Receptor 
S2169 Rosuvastatin Calcium Endocrinology & Hormones HMG-CoA Reductase 
S2170 Givinostat (ITF2357) Cytoskeletal Signaling HDAC 
S2173 Telotristat Etiprate (LX 1606 Hippurate) Metabolism Hydroxylase 
S2178 AG-14361 DNA Damage PARP 
S2179 LY2784544 JAK/STAT JAK 
S2180 MLN2238 Proteases Proteasome 
S2181 MLN9708 Proteases Proteasome 
S2183 BGJ398 (NVP-BGJ398) Angiogenesis FGFR 
S2185 AST-1306 Protein Tyrosine Kinase EGFR 
S2186 SB505124 TGF-beta/Smad TGF-beta/Smad 
S2187 Avasimibe Metabolism P450 (e.g. CYP17) 
S2192 AZD8931 (Sapitinib) Protein Tyrosine Kinase EGFR,HER2 
S2193 GSK461364 Cell Cycle PLK 
S2194 R406 Angiogenesis FLT3,Syk 
S2195 CYT997 (Lexibulin) Cytoskeletal Signaling Microtubule Associated 
S2197 A-966492 DNA Damage PARP 
S2198 SGI-1776 free base JAK/STAT Pim 
S2199 Aliskiren Hemifumarate Endocrinology & Hormones RAAS 
S2201 BMS-794833 Protein Tyrosine Kinase VEGFR,c-Met 
S2202 NVP-BHG712 Protein Tyrosine Kinase Raf,Bcr-Abl,Src,Ephrin receptor 
S2205 OSI-420 Protein Tyrosine Kinase EGFR 
S2207 PIK-293 PI3K/Akt/mTOR PI3K 
S2208 Formestane Endocrinology & Hormones Aromatase 
S2209 Vinflunine Tartrate Cytoskeletal Signaling Microtubule Associated 
S2214 AZ 960 JAK/STAT JAK 
S2215 DAPT (GSI-IX) Proteases Gamma-secretase,Beta Amyloid 
S2216 Mubritinib (TAK 165) Protein Tyrosine Kinase HER2 
S2217 Irinotecan HCl Trihydrate DNA Damage Topoisomerase 
S2218 PP242 PI3K/Akt/mTOR mTOR,Autophagy 
S2219 CYT387 JAK/STAT JAK 
S2220 SB590885 MAPK Raf 
S2221 Apatinib Protein Tyrosine Kinase VEGFR 
S2224 UK 383367 Metabolism Procollagen C Proteinase 
S2225 TAME Cell Cycle APC,E3 Ligase 
S2226 CAL-101 (Idelalisib, GS-1101) PI3K/Akt/mTOR PI3K 
S2227 PIK-294 PI3K/Akt/mTOR PI3K 
S2228 VX-765 Apoptosis Caspase 
S2230 LY2157299 TGF-beta/Smad TGF-beta/Smad 
S2231 Telatinib Protein Tyrosine Kinase VEGFR,PDGFR,c-Kit 
S2232 Ketanserin Neuronal Signaling 5-HT Receptor 
S2233 Esomeprazole Sodium Transmembrane Transporters ATPase 
S2235 Volasertib (BI 6727) Cell Cycle PLK 
S2239 Tubacin Cytoskeletal Signaling HDAC 
S2240 Fesoterodine Fumarate Neuronal Signaling AChR 
S2243 Degrasyn (WP1130) Angiogenesis Bcr-Abl,DUB 
S2247 BKM120 (NVP-BKM120, Buparlisib) PI3K/Akt/mTOR PI3K 
S2262 Apigenin Metabolism P450 (e.g. CYP17) 
S2266 Asiatic Acid MAPK p38 MAPK 
S2268 Baicalein Metabolism P450 (e.g. CYP17) 
S2285 Cryptotanshinone JAK/STAT STAT 




S2310 Honokiol PI3K/Akt/mTOR MEK,Akt 
S2312 Icariin Metabolism PDE 
S2320 Luteolin Metabolism PDE 
S2322 (+)-Matrine Neuronal Signaling Opioid Receptor 
S2341 (-)-Parthenolide Ubiquitin E3 Ligase 
S2362 Synephrine GPCR & G Protein Adrenergic Receptor 
S2386 Indirubin PI3K/Akt/mTOR GSK-3 
S2391 Quercetin Epigenetics Sirtuin,PI3K,Src,PKC 
S2394 Naringenin Metabolism P450 (e.g. CYP17) 
S2401 Sodium Danshensu Others P450 (e.g. CYP17) 
S2406 Chrysophanic Acid Protein Tyrosine Kinase EGFR,mTOR 
S2415 Astragaloside A TGF-beta/Smad Others 
S2423 (S)-10-Hydroxycamptothecin DNA Damage Topoisomerase 
S2437 Rotundine Neuronal Signaling Dopamine Receptor 
S2438 Synephrine HCl Neuronal Signaling Adrenergic Receptor 
S2443 Tolbutamide Transmembrane Transporters Potassium Channel 
S2448 Gambogic Acid Apoptosis Caspase,Bcl-2 
S2449 Forskolin GPCR & G Protein cAMP 
S2450 Equol Endocrinology & Hormones Estrogen/progestogen Receptor 
S2451 Amantadine HCl Neuronal Signaling Dopamine Receptor 
S2452 Amfebutamone HCl Neuronal Signaling AChR,Dopamine Receptor 
S2453 Benserazide HCl Others Others 
S2454 Bupivacaine HCl GPCR & G Protein Sodium Channel 
S2455 Bethanechol chloride Neuronal Signaling AChR 
S2456 Chlorpromazine HCl Neuronal Signaling Dopamine Receptor,Potassium Channel 
S2458 Clonidine HCl Neuronal Signaling Autophagy,Adrenergic Receptor 
S2459 Clozapine Neuronal Signaling 5-HT Receptor 
S2460 Pramipexole Neuronal Signaling Dopamine Receptor 
S2461 Domperidone Neuronal Signaling Dopamine Receptor 
S2466 Estriol Endocrinology & Hormones Estrogen/progestogen Receptor 
S2471 Gallamine Triethiodide Neuronal Signaling AChR 
S2473 Hexestrol Endocrinology & Hormones Estrogen/progestogen Receptor 
S2475 Imatinib (STI571) Protein Tyrosine Kinase PDGFR 
S2480 Loperamide HCl Neuronal Signaling Autophagy,Opioid Receptor 
S2481 Manidipine Transmembrane Transporters Calcium Channel 
S2482 Manidipine 2HCl Transmembrane Transporters Calcium Channel 
S2484 Milrinone Metabolism ATPase,PDE 
S2489 Nateglinide Transmembrane Transporters Potassium Channel 
S2491 Nitrendipine Transmembrane Transporters Calcium Channel,Autophagy 
S2493 Olanzapine Neuronal Signaling 5-HT Receptor,Dopamine Receptor 
S2494 Olopatadine HCl Neuronal Signaling Histamine Receptor 
S2495 Oxymetazoline HCl Neuronal Signaling Adrenergic Receptor 
S2496 Ozagrel Metabolism P450 (e.g. CYP17) 
S2497 Pancuronium dibromide Neuronal Signaling AChR 
S2499 Phenoxybenzamine HCl GPCR & G Protein Adrenergic Receptor 
S2500 Propafenone HCl Transmembrane Transporters Sodium Channel 
S2503 Racecadotril Neuronal Signaling Opioid Receptor 
S2508 Scopolamine HBr Neuronal Signaling AChR 
S2509 Sotalol Neuronal Signaling Adrenergic Receptor 
S2515 Vardenafil HCl Trihydrate Metabolism PDE 
S2516 Xylazine HCl Neuronal Signaling Adrenergic Receptor 
S2517 Maprotiline HCl Neuronal Signaling Adrenergic Receptor 
S2519 Naphazoline HCl Neuronal Signaling Adrenergic Receptor 
S2521 Epinephrine Bitartrate GPCR & G Protein Adrenergic Receptor 
S2522 L-Adrenaline Neuronal Signaling Adrenergic Receptor 
S2524 Phenytoin sodium Transmembrane Transporters Sodium Channel 
S2525 Phenytoin Transmembrane Transporters Sodium Channel 
S2526 Alizarin Metabolism P450 (e.g. CYP17) 
S2529 Dopamine HCl Neuronal Signaling Dopamine Receptor 
S2531 Asaraldehyde Neuronal Signaling COX 
S2533 Ritodrine HCl Neuronal Signaling Adrenergic Receptor 
S2542 Phenformin HCl PI3K/Akt/mTOR AMPK 
S2545 Scopine Neuronal Signaling Adrenergic Receptor 
S2547 Tiotropium Bromide hydrate Neuronal Signaling AChR 
S2549 Trospium chloride Neuronal Signaling AChR 
S2550 Tolterodine tartrate Neuronal Signaling AChR 
S2552 Azelastine HCl Neuronal Signaling Histamine Receptor 
S2555 Clarithromycin Metabolism P450 (e.g. CYP17) 
S2556 Rosiglitazone DNA Damage PPAR 
S2561 Clomifene citrate Endocrinology & Hormones Estrogen/progestogen Receptor 
S2566 Isoprenaline HCl Neuronal Signaling Adrenergic Receptor 
S2567 Medroxyprogesterone acetate Endocrinology & Hormones Estrogen/progestogen Receptor 
S2569 Phenylephrine HCl GPCR & G Protein Adrenergic Receptor 
S2573 Tetracaine HCl Transmembrane Transporters Calcium Channel 
S2577 Phenacetin Neuronal Signaling COX 




S2581 Quinapril HCl Endocrinology & Hormones RAAS 
S2585 Brompheniramine hydrogen maleate Neuronal Signaling Histamine Receptor 
S2593 Tolvaptan GPCR & G Protein Vasopressin Receptor 
S2601 Gliclazide Transmembrane Transporters Potassium Channel 
S2602 Acemetacin Neuronal Signaling COX 
S2603 Tioxolone Metabolism Carbonic Anhydrase 
S2604 Dehydroepiandrosterone (DHEA) Endocrinology & Hormones Estrogen/progestogen Receptor,Androgen Receptor 
S2606 Mifepristone Endocrinology & Hormones Estrogen/progestogen Receptor 
S2614 Arecoline Neuronal Signaling AChR 
S2617 TAK-733 MAPK MEK 
S2619 MG-132 Proteases Proteasome 
S2620 GSK256066 Metabolism PDE 
S2621 AZD5438 Cell Cycle CDK 
S2622 PP121 Protein Tyrosine Kinase PDGFR,mTOR,DNA-PK 
S2623 Omecamtiv mecarbil (CK-1827452) Transmembrane Transporters ATPase 
S2624 OSI-027 PI3K/Akt/mTOR mTOR 
S2625 Fostamatinib (R788) Angiogenesis Syk 
S2626 LY2603618 Cell Cycle Chk 
S2627 Tubastatin A HCl Epigenetics HDAC 
S2629 PNU-120596 Neuronal Signaling AChR 
S2630 GW3965 HCl Others Liver X Receptor 
S2631 URB597 Metabolism FAAH 
S2633 NPS-2143 GPCR & G Protein CaSR 
S2634 DCC-2036 (Rebastinib) Angiogenesis Bcr-Abl 
S2635 CCT128930 PI3K/Akt/mTOR Akt 
S2636 A66 PI3K/Akt/mTOR PI3K 
S2637 TAK-875 Endocrinology & Hormones GPR 
S2638 NU7441 (KU-57788) DNA Damage DNA-PK,PI3K 
S2639 SNX-2112 (PF-04928473) Cytoskeletal Signaling HSP (e.g. HSP90) 
S2656 PF-04929113 (SNX-5422) Cytoskeletal Signaling HSP (e.g. HSP90) 
S2658 GSK2126458 (GSK458) PI3K/Akt/mTOR mTOR,PI3K 
S2659 5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM) Neuronal Signaling AChR 
S2660 MK-0752 Proteases Gamma-secretase,Beta Amyloid 
S2661 WYE-125132 (WYE-132) PI3K/Akt/mTOR mTOR 
S2662 ICG-001 Stem Cells &  Wnt Wnt/beta-catenin 
S2663 WAY-100635 Maleate Neuronal Signaling 5-HT Receptor 
S2664 Clinofibrate Endocrinology & Hormones HMG-CoA Reductase 
S2665 Ciprofibrate DNA Damage PPAR 
S2666 PF-3845 Metabolism FAAH 
S2667 Dolutegravir (GSK1349572) Microbiology Integrase 
S2670 A-674563 PI3K/Akt/mTOR PKA,Akt,CDK 
S2671 AS-252424 PI3K/Akt/mTOR PI3K 
S2672 PF-00562271 Angiogenesis FAK 
S2673 Trametinib (GSK1120212) MAPK MEK 
S2674 A922500 Metabolism Transferase 
S2677 BRL-15572 Neuronal Signaling 5-HT Receptor 
S2679 Flavopiridol HCl Cell Cycle CDK 
S2680 Ibrutinib (PCI-32765) Angiogenesis BTK 
S2681 AS-604850 PI3K/Akt/mTOR PI3K 
S2683 CHIR-124 Cell Cycle Chk 
S2685 KW-2478 Cytoskeletal Signaling HSP (e.g. HSP90) 
S2686 NVP-BSK805 2HCl JAK/STAT JAK 
S2687 PF-2545920 Metabolism PDE 
S2688 R547 Cell Cycle CDK 
S2689 WAY-600 PI3K/Akt/mTOR mTOR 
S2690 ADX-47273 Neuronal Signaling GluR 
S2691 BMY 7378 Neuronal Signaling 5-HT Receptor,Adrenergic Receptor 
S2692 TG101209 JAK/STAT JAK,FLT3,c-RET 
S2693 Resminostat Epigenetics HDAC 
S2694 XL335 Others FXR 
S2695 Nepicastat (SYN-117) HCl Metabolism Hydroxylase 
S2696 GDC-0980 (RG7422) PI3K/Akt/mTOR mTOR,PI3K 
S2697 A-769662 PI3K/Akt/mTOR AMPK 
S2698 RS-127445 Neuronal Signaling 5-HT Receptor 
S2699 CH5132799 PI3K/Akt/mTOR mTOR,PI3K 
S2700 KX2-391 Angiogenesis Src 
S2703 GSK1838705A Protein Tyrosine Kinase ALK,IGF-1R 
S2711 YO-01027 Proteases Gamma-secretase 
S2713 Geldanamycin Cytoskeletal Signaling HSP (e.g. HSP90),Autophagy 
S2714 LY411575 Proteases Gamma-secretase 
S2717 CP-91149 Metabolism Phosphorylase 
S2718 TAK-901 Cell Cycle Aurora Kinase 
S2719 AMG-900 Cell Cycle Aurora Kinase 
S2720 ZM 336372 MAPK Raf 
S2721 Nilvadipine Transmembrane Transporters Calcium Channel 




S2726 PH-797804 MAPK p38 MAPK 
S2727 Dacomitinib (PF299804, PF299) Protein Tyrosine Kinase EGFR 
S2728 AG-1478 (Tyrphostin AG-1478) Protein Tyrosine Kinase EGFR 
S2729 SB415286 PI3K/Akt/mTOR GSK-3 
S2730 Crenolanib (CP-868596) Protein Tyrosine Kinase PDGFR 
S2731 AZ 3146 Cytoskeletal Signaling Kinesin 
S2735 MK-8776 (SCH 900776) Cell Cycle Chk,CDK 
S2736 TG101348 (SAR302503) JAK/STAT JAK 
S2738 PAC-1 Apoptosis Caspase 
S2742 PHA-767491 Cell Cycle CDK 
S2743 PF-04691502 PI3K/Akt/mTOR mTOR,Akt,PI3K 
S2744 CCT137690 Cell Cycle Aurora Kinase 
S2745 CHIR-98014 PI3K/Akt/mTOR GSK-3 
S2746 AZ 628 MAPK Raf 
S2747 AMG-458 Protein Tyrosine Kinase c-Met 
S2749 BGT226 (NVP-BGT226) PI3K/Akt/mTOR mTOR,PI3K 
S2750 GW788388 TGF-beta/Smad TGF-beta/Smad 
S2751 Milciclib (PHA-848125) Cell Cycle CDK 
S2753 Tivantinib (ARQ 197) Protein Tyrosine Kinase c-Met 
S2755 Varlitinib Protein Tyrosine Kinase EGFR 
S2757 TH-302 Others Others 
S2758 Wortmannin PI3K/Akt/mTOR PI3K,ATM/ATR,Autophagy 
S2759 CUDC-907 Cytoskeletal Signaling PI3K,HDAC 
S2760 Canagliflozin GPCR & G Protein SGLT 
S2761 NVP-BVU972 Protein Tyrosine Kinase c-Met 
S2765 MK-2048 Microbiology Integrase 
S2767 3-Methyladenine PI3K/Akt/mTOR PI3K,Autophagy 
S2768 Dinaciclib (SCH727965) Cell Cycle CDK 
S2769 Dovitinib (TKI-258) Dilactic Acid Angiogenesis FGFR,PDGFR,VEGFR,c-Kit,FLT3 
S2770 MK-5108 (VX-689) Cell Cycle Aurora Kinase 
S2772 Dalcetrapib (JTT-705, RO4607381) Metabolism CETP 
S2773 SB705498 Others TRPV 
S2774 MK-2461 Protein Tyrosine Kinase FGFR,PDGFR,c-Met 
S2775 Nocodazole cytoskeletal signaling Autophagy,Microtubule Associated 
S2776 CPI-613 Metabolism Dehydrogenase 
S2778 GW842166X GPCR & G Protein Cannabinoid Receptor 
S2779 M344 Cytoskeletal Signaling HDAC 
S2781 RITA (NSC 652287) Apoptosis E3 Ligase ,p53 
S2782 GW4064 Others FXR 
S2783 AZD2014 PI3K/Akt/mTOR mTOR 
S2784 TAK-285 Protein Tyrosine Kinase HER2,EGFR 
S2785 A-803467 Transmembrane Transporters Sodium Channel 
S2787 Laquinimod Others Others 
S2789 Tofacitinib (CP-690550,Tasocitinib) JAK/STAT JAK 
S2791 Sotrastaurin TGF-beta/Smad PKC 
S2792 Torcetrapib Metabolism CETP 
S2794 Sofosbuvir (PSI-7977, GS-7977) DNA Damage DNA/RNA Synthesis 
S2795 VU 0357121 Neuronal Signaling GluR 
S2796 WP1066 JAK/STAT JAK 
S2797 Lonafarnib Metabolism Transferase 
S2801 AZD4547 Angiogenesis FGFR 
S2803 Galeterone Endocrinology & Hormones P450 (e.g. CYP17),Androgen Receptor 
S2804 Sirtinol Epigenetics Sirtuin 
S2806 CEP-33779 JAK/STAT JAK 
S2807 Dabrafenib (GSK2118436) MAPK Raf 
S2808 GDC-0068 PI3K/Akt/mTOR Akt 
S2809 MPEP Neuronal Signaling GluR 
S2811 INK 128 (MLN0128) PI3K/Akt/mTOR mTOR 
S2812 AT101 Apoptosis Bcl-2 
S2813 Ciproxifan Neuronal Signaling Histamine Receptor 
S2814 BYL719 PI3K/Akt/mTOR PI3K 
S2816 Tyrphostin AG 879 Protein Tyrosine Kinase HER2 
S2817 Torin 2 PI3K/Akt/mTOR mTOR,ATM/ATR 
S2818 CI994 (Tacedinaline) Epigenetics HDAC 
S2819 AM251 GPCR & G Protein Cannabinoid Receptor 
S2820 TAE226 (NVP-TAE226) Angiogenesis FAK 
S2821 RG108 Epigenetics Transferase,DNA Methyltransferase 
S2822 OC000459 Endocrinology & Hormones GPR 
S2824 TPCA-1 NF-κB IκB/IKK 
S2825 ML133 HCl Transmembrane Transporters Potassium Channel 
S2828 JNJ-1661010 Metabolism FAAH 
S2832 Epiandrosterone Endocrinology & Hormones Androgen Receptor,Estrogen/progestogen Receptor 
S2840 ARN-509 Endocrinology & Hormones Androgen Receptor 
S2841 R428 (BGB324) Protein Tyrosine Kinase TAM Receptor 
S2843 BI-D1870 PI3K/Akt/mTOR S6 Kinase 




S2849 SB269970 HCl Neuronal Signaling 5-HT Receptor 
S2851 Baricitinib (LY3009104, INCB028050) Epigenetics JAK 
S2852 BRL-54443 Neuronal Signaling 5-HT Receptor 
S2853 Carfilzomib (PR-171) Proteases Proteasome 
S2854 BML-190 GPCR & G Protein Cannabinoid Receptor 
S2855 MRS 2578 Neuronal Signaling P2 Receptor 
S2856 SB271046 Neuronal Signaling 5-HT Receptor 
S2857 MK-801 (Dizocilpine) Neuronal Signaling GluR 
S2859 Golvatinib (E7050) Protein Tyrosine Kinase VEGFR,c-Met 
S2860 IEM 1754 dihydrobroMide Neuronal Signaling GluR 
S2861 CTEP (RO4956371) Neuronal Signaling GluR 
S2862 VU 0364770 Neuronal Signaling GluR 
S2863 ML130 (Nodinitib-1) NF-κB NOD1 
S2864 IMD 0354 NF-κB IκB/IKK 
S2865 VUF 10166 Neuronal Signaling 5-HT Receptor 
S2866 U-104 Metabolism Carbonic Anhydrase 
S2867 WHI-P154 JAK/STAT JAK,EGFR 
S2868 Alogliptin Proteases DPP-4 
S2870 TG100713 PI3K/Akt/mTOR PI3K 
S2871 T0070907 DNA Damage PPAR 
S2872 GW5074 MAPK Raf 
S2875 Prucalopride Neuronal Signaling 5-HT Receptor 
S2876 (-)-MK 801 Maleate Neuronal Signaling GluR 
S2882 IKK-16 (IKK Inhibitor VII) NF-κB IκB/IKK 
S2890 PF-562271 Angiogenesis FAK 
S2891 GW441756 Protein Tyrosine Kinase Trk receptor 
S2892 VU 0361737 Neuronal Signaling GluR 
S2894 SB742457 Neuronal Signaling 5-HT Receptor 
S2895 Tyrphostin 9 Protein Tyrosine Kinase EGFR 
S2896 ZM 323881 HCl Protein Tyrosine Kinase VEGFR 
S2897 ZM 306416 Protein Tyrosine Kinase VEGFR 
S2898 MLN0905 Cell Cycle PLK 
S2899 GNF-2 Angiogenesis Bcr-Abl 
S2900 Cobicistat (GS-9350) Metabolism P450 (e.g. CYP17) 
S2902 S-Ruxolitinib (INCB018424) JAK/STAT JAK 
S2903 Lumiracoxib Neuronal Signaling COX 
S2904 PF-477736 Cell Cycle Chk 
S2905 JNJ-7777120 Neuronal Signaling Histamine Receptor 
S2906 Ki16198 GPCR & G Protein LPA Receptor 
S2907 Pirfenidone TGF-beta/Smad TGF-beta/Smad 
S2911 Go 6983 TGF-beta/Smad PKC 
S2912 WZ811 GPCR & G Protein CXCR 
S2913 BAY 11-7082 NF-κB E2 conjugating,IκB/IKK 
S2914 Dapivirine (TMC120) Microbiology Reverse Transcriptase 
S2915 GW9662 DNA Damage PPAR 
S2919 IOX2 Angiogenesis HIF 
S2921 PF-4981517 Metabolism P450 (e.g. CYP17) 
S2922 Icotinib Protein Tyrosine Kinase EGFR 
S2925 Evacetrapib (LY2484595) Metabolism CETP 
S2926 TDZD-8 PI3K/Akt/mTOR GSK-3 
S2927 Apoptosis Activator 2 Apoptosis Caspase 
S2928 TAK-715 MAPK p38 MAPK 
S2929 Pifithrin-α (PFTα) Apoptosis Autophagy,p53 
S2930 Pifithrin-μ Apoptosis p53 
S3002 Rivaroxaban Metabolism Factor Xa 
S3005 Paroxetine HCl Neuronal Signaling 5-HT Receptor,AChR 
S3008 Zaltoprofen Neuronal Signaling COX 
S3012 Pazopanib Protein Tyrosine Kinase PDGFR,VEGFR,c-Kit 
S3017 Aspirin Proteases COX 
S3018 Niflumic acid Neuronal Signaling GABA Receptor,COX 
S3019 Ciclopirox ethanolamine Transmembrane Transporters ATPase 
S3021 Rimonabant GPCR & G Protein Cannabinoid Receptor 
S3023 Bufexamac Neuronal Signaling COX 
S3024 Lamotrigine Transmembrane Transporters 5-HT Receptor,Sodium Channel 
S3026 Piceatannol Angiogenesis Syk 
S3031 Linagliptin Proteases DPP-4 
S3033 Vildagliptin (LAF-237) Proteases DPP-4 
S3035 Daunorubicin HCl DNA Damage Topoisomerase 
S3036 Pravastatin sodium Metabolism HMG-CoA Reductase 
S3037 Bepotastine Besilate Neuronal Signaling Histamine Receptor 
S3042 Purmorphamine Stem Cells &  Wnt Hedgehog/Smoothened 
S3043 Rofecoxib Neuronal Signaling COX 
S3046 Azilsartan Endocrinology & Hormones RAAS 
S3047 Otilonium Bromide Neuronal Signaling AChR 
S3048 Solifenacin succinate Neuronal Signaling AChR 




S3052 Rupatadine Fumarate Neuronal Signaling Histamine Receptor 
S3053 Azelnidipine Transmembrane Transporters Calcium Channel 
S3057 Azilsartan Medoxomil Endocrinology & Hormones RAAS 
S3060 Medetomidine HCl Neuronal Signaling Adrenergic Receptor 
S3061 Epinephrine HCl Neuronal Signaling Adrenergic Receptor 
S3064 Ambroxol HCl Transmembrane Transporters Sodium Channel 
S3066 Naloxone HCl Neuronal Signaling Opioid Receptor 
S3075 Dexmedetomidine Neuronal Signaling Adrenergic Receptor 
S3080 Etravirine (TMC125) Microbiology Reverse Transcriptase 
S3083 Indacaterol Maleate Neuronal Signaling Adrenergic Receptor 
S3117 Oxybutynin chloride Neuronal Signaling AChR 
S3144 Darifenacin HBr Neuronal Signaling AChR 
S3146 Tripelennamine HCl Neuronal Signaling Histamine Receptor 
S3147 Entacapone Epigenetics Histone Methyltransferase 
S3149 Estradiol valerate Endocrinology & Hormones Estrogen/progestogen Receptor 
S3151 Gliquidone Transmembrane Transporters Potassium Channel 
S3160 Ethynodiol diacetate Endocrinology & Hormones Estrogen/progestogen Receptor 
S3163 Benztropine mesylate Neuronal Signaling Dopamine Receptor 
S3167 Altrenogest Endocrinology & Hormones Estrogen/progestogen Receptor 
S3172 Anagrelide HCl Metabolism PDE 
S3175 Atomoxetine HCl Neuronal Signaling 5-HT Receptor 
S3178 Brinzolamide Metabolism Carbonic Anhydrase 
S3180 Eletriptan HBr Neuronal Signaling 5-HT Receptor 
S3181 Flumequine DNA Damage Topoisomerase 
S3183 Amitriptyline HCl Neuronal Signaling 5-HT Receptor 
S3185 Adrenalone HCl Neuronal Signaling Adrenergic Receptor 
S3186 Azatadine dimaleate Neuronal Signaling Histamine Receptor 
S3200 Triflusal Neuronal Signaling COX 
S3201 Trifluoperazine 2HCl Ubiquitin Autophagy 
S3208 Fexofenadine HCl Neuronal Signaling Histamine Receptor 
S3212 Moclobemide (Ro 111163) Metabolism MAO 
S3603 Betulinic acid DNA Damage Topoisomerase 
S4000 Pergolide mesylate Neuronal Signaling Dopamine Receptor 
S4001 Cabozantinib malate (XL184) Protein Tyrosine Kinase VEGFR,TAM Receptor 
S4002 Sitagliptin phosphate monohydrate Proteases DPP-4 
S4009 Mirabegron Neuronal Signaling Adrenergic Receptor 
S4010 Acebutolol HCl Neuronal Signaling Adrenergic Receptor 
S4011 Ampiroxicam Neuronal Signaling COX 
S4012 Desloratadine Neuronal Signaling Histamine Receptor 
S4014 Hyoscyamine Neuronal Signaling AChR 
S4016 Ouabain Transmembrane Transporters Sodium Channel 
S4019 Avanafil Metabolism PDE 
S4021 Tolcapone Metabolism Transferase 
S4023 Procaine HCl Transmembrane Transporters Sodium Channel 
S4024 Homatropine Methylbromide Neuronal Signaling AChR 
S4025 Homatropine Bromide Neuronal Signaling AChR 
S4026 Hydroxyzine 2HCl Neuronal Signaling Histamine Receptor 
S4027 Flavoxate HCl Neuronal Signaling AChR 
S4031 Aclidinium Bromide Neuronal Signaling AChR 
S4034 Diphemanil Methylsulfate Neuronal Signaling AChR 
S4038 Dibucaine HCl Transmembrane Transporters Sodium Channel 
S4039 Methazolamide Metabolism Carbonic Anhydrase 
S4043 Tetrahydrozoline HCl Neuronal Signaling Adrenergic Receptor 
S4046 Estradiol Cypionate Endocrinology & Hormones Estrogen/progestogen Receptor 
S4049 Valdecoxib Neuronal Signaling COX 
S4051 Nabumetone Neuronal Signaling COX 
S4053 Sertraline HCl Neuronal Signaling 5-HT Receptor 
S4054 Spironolactone Endocrinology & Hormones Androgen Receptor 
S4061 Levobupivacaine HCl Transmembrane Transporters Sodium Channel 
S4064 Escitalopram Oxalate Neuronal Signaling 5-HT Receptor 
S4065 Guanabenz Acetate Neuronal Signaling Adrenergic Receptor 
S4072 Decamethonium Bromide Neuronal Signaling AChR 
S4073 Sodium 4-Aminosalicylate NF-κB NF-κB 
S4075 Zinc Pyrithione Transmembrane Transporters Proton Pump 
S4076 Propranolol HCl GPCR & G Protein Adrenergic Receptor 
S4078 Mefenamic Acid Neuronal Signaling COX 
S4079 Ticagrelor Neuronal Signaling P2 Receptor 
S4080 Triamterene Transmembrane Transporters Sodium Channel 
S4081 Sulfacetamide Sodium Ubiquitin Autophagy 
S4091 Ifenprodil Tartrate Neuronal Signaling GluR 
S4109 Lorcaserin HCl Neuronal Signaling 5-HT Receptor 
S4110 Estradiol Benzoate Others Estrogen/progestogen Receptor 
S4112 Desvenlafaxine Succinate Neuronal Signaling 5-HT Receptor 
S4113 Desvenlafaxine Neuronal Signaling 5-HT Receptor 
S4118 Histamine 2HCl Neuronal Signaling Histamine Receptor 




S4123 Timolol Maleate Neuronal Signaling Adrenergic Receptor 
S4124 Tolazoline HCl Neuronal Signaling Adrenergic Receptor 
S4125 Sodium Phenylbutyrate DNA Damage HDAC 
S4131 Levodropropizine Neuronal Signaling Histamine Receptor 
S4139 Cyclizine 2HCl Neuronal Signaling Histamine Receptor 
S4212 Tenatoprazole Transmembrane Transporters Proton Pump 
S4220 Bosentan GPCR & G Protein Endothelin Receptor 
S4246 Tranylcypromine (2-PCPA) HCl Epigenetics MAO 
S4261 EUK 134 Neuronal Signaling Beta Amyloid 
S4269 Vinorelbine Tartrate Cytoskeletal Signaling Microtubule Associated 
S4270 Oxiracetam Others Others 
S4274 Rotigotine Neuronal Signaling Dopamine Receptor 
S4276 Etizolam Others Others 
S4277 Bambuterol HCl GPCR & G Protein Adrenergic Receptor 
S4278 Carteolol HCl GPCR & G Protein Adrenergic Receptor 
S4279 Demeclocycline HCl Others Others 
S4282 Nelfinavir Mesylate Proteases HIV Protease 
S4283 Cyclobenzaprine HCl Others Others 
S4285 Ospemifene Endocrinology & Hormones Estrogen/progestogen Receptor 
S4286 Anidulafungin (LY303366) Others Others 
S4288 Chloroambucil DNA Damage DNA/RNA Synthesis 
S4289 MetoclopraMide HCl Neuronal Signaling Dopamine Receptor 
S4290 Digoxin Transmembrane Transporters Sodium Channel 
S4291 Labetalol HCl GPCR & G Protein Adrenergic Receptor 
S4292 Diphenidol HCl Neuronal Signaling AChR 
S4293 Promethazine HCl Neuronal Signaling Histamine Receptor 
S4294 Procainamide HCl Transmembrane Transporters DNA Methyltransferase,Sodium Channel 
S4295 Meclofenamate Sodium Neuronal Signaling COX 
S4297 Mupirocin DNA Damage DNA/RNA Synthesis 
S4299 Dicoumarol Others Others 
S4420 Mefloquine HCl Others Others 
S4504 6-Mercaptopurine (6-MP) Monohydrate DNA Damage DNA/RNA Synthesis 
S4900 Tenovin-6 Apoptosis p53,Sirtuin 
S4901 JNK-IN-8 MAPK JNK 
S4902 QNZ (EVP4593) NF-κB NF-κB,TNF-alpha 
S4907 SC-514 NF-κB IκB/IKK 
S4908 SN-38 DNA Damage Topoisomerase 
S4920 b-AP15 Ubiquitin DUB 
S4921 MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN) Ubiquitin p97 
S4926 (R)-Nepicastat HCl Metabolism Hydroxylase 
S5001 Tofacitinib (CP-690550) Citrate JAK/STAT JAK 
S5002 Fingolimod (FTY720) HCl GPCR & G Protein S1P Receptor 
S6003 Ataluren (PTC124) Transmembrane Transporters CFTR 
S6005 VX-702 MAPK p38 MAPK 
S7000 AP26113 Protein Tyrosine Kinase ALK 
S7003 AZD2932 Protein Tyrosine Kinase VEGFR,c-Kit,PDGFR,FLT3 
S7007 MEK162 (ARRY-162, ARRY-438162) MAPK MEK 
S7008 PP2 Angiogenesis Src 
S7009 LCL161 Apoptosis IAP 
S7010 GDC-0152 Apoptosis IAP 
S7015 Birinapant Apoptosis IAP 
S7016 VS-5584 (SB2343) PI3K/Akt/mTOR PI3K 
S7018 CZC24832 PI3K/Akt/mTOR PI3K 
S7023 Z-VAD-FMK Apoptosis Caspase 
S7024 Stattic JAK/STAT STAT 
S7025 Embelin Apoptosis IAP 
S7028 IPI-145 (INK1197) Angiogenesis PI3K 
S7029 AZD2461 DNA Damage PARP 
S7030 RG-7112 Apoptosis Mdm2 
S7033 GSK2656157 Apoptosis PERK 
S7035 XL388 PI3K/Akt/mTOR mTOR 
S7036 XL019 JAK/STAT JAK 
S7037 Wnt-C59 (C59) Stem Cells &  Wnt Wnt/beta-catenin 
S7039 PD168393 Protein Tyrosine Kinase EGFR 
S7040 AZD3514 Endocrinology & Hormones Androgen Receptor 
S7041 CX-6258 HCl JAK/STAT Pim 
S7046 Brefeldin A Transmembrane Transporters ATPase,Autophagy 
S7048 BMN 673 Epigenetics PARP 
S7049 Oprozomib (ONX 0912) Proteases Proteasome 
S7050 AZ20 PI3K/Akt/mTOR ATM/ATR 
S7051 CGI1746 Angiogenesis BTK 
S7057 LY2874455 Protein Tyrosine Kinase VEGFR,FGFR 
S7059 VX-661 Transmembrane Transporters CFTR 
S7060 PP1 Angiogenesis Src 
S7061 GSK126 Epigenetics Histone Methyltransferase 




S7063 LY2090314 PI3K/Akt/mTOR GSK-3 
S7065 MK-8745 Cell Cycle Aurora Kinase 
S7067 Tepotinib (EMD 1214063) Protein Tyrosine Kinase c-Met 
S7070 GSK J4 HCl Epigenetics Histone Demethylase 
S7072 NMDA (N-Methyl-D-aspartic acid) Neuronal Signaling GluR 
S7076 T0901317 Others Liver X Receptor 
S7077 Cilengitide Others Integrin 
S7079 SGC 0946 Epigenetics Histone Methyltransferase 
S7080 RN486 Angiogenesis BTK 
S7083 LDK378 Protein Tyrosine Kinase ALK 
S7085 IWP-2 Stem Cells &  Wnt Wnt/beta-catenin 
S7086 IWR-1-endo Stem Cells &  Wnt Wnt/beta-catenin 
S7087 GSK2334470 PI3K/Akt/mTOR PDK-1 
S7088 UNC1215 Epigenetics Epigenetic Reader Domain 
S7090 GSK923295 Cytoskeletal Signaling Kinesin 
S7091 Zotarolimus(ABT-578) PI3K/Akt/mTOR mTOR 
S7092 SANT-1 Stem Cells &  Wnt Hedgehog/Smoothened 
S7093 IPA-3 Cytoskeletal Signaling PAK 
S7094 PF-3758309 Cytoskeletal Signaling PAK 
S7096 KY02111 Stem Cells &  Wnt Wnt/beta-catenin 
S7097 HSP990 (NVP-HSP990) Cytoskeletal Signaling HSP (e.g. HSP90) 
S7098 PD123319 Endocrinology & Hormones RAAS 
S7099 (-)-Blebbistatin Transmembrane Transporters ATPase 
S7102 VE-822 PI3K/Akt/mTOR ATM/ATR 
S7103 GDC-0032 PI3K/Akt/mTOR PI3K 
S7104 AZD1208 JAK/STAT Pim 
S7106 AZD3463 Protein Tyrosine Kinase ALK 
S7108 LGX818 MAPK Raf 
S7110 (+)-JQ1 Epigenetics Epigenetic Reader Domain 
S7111 NLG919 Metabolism IDO 
S7113 Zebularine Epigenetics DNA Methyltransferase 
S7114 NU6027 Cell Cycle CDK 
S7115 AMG-517 Others TRPV 
S7119 Go6976 TGF-beta/Smad JAK,FLT3,PKC 
S7120 3-Deazaneplanocin A (DZNeP) Epigenetics Histone Methyltransferase 
S7122 XL888 Cytoskeletal Signaling HSP (e.g. HSP90) 
S7125 KPT-185 Transmembrane Transporters CRM1 
S7127 TIC10 PI3K/Akt/mTOR Akt 
S7128 EPZ-6438 Epigenetics Histone Methyltransferase 
S7129 PYR-41 Ubiquitin E1 Activating 
S7130 PR-619 Ubiquitin DUB 
S7132 P5091 (P005091) Ubiquitin DUB 
S7133 P22077 Ubiquitin DUB 
S7134 IU1 Proteases DUB 
S7135 LDN-57444 Proteases DUB 
S7136 CGK 733 DNA Damage ATM/ATR 
S7138 BMS-833923 GPCR & G Protein Hedgehog/Smoothened 
S7139 CFTRinh-172 Transmembrane Transporters CFTR 
S7140 TCID Ubiquitin DUB 
S7142 NSC697923 Ubiquitin E2 conjugating 
S7143 LGK-974 Stem Cells &  Wnt Wnt/beta-catenin 
S7145 AZD1080 PI3K/Akt/mTOR GSK-3 
S7146 DMH1 TGF-beta/Smad TGF-beta/Smad 
S7147 LDN-212854 TGF-beta/Smad TGF-beta/Smad 
S7148 ML347 TGF-beta/Smad TGF-beta/Smad 
S7149 NSC 319726 Apoptosis p53 
S7152 C646 Epigenetics Histone Acetyltransferase 
S7153 10058-F4 Cell Cycle c-Myc 
S7155 Batimastat (BB-94) Proteases MMP 
S7156 Marimastat(BB-2516) Proteases MMP 
S7158 LY2835219 Cell Cycle CDK 
S7162 Mdivi-1 Cytoskeletal Signaling Dynamin 
S7163 Dyngo-4a Cytoskeletal Signaling Dynamin 
S7165 UNC1999 Epigenetics Histone Methyltransferase 
S7167 SSR128129E Angiogenesis FGFR 
S7170 RO5126766 (CH5126766) MAPK Raf 
S7171 GKT137831 Others Others 
S7172 ONX-0914 (PR-957) Proteases Proteasome 
S7173 AVL-292 Angiogenesis BTK 
S7174 ABC294640 GPCR & G Protein S1P Receptor 
S7176 SKI II GPCR & G Protein S1P Receptor 
S7177 PF-543 GPCR & G Protein S1P Receptor 
S7185 AGI-5198 Metabolism Dehydrogenase 
S7188 CID755673 Others Others 
S7189 I-BET-762 Epigenetics Epigenetic Reader Domain 




S7193 1-Azakenpaullone PI3K/Akt/mTOR GSK-3 
S7194 GZD824 Angiogenesis Bcr-Abl 
S7195 RKI-1447 Cell Cycle ROCK 
S7198 BIO PI3K/Akt/mTOR GSK-3 
S7199 DBeQ Ubiquitin p97 
S7205 Idasanutlin (RG-7388) Apoptosis Mdm2 
S7206 CNX-2006 Protein Tyrosine Kinase EGFR 
S7208 GF109203X TGF-beta/Smad PKC 
S7214 Skepinone-L MAPK p38 MAPK 
S7215 Losmapimod (GW856553X) MAPK p38 MAPK 
S7218 Alvelestat (AZD9668) Proteases Serine Protease 
S7223 RepSox TGF-beta/Smad TGF-beta/Smad 
S7224 Deltarasin Metabolism PDE 
S7229 RGFP966 Epigenetics HDAC 
S7231 GSK2801 Epigenetics Epigenetic Reader Domain 
S7233 Bromosporine Epigenetics Epigenetic Reader Domain 
S7234 IOX1 Epigenetics Histone Demethylase 
S7237 OG-L002 Epigenetics Histone Demethylase 
S7239 G007-LK DNA Damage PARP 
S7241 AGI-6780 Metabolism Dehydrogenase 
S7242 Erastin Metabolism Ferroptosis 
S7243 Ferrostatin-1 (Fer-1) Metabolism Ferroptosis 
S7248 Ro3280 Cell Cycle PLK 
S7251 KPT-276 Transmembrane Transporters CRM1 
S7252 KPT-330 Transmembrane Transporters CRM1 
S7253 AZD2858 PI3K/Akt/mTOR GSK-3 
S7256 SGC-CBP30 Epigenetics Epigenetic Reader Domain 
S7257 CNX-774 Angiogenesis BTK 
S7258 SKLB1002 Protein Tyrosine Kinase VEGFR 
S7259 FLLL32 JAK/STAT JAK 
S7261 Beta-Lapachone DNA Damage Topoisomerase 
S7262 Vidofludimus Metabolism Dehydrogenase 
S7263 AZD1981 Endocrinology & Hormones GPR 
S7265 MM-102 Epigenetics Histone Methyltransferase 
S7266 Golgicide A Transmembrane Transporters ATPase 
S7269 PD173955 Angiogenesis Bcr-Abl 
S7271 FRAX597 Cytoskeletal Signaling PAK 
S7273 SC75741 NF-κB NF-κB 
S7276 SGI-1027 Epigenetics DNA Methyltransferase 
S7278 HPOB Cytoskeletal Signaling HDAC 
S7279 Suvorexant (MK-4305) GPCR & G Protein OX Receptor 
S7280 Edoxaban Metabolism Factor Xa 
S7281 JIB-04 Epigenetics Histone Demethylase 
S7282 NMS-E973 Cytoskeletal Signaling HSP (e.g. HSP90) 
S7284 CO-1686 (AVL-301) Protein Tyrosine Kinase EGFR 
S7285 NMS-873 Ubiquitin p97 
S7289 PFK15 Others Others 
S7291 TAK-632 MAPK Raf 
S7292 RG2833 (RGFP109) Epigenetics HDAC 
S7293 ZCL278 Cell Cycle Rho 
S7294 PFI-2 Epigenetics Histone Methyltransferase 
S7295 RVX-208 Epigenetics Epigenetic Reader Domain 
S7296 ML324 Epigenetics Histone Demethylase 
S7297 AZD9291 Protein Tyrosine Kinase EGFR 
S7298 AZ5104 Protein Tyrosine Kinase EGFR 
S7300 PJ34 HCl DNA Damage PARP 
S7301 IWP-L6 Stem Cells &  Wnt Wnt/beta-catenin 
S7303 Rilpivirine Microbiology Reverse Transcriptase 
S7304 CPI-203 Epigenetics Epigenetic Reader Domain 
S7305 MS436 Epigenetics Epigenetic Reader Domain 
S7307 GSK2606414 Apoptosis PERK 
S7310 SF1670 Others Others 
S7315 PFI-3 Epigenetics Epigenetic Reader Domain 
S7317 WZ4003 PI3K/Akt/mTOR AMPK 
S7318 HTH-01-015 PI3K/Akt/mTOR AMPK 
S7319 EHop-016 Cell Cycle Rho 
S7320 TG003 Cell Cycle CDK 
S7324 TMP269 Epigenetics HDAC 
S7325 UNC2881 Others TAM Receptor 
S7326 Tasisulam Apoptosis Caspase 
S7329 IOWH032 Transmembrane Transporters CFTR 
S7330 6H05 Cell Cycle Rho 
S7331 K-Ras(G12C) inhibitor 12 Cell Cycle Rho 
S7332 K-Ras(G12C) inhibitor 9 Cell Cycle Rho 
S7333 K-Ras(G12C) inhibitor 6 Cell Cycle Rho 




S7336 CW069 Cytoskeletal Signaling Microtubule Associated 
S7337 SH-4-54 JAK/STAT STAT 
S7340 CH5138303 Cytoskeletal Signaling HSP (e.g. HSP90) 
S7343 URMC-099 Others MLK,LRRK,Abl,VEGFR/FLT 
S7351 JSH-23 NF-κB NF-κB 
S7352 Bay 11-7085 NF-κB IκB/IKK 
S7353 EPZ004777 Epigenetics Histone Methyltransferase 
S7355 ARQ 621 Cytoskeletal Signaling Kinesin 
S7356 HS-173 PI3K/Akt/mTOR PI3K 
S7357 PF-562271 HCl Angiogenesis FAK 
S7358 Poziotinib (HM781-36B) Protein Tyrosine Kinase EGFR 
S7359 K02288 TGF-beta/Smad TGF-beta/Smad 
S7360 OTX015 Epigenetics Epigenetic Reader Domain 
S7364 Atglistatin Others Others 
S7367 GNE-0877 Autophagy LRRK2 
S7368 GNE-9605 Autophagy LRRK2 
S7369 4EGI-1 Others Others 
S7370 4E1RCat Others Others 
S7372 PTC-209 Others Others 
S7373 UNC669 Epigenetics Epigenetic Reader Domain 
S7378 AEBSF HCl Proteases Serine Protease 
S7379 E-64 Proteases Cysteine Protease 
S7382 Phosphoramidon Disodium Salt Others Others 
S7383 (-)-p-Bromotetramisole Oxalate Others Others 
S7386 MG-101 (ALLN) Proteases Cysteine Protease 
S7391 Z-FA-FMK Proteases Cysteine Protease 
S7392 Loxistatin Acid (E-64C) Proteases Cysteine Protease 
S7393 Aloxistatin Proteases Cysteine Protease 
S7396 Calpeptin Proteases Cysteine Protease 
S7397 Sorafenib MAPK Raf 
S7399 FLI-06 Stem Cells &  Wnt Gamma-secretase 
S7400 ISRIB (trans-isomer) Apoptosis PERK 
S7409 Anisomycin MAPK JNK 
S7414 Caffeic Acid Phenethyl Ester NF-κB NF-κB 
S7421 CGP 57380 Others Others 
S7422 KN-62 Others CaMK 
S7423 KN-93 Phosphate Others CaMK 
S7424 PD 151746 Proteases Cysteine Protease 
S7429 MI-2 (MALT1 inhibitor) Others Others 
S7430 SB-3CT Proteases MMP 
S7434 TAPI-1 Others Others 
S7435 AR-A014418 PI3K/Akt/mTOR GSK-3 
S7436 NH125 Others CaMK 
S7437 Sal003 Others Others 
S7438 ME0328 Epigenetics PARP 
S7440 LEE011 Cell Cycle CDK 
S7441 WS3 NF-κB IκB/IKK 
S7442 WS6 NF-κB IκB/IKK 
S7445 E3330 DNA Damage DNA/RNA Synthesis 
S7448 CORM-3 Others Others 
S7449 CRT0044876 DNA Damage DNA/RNA Synthesis 
S7452 FPH2 (BRD-9424) Others Others 
S7457 XEN445 Others Others 
S7458 VER-49009 Cytoskeletal Signaling HSP (e.g. HSP90) 
S7459 VER-50589 Cytoskeletal Signaling HSP (e.g. HSP90) 
S7460 BTB06584 Transmembrane Transporters ATPase 
S7461 LDC000067 Cell Cycle CDK 
S7462 PI-1840 Proteases Proteasome 
S7465 FTI 277 HCl Metabolism Transferase 
S7467 LB42708 Metabolism Transferase 
S7470 Triapine DNA Damage DNA/RNA Synthesis 
S7473 Nexturastat A Epigenetics HDAC 
S7476 MG149 Epigenetics Histone Acetyltransferase 
S7482 EHT 1864 Cell Cycle Rho 
S7484 FH535 Stem Cells &  Wnt Wnt/beta-catenin,PPAR 
S7488 MPI-0479605 Cytoskeletal Signaling Kinesin 
S7489 YH239-EE Apoptosis Mdm2 
S7490 WIKI4 Stem Cells &  Wnt Wnt/beta-catenin 
S7493 INH1 Cytoskeletal Signaling Microtubule Associated 
S7494 INH6 Cytoskeletal Signaling Microtubule Associated 
S7495 TAI-1 Cytoskeletal Signaling Microtubule Associated 
S7497 CK-636 Cytoskeletal Signaling Microtubule Associated 
S7498 DDR1-IN-1 Others Others 
S7499 ESI-09 Others Others 
S7500 HJC0350 Others Others 




S7505 (S)-crizotinib Others Others 
S7508 JNK Inhibitor IX MAPK JNK 
S7509 ML167 Cell Cycle CDK 
S7513 Trelagliptin Proteases DPP-4 
S7517 AZD7545 Others Others 
S7518 Voreloxin (SNS-595) DNA Damage Topoisomerase 
S7519 GNF-5837 Protein Tyrosine Kinase Trk receptor 
S7520 Darapladib (SB-480848) Metabolism Phospholipase (e.g. PLA) 
S7521 Afuresertib (GSK2110183) PI3K/Akt/mTOR Akt 
S7523 GS-9973 Angiogenesis Syk 
S7524 FR 180204 MAPK ERK 
S7525 XMD8-92 MAPK ERK 
S7526 GNF-5 Angiogenesis Bcr-Abl 
S7528 GNE-7915 Autophagy LRRK2 
S7529 ML323 Ubiquitin DUB 
S7530 EW-7197 TGF-beta/Smad TGF-beta/Smad 
S7531 UMI-77 Apoptosis Bcl-2 
S7534 BAPTA-AM Others Others 
S7536 PF-06463922 Protein Tyrosine Kinase ALK 
S7539 PTC-209 HBr Others Others 
S7540 SB273005 Cytoskeletal Signaling Integrin 
S7545 G-749 Angiogenesis FLT3 
S7546 Pritelivir (BAY 57-1293) Others Others 
S7553 GDC-0623 MAPK MEK 
S7554 GDC-0994 MAPK ERK 
S7555 4SC-202 Epigenetics HDAC 
S7557 CL-387785 (EKI-785) Protein Tyrosine Kinase EGFR 
S7563 AT13148 PI3K/Akt/mTOR Akt,ROCK,PKA,S6 Kinase 
S7565 WH-4-023 Angiogenesis Src 
S7566 IM-12 PI3K/Akt/mTOR GSK-3 
S7569 LMK-235 DNA Damage HDAC 
S7570 UNC0379 Epigenetics Histone Methyltransferase 
S7573 GSK2830371 Angiogenesis Wip1 phosphatase 
S7574 GSK-LSD1 2HCl Epigenetics Histone Demethylase 
S7576 UNC-2025 Protein Tyrosine Kinase TAM Receptor,FLT3 
S7577 AGK2 Cytoskeletal Signaling Sirtuin 
S7579 Ledipasvir (GS5885) Microbiology HCV Protease 
S7581 GSK J1 Epigenetics Histone Demethylase 
S7582 Anacardic Acid Epigenetics Histone Acetyltransferase 
S7584 LRRK2-IN-1 Autophagy LRRK2 
S7587 INCB024360 Metabolism IDO 
S7589 N6022 Others Others 
S7591 BRD4770 Epigenetics Histone Methyltransferase 
S7593 Splitomicin Cytoskeletal Signaling Sirtuin 
S7595 Santacruzamate A (CAY10683) DNA Damage HDAC 
S7596 CAY10603 DNA Damage HDAC 
S7597 BV-6 Apoptosis IAP 
S7605 Filgotinib (GLPG0634) JAK/STAT JAK 
S7606 RBC8 Others GTPases RalA/RalB 
S7607 BQU57 Others Others 
S7610 UNC0631 Epigenetics Histone Methyltransferase 
S7611 EI1 Epigenetics Histone Methyltransferase 
S7612 PX-478 2HCl Angiogenesis HIF 
S7616 CPI-169 Epigenetics Histone Methyltransferase 
S7617 Tasquinimod Angiogenesis HDAC 
S7618 MI-2 (Menin-MLL Inhibitor) Epigenetics Histone Methyltransferase 
S7619 MI-3 (Menin-MLL Inhibitor) Epigenetics Histone Methyltransferase 
S7620 GSK1324726A (I-BET726) Epigenetics Epigenetic Reader Domain 
S7623 PI-3065 PI3K/Akt/mTOR PI3K 
S7624 SD-208 TGF-beta/Smad TGF-beta/Smad 
S7627 LDN-214117 TGF-beta/Smad TGF-beta/Smad 
S7631 TH287 Others Others 
S7634 Cerdulatinib (PRT062070, PRT2070) JAK/STAT JAK 
S7636 SU9516 Cell Cycle CDK 
S7637 DTP3 MAPK JNK 
S7638 LDC1267 Protein Tyrosine Kinase TAM Receptor 
S7641 Remodelin Epigenetics Histone Acetyltransferase 
S7642 D 4476 Metabolism Casein Kinase 
S7644 PF-431396 Angiogenesis FAK 
S7645 Pilaralisib (XL147) PI3K/Akt/mTOR PI3K 
S7650 Peficitinb (ASP015K, JNJ-54781532) JAK/STAT JAK 
S7653 PND-1186 (VS-4718) Angiogenesis FAK 
S7654 Defactinib (VS-6063, PF-04554878) Angiogenesis FAK 
S7655 CB-839 Others Others 
S7656 CPI-360 Epigenetics Histone Methyltransferase 




S7665 CH5183284 (Debio-1347) Angiogenesis FGFR 
S7667 SU5402 Protein Tyrosine Kinase FGFR,VEGFR 
S7668 Picropodophyllin (PPP) Protein Tyrosine Kinase IGF-1R 
S7669 NPS-1034 Protein Tyrosine Kinase TAM Receptor,c-Met 
S7672 Omaveloxolone (RTA-408) Others Others 
S7673 L-685,458 Neuronal Signaling Gamma-secretase 
S7675 PF-4989216 PI3K/Akt/mTOR PI3K 
S7678 LCZ696 Endocrinology & Hormones RAAS 
S7679 YK-4-279 Cell Cycle DNA/RNA Synthesis 
S7680 SP2509 Epigenetics Histone Demethylase 
S7681 OF-1 Epigenetics Epigenetic Reader Domain 
S7685 SecinH3 Others hCyh,drosophila steppke,yGea2-S7 
S7686 ML141 Cell Cycle Rho 
S7689 BG45 DNA Damage HDAC 
S7693 AZD6738 PI3K/Akt/mTOR ATM/ATR 
S7694 AZD8186 PI3K/Akt/mTOR PI3K 
S7697 LY2409881 NF-κB IκB/IKK 
S7699 Liproxstatin-1 Metabolism Ferroptosis 
S7704 LY2584702 Tosylate PI3K/Akt/mTOR S6 Kinase 
S7707 Verdinexor (KPT-335) Transmembrane Transporters CRM1 
S7714 FIIN-2 Protein Tyrosine Kinase FGFR 
S7718 BMH-21 DNA Damage DNA/RNA Synthesis 
S7719 CCG-1423 Cell Cycle Rho 
S7720 SBE 13 HCl Cell Cycle PLK 
S7722 Bikinin PI3K/Akt/mTOR GSK-3 
S7725 BLZ945 Protein Tyrosine Kinase CSF-1R 
S7726 BRD73954 DNA Damage HDAC 
S7730 NU1025 DNA Damage PARP 
S7731 AZD3839 Neuronal Signaling BACE 
S7734 LFM-A13 Angiogenesis BTK 
S7741 SB239063 MAPK p38 MAPK 
S7742 SCR7 DNA Damage DNA/RNA Synthesis 
S7747 Ro-3306 Cell Cycle CDK 
S7748 EPZ015666 Epigenetics Histone Methyltransferase 
S7750 KNK437 Cell Cycle HSP (e.g. HSP90) 
S7751 VER155008 Cytoskeletal Signaling HSP (e.g. HSP90) 
S7753 BPTES Others Others 
S7765 Dovitinib (TKI258) Lactate Angiogenesis FGFR,VEGFR,c-Kit,PDGFR,FLT3 
S7766 Cabotegravir (GSK744, GSK1265744) Microbiology Integrase 
S7771 STF-083010 Others Others 
S7772 Elacridar (GF120918) Transmembrane Transporters P-gp 
S7774 SU6656 Angiogenesis Src 
S7776 Akti-1/2 PI3K/Akt/mTOR Akt 
S7781 Sunitinib Protein Tyrosine Kinase VEGFR,PDGFR,c-Kit 
S7783 Combretastatin A4 Cytoskeletal Signaling Microtubule Associated 
S7786 Erlotinib Protein Tyrosine Kinase EGFR 
S7787 Docetaxel Trihydrate Cytoskeletal Signaling Microtubule Associated 
S7790 A-1210477 Apoptosis Bcl-2 
S7793 Purvalanol A Cell Cycle CDK 
S7795 ORY-1001 (RG-6016) Epigenetics Histone Demethylase 
S7798 GNE-317 PI3K/Akt/mTOR PI3K 
S7799 Pexmetinib (ARRY-614) MAPK Tie-2,p38 MAPK 
S7804 GSK503 Epigenetics Histone Methyltransferase 
S7808 AT7519 HCl Cell Cycle CDK 
S7810 Afatinib (BIBW2992) Dimaleate Protein Tyrosine Kinase HER2,EGFR 
S7811 MHY1485 PI3K/Akt/mTOR mTOR,Autophagy 
S7813 AMG319 PI3K/Akt/mTOR PI3K 
S7818 Pexidartinib (PLX3397) Protein Tyrosine Kinase CSF-1R,c-Kit 
S7819 BLU9931 Angiogenesis FGFR 
S7834 Cyclo (-RGDfK) Cytoskeletal Signaling Integrin 
S7840 Dorsomorphin (Compound C) PI3K/Akt/mTOR AMPK 
S7842 LY3009120 MAPK Raf 
S7843 BI-847325 MAPK MEK,Aurora Kinase 
S7844 Cyclo(RGDyK) Cytoskeletal Signaling Integrin 
S7845 SirReal2 Epigenetics Sirtuin 
S7846 TP-0903 Protein Tyrosine Kinase TAM Receptor 
S7851 AZD3264 NF-κB IκB/IKK 
S7854 Ulixertinib (BVD-523, VRT752271) MAPK ERK 
S7856 Tenofovir Alafenamide (GS-7340) Microbiology Reverse Transcriptase 
S7863 SC79 PI3K/Akt/mTOR Akt 
S7877 ONO-4059 Angiogenesis BTK 
S7884 AMI-1 Epigenetics Histone Methyltransferase 
S7885 SBI-0206965 Autophagy Autophagy 
S7888 Spautin-1 Autophagy Autophagy 
S7889 Xanthohumol Metabolism COX 




S7910 Epacadostat (INCB024360) Metabolism IDO 
S7912 PD-1/PD-L1 inhibitor 2 Apoptosis PD-1/PD-L1 
S7915 BIO-acetoxime PI3K/Akt/mTOR GSK-3 
S7918 Bromodeoxyuridine (BrdU) DNA Damage DNA/RNA Synthesis 
S7921 DEL-22379 MAPK ERK 
S7922 Tiplaxtinin (PAI-039) Others Others 
S7931 STF-31 Others Others 
S7933 VR23 Proteases Proteasome 
S7946 KC7F2 Angiogenesis HIF 
S7963 TIC10 PI3K/Akt/mTOR Akt 
S7975 Favipiravir (T-705) DNA Damage DNA/RNA Synthesis 
S7998 Entrectinib (RXDX-101) Protein Tyrosine Kinase ALK,Trk receptor 
S8000 Tenovin-1 Apoptosis E3 Ligase ,p53 
S8001 Rocilinostat (ACY-1215) Epigenetics HDAC 
S8002 GSK2636771 PI3K/Akt/mTOR PI3K 
S8003 PQ 401 Protein Tyrosine Kinase IGF-1R 
S8004 ZM 39923 HCl JAK/STAT JAK 
S8005 SMI-4a JAK/STAT Pim 
S8006 BIX 01294 Epigenetics Histone Methyltransferase 
S8007 VE-821 DNA Damage ATM/ATR 
S8009 AG-18 Protein Tyrosine Kinase EGFR 
S8010 PRX-08066 Maleic acid Neuronal Signaling 5-HT Receptor 
S8011 U73122 Metabolism Phospholipase (e.g. PLA) 
S8014 GW9508 Endocrinology & Hormones GPR 
S8015 CEP-32496 MAPK CSF-1R,Raf 
S8016 TAK-438 Transmembrane Transporters Potassium Channel 
S8018 PF-03084014 (PF-3084014) Neuronal Signaling Gamma-secretase 
S8019 AZD5363 PI3K/Akt/mTOR Akt 
S8020 GW0742 Metabolism PPAR 
S8021 Vortioxetine (Lu AA21004) HBr Neuronal Signaling 5-HT Receptor 
S8022 Empagliflozin (BI 10773) GPCR & G Protein SGLT 
S8023 TCS 359 Angiogenesis FLT3 
S8024 Tyrphostin AG 1296 Protein Tyrosine Kinase PDGFR,FGFR,c-Kit 
S8025 GSK3787 Metabolism PPAR 
S8028 Tariquidar Transmembrane Transporters P-gp 
S8029 WY-14643 (Pirinixic Acid) Metabolism PPAR 
S8031 NSC 23766 Cell Cycle Rho 
S8032 PRT062607 (P505-15, BIIB057) HCl Angiogenesis Syk 
S8034 Apremilast (CC-10004) Metabolism PDE 
S8035 VU 0364439 Neuronal Signaling GluR 
S8036 Butein Protein Tyrosine Kinase EGFR 
S8037 Necrostatin-1 Apoptosis TNF-alpha 
S8038 UPF 1069 DNA Damage PARP 
S8039 PU-H71 Cytoskeletal Signaling HSP (e.g. HSP90) 
S8040 GDC-0349 PI3K/Akt/mTOR mTOR 
S8041 Cobimetinib (GDC-0973, RG7420) MAPK MEK 
S8042 GW2580 Protein Tyrosine Kinase CSF-1R 
S8043 Scriptaid DNA Damage HDAC 
S8044 BMS-345541 NF-κB IκB/IKK 
S8047 Dynasore Others Dynamin 
S8048 ABT-199 (GDC-0199) Apoptosis Bcl-2 
S8049 Tubastatin A Epigenetics HDAC 
S8050 ETP-46464 PI3K/Akt/mTOR ATM/ATR,mTOR 
S8051 Macitentan GPCR & G Protein Endothelin Receptor 
S8056 Lomeguatrib Epigenetics DNA Methyltransferase 
S8057 Pacritinib (SB1518) JAK/STAT FLT3,JAK 
S8058 P276-00 Cell Cycle CDK 
S8059 Nutlin-3a Apoptosis Mdm2 
S8065 Nutlin-3b Apoptosis Mdm2 
S8072 NSC 405020 Proteases MMP 
S8073 Optovin Others Others 
S8076 PluriSIn #1 (NSC 14613) Metabolism Dehydrogenase 
S8103 Sotagliflozin (LX4211) GPCR & G Protein SGLT 
 
